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PREFACE 
Nonsteroidal anti-inflammatory drugs (NSAIDs) have an important place in the 
symptomatic treatment of rheumatologic disorders. They can exert a wide range of side-effects 
on the kidney. Inhibition of the prostaglandin synthesis plays a central role in the mechanism of 
these side-effects. The way NSAIDs are transported by the kidney is probably also important. 
These drugs are weak acids and are probably actively secreted. As a result of this process, 
NSAIDs can accumulate in the kidney, thereby causing an effect on kidney function. 
Phannacodynamically NSAIDs do not differ substantially. However, considerable differences 
exist in their pharmacokinetics. 
This thesis deals with a fundamental study on renal disposition and effects of NSAIDs. 
Two study models were used: the isolated perfused rat kidney and proximal tubular cells from 
the rat kidney. A number of different NSAIDs were characterized and the results might 
contribute to a more rational use of these drugs. 
The thesis is divided into four parts. Part I contains a general introduction and a 
detailed description of the isolated perfused rat kidney preparation. In part Π, renal disposition 
and effects on kidney function of salicyluric acid, salicylic acid and indomethacin are 
described. Part ΠΙ deals with the contribution to the effects on renal function of the separate 
enantiomers of the chiral NSAIDs naproxen and Ibuprofen. In the last section, part Г , studies 
are presented on the transport mechanisms of salicylic acid and indomethacin in proximal 
tubular cells. Finally, the thesis is concluded with a summary. 
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ABBREVIATIONS 
aMG a-methylglucose 
DroS 4,4'-diisoÜiiocyanostilbene-2,2'-(lisulfonic acid 
DMBA 3,4-dimethoxybenzoic acid 
DMN desmethyl-naproxen 
d-NA naproxen, (+)-6-methoxy-a-methyl-2-naphtaleneacetic acid 
GFR glomerular filtration rate 
I/E ratio intracellular/extracellular concentration ratio 
IPK isolated perfused rat kidney 
K„ Michaelis-Menten constant (mM) 
K, Micbaelis-Menten constant of tubular secretory system 
(Mg/ml) 
K/P ratio 
1-NA 
MS 
NSATOs 
PAH 
PAS 
PT cells 
PG 
PGE, 
SA 
SU 
TAL 
т. 
V™ 
kidney to perfusate ratio 
(-)-6-metlioxy-a-methyl-2-naphtaleneacetic acid 
methamine silver 
nonsteroidal anti-inflammatory drags 
para-aminobippurate 
periodic acid Schiff 
proximal tubular cells 
prostaglandin 
prostaglandin E, 
salicylic acid 
salicyluric acid 
thick ascending limb 
maximum transport capacity of the tubular secretory 
system (jig/min) 
maximum rate of transport (nmol/mg protein.min) 
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1.1 NONSTEROIDAL ANTI-INFLAMMATORY DRUGS 
1.1.1 Historical development 
Salicylic acid (SA) is the oldest and the progenitor of the nonsteroidal anti-
inflammatory drugs (NSAIDs). Already in ancient times, there was a widespread use of plants 
containing salicylates for the treatment of pain, fever, inflammation and rheumatic diseases (12, 
92). In old Greece, Hippocrates used juices of the poplar tree and willow bark for the treatment 
of eye disease and pain in childbirth. The North-American indians used willow bark juice as an 
antipyretic and South African Hottentots drank similar mixtures as an antirheumatic. In the 
nineteenth century organic synthesis had developed so far that SA could be produced 
synthetically. From SA other NSAIDs were developed. Today at least 60 NSAIDs are on the 
market or reported in clinical literature (69, 114). They can be divided into several subclasses 
which are listed in table 1.1 (12, 25, 27, 49). Indomethacin has voy strong anti-inflammatory 
potency. Therefore, this drag has been used as a standard of comparison for other NSAIDs (87). 
Table 1.1. NSAID classes 
class class members 
salicylates salicylic acid 
acetylsalicylic acid 
diflunisal 
indoles indomethacin 
sulindac 
tolmetin 
propionic acids* ibuprofen 
ketoprofen 
fenoprofen 
naproxen 
suprofen 
fenamates mefenamic acid 
diclofenac sodium 
oxicams Piroxicam 
tenoxicam 
pyrazoles phenylbutazone 
oxyphenbutazone 
* Chiral compounds. 
1.1.2 Mechanisms of action 
NSAIDs are used for many therapeutic indications such as mild to moderate pain, 
fever, rheumatoid arthritis, and acute gouty arthritis (12). For a long time the mechanism of 
action of NSAIDs was unknown. Only in 1971 evidence was reported that these drugs act by 
inhibiting cyclo-oxygenase (37). This enzyme transforms aiachidonic acid to prostaglandin G2 
(27, 40, 114). From prostaglandin G2 several other prostaglandins and tromboxanes are formed. 
These substances play an important role in many physiological processes such as reproduction, 
blood pressure regulation, nervous system and renal function. However, many influences and 
effects of prostaglandins are still unknown. Thus, by the inhibition of cyclo-oxygenase, NSAIDs 
inhibit the prostaglandin synthesis. 
The potency of inhibiting the prostaglandin synthesis correlates well with the anti-
inflammatory potency for the classical acidic NSAIDs (38, 72). However, it has become clear 
that inhibition of cyclo-oxygenase alone is not sufficient to explain the mode of action of 
NSAIDs (12, 19, 35, 49). For example, weak cyclo-oxygenase inhibitors like nonacetylated 
salicylates have anti-inflammatory efficacy that is comparable to aspirin, which is a much more 
potent cyclo-oxygenase inhibitor (2). There are a number of different mechanisms potentially 
important for anti-inflammatory activity (12, 35, 49). All NSAIDs (at concentrations existing in 
vivo during medical use) appear to inhibit 15 - and 11 - lipoxygenase (101). These enzymes are 
involved in the generation of leukotrienes, a family of mediators of inflammation also produced 
from arachidonic acid (79). NSAIDs (at higher concentrations) inhibit the mitochondrial ATP 
synthesis by uncoupling of the oxidative phosphorylation (73, 105, 115). The disruption of the 
cellular energy production might also contribute to the anti-inflammatory activity. Furthermore, 
indomethacin is reported to inhibit the cyclic-AMP dependent protein kinase (57). This protein 
kinase is important for the function of cAMP as an intracellular messenger. NSAIDs appear to 
reach relatively high concentrations in inflamed areas (8, 47, 90, 91). Obviously, this 
accumulation is important for the anti-inflammatory action because NSAIDs reach concentrations 
in inflamed tissues which are high enough to inhibit the prostaglandin synthesis. Leukocyte 
Chemotaxis or migration, and other functions such as superoxide anion generation, lysosomal 
enzyme release, and leukocyte aggregation are also affected to a different extent by NSAIDs (1, 
2, 31, 84). These effects may be related to events associated with membrane calcium movement 
and not to the prostaglandin or leukotriene pathways (31, 49). NSAIDs are also able to inhibit 
the monocyte collagenase production and cell migration. This is probably caused by inhibition 
of the prostaglandin E synthesis (111). 
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1Л lODNEY STRUCTURE, FUNCTION AND DRUG TRANSPORT 
1.2.1 Kidney anatomy 
The main function of the kidney is to regulate the internal volume and the composition 
of the body fluids. It excretes waste products and toxic exogenous substrates. To perform its 
action, the kidney has a specific anatomical structure. The functional unit is the nephron. The 
human kidney contains about 1.10' nephrons and the rat kidney approximately ЗЛО9. The 
nephron consists of a glomerulus in which the blood is filtered, and a tubule. The tubule can be 
divided into several parts (figure 1.1): proximal convoluted and straight tubule, Henle's loop, 
distal convoluted tubule, connecting tubule, and collecting duct. Henle's loop can be divided in 
the descending thin limb, ascending thin limb, and the thick ascending limb. The tubule is 
surrounded by a single layer of epithelial cells. Along the tubule there are at least IS specialized 
cell types. A close network of arterial and venous capillaries provides a close contact between 
blood circulation and tubular cells. 
1.2.2 Filtration, reabsorption and secretion 
In the glomeruli arterial blood is filtered. Blood constituents with a molecular weight 
less than approximately 64.5 kDa are excreted in the glomerular filtrate. Per minute about 125 
ml fluid is filtered by human kidneys in the healthy adult. The driving force needed for this 
process is supplied by the hydrostatic blood pressure. The net filtration pressure is the resultant 
of the hydrostatic blood pressure, the intracapsular pressure, and the plasma colloid osmotic 
pressure. 
Less than 1 % of the filtrate leaves the body as urine. The composition of the urine is 
completely different from the filtrate. The changes in composition occur as the filtrate flows 
along the tubule. Several processes influence the filtrate composition: passive reabsorption, active 
reabsorption and active secretion. 
More than 99 % of the filtered water is reabsorbed along the tubule. This is a passive 
process driven by osmotic pressure differences. Due to this extensive reabsorption, concentration 
of solutes occurs in the filtrate. Because of the high concentration gradient between tubular fluid 
and blood, these solutes can diffuse passively from lumen to blood. However, such passive 
diffusion can only occur if the compounds are sufficiently lipophilic. At normal tubular fluid 
pH, acidic NSAJDs are sufficiently lipophilic because they are not ionized. As a result they can 
be reabsorbed passively. This process is dependent on the pK
a
 of the NSAID and the pH of the 
tubular fluid. Normally, tubular fluid is slightly acidic and NSAIDs such as SA are passively 
reabsorbed. If urinary pH is increased, non-ionic back-diffusion decreases and NSAID excretion 
increases (10, 24). Urinary flow is another important factor in passive diffusion. If water 
reabsorption decreases, urine flow will increase. As a result, the concentration of compounds in 
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Figure 2.1, Schematic representation of a nephron, the functional unit of the kidney (from [56] 
with permission). 
the filtrate is smaller, which leads to a decrease in passive reabsorption. 
Many valuable endogenous compounds, such as glucose and amino acids, are freely 
filtered by the kidney. Subsequently, they are actively reabsorbed by a carrier-mediated process. 
Under nonnal conditions no glucose is present in the urine. The active reabsorption of glucose 
occurs within the first part of the nephron, the proximal tubule. 
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Besides passive and active reabsorption, active secretion can take place. During the 
secretory process compounds are transported from blood, through the tubular cells, into the 
luminal fluid. Secretion is a selective carrier-mediated process. There are two different canier 
systems for organic compounds, one for organic anions and one for organic cations (20, 75, 
103, 107, 109). Secretion is limited by a maximum transport capacity and susceptible to 
competition by various substances which are transported by the same system (109). 
1Λ3 Secretion of organic compounds 
Active secretion of organic compounds occurs in the proximal tubule. The cells of the 
proximal tubule have two distinct membrane sites. One site facing the lumen, the brash-border 
membrane (BBM), and one site facing the interstitial fluid, the basolateral membrane (BLM). 
Organic anions and cations are substrates of two distinct secretory transport systems (95) (figure 
1.2). 
Lumen " N / \/* Blood 
NMN 
PAH 
Figure 1.2. Transport mechanisms of organic anions and cations in the proximal tubular cells. 
Shaded circles represent direct or indirect active transport carriers. Closed circles represent 
carriers for facilitated transport. NMN* (N-methyl-nicotinamide) is the prototype for organic 
cation transport and PAH" (p-aminohtppurate) is the prototype for organic anion transport. 
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Organic cations enter the cell across the BLM probably via facilitated diffusion. 
Secretion into the urine across the BBM occurs via a cation-proton exchanger (103). This 
process can be considered as tertiary active. Protons are excreted via the sodium-proton 
exchanger. The energy needed for this process steins from ATP, which is used by the sodium-
potassium ATPase to build up a sodium gradient. 
Organic anions are secreted in a similar way, although the active step lakes place at 
the BLM (8, 20, 75, 88, 97, 99, 107). Much of what is known about this secretory system, 
stems from investigations with p-aminohippurate (PAH) which is the prototype of organic 
anions. PAH is probably transported across the BLM into the cells via an anion exchanger. Like 
the cation transport, this process is tertiary active. The higher intracellular concentration of 
Krebs cycle intermediates, anions such as dicarboxylates, is the driving force for the exchange 
of an intracellular anion for PAH. These high concentrations are realized by the uptake of the 
intennediates into the cells simultaneously with sodium. The driving force of this process is the 
sodium gradient across the cell membrane which is created by the sodium-potassium ATPase. 
The latter carrier primarily delivers the energy required for the anion transport. After entering 
the cell, PAH leaves the cell down its concentration gradient via an anion exchanger across the 
BBM into the tubular fluid. The high intracellular concentration provides the driving force for 
the movement across the BBM into the tubular fluid. As a result of the active uptake of PAH 
across the BLM and the facilitated diffusion across the BBM, PAH can accumulate in the 
proximal tubular cells. 
13. NSAIDs AND KIDNEY FUNCTION 
1.3.1 Prostaglandins and the kidney 
Prostaglandins can exert a wide range of effects on kidney function (S, 28, 112). A 
schematic representation of these influences is given in figure 1.3 (S, 112, 117). 
There are several different cyclo-oxygenase products which are formed in the kidney, 
and which act at different sites. The most important cyclo-oxygenase products are prostaglandin 
E, (PGE,) and prostaglandin I2 (PGIj), which are both strong vasodilators. PGE, acts mainly as a 
medullary vasodilator, whereas PGI, has vasodilatory effects on the cortex and the medulla (112, 
117). 
Under normal conditions, the maintenance of renal function does not appear to be 
dependent on prostaglandins. However, in patients with mild or moderate impairment of renal 
function prostaglandins play a significant role in autoregulation. This is important for the 
occurrence of renal adverse effects of NSAIDs. 
22 
phospholipid 
phospholipase 
orachidonic acid 
ι 
cyclo-oxy genäse 
\r 
prostaglandins 
I 
¡ l i l i 
vasodilatation Cf reabsorption ADH 
1 in loop of Henle^ effect ¿ 
Ψ 
RBF ƒ 
Ψ 
GFR/ 
ψ > 
proxin 
reabsi 
\ 
water 
nal tubular , 
>rption ^ 
* \ 
and salt excretion^ 
aldost 
' 
> 
K* ex 
renin f 
e r o n e / 
cretion^t 
angiot ensin II/1 
\f 
vasoconstriction 
Figure 13. Schematic representation of the role of prostaglandins in kidney autoregulation. RBF 
= renal blood flow. GFR = glomerular filtration rate. ADH = anti-diuretic hormone. 
13.2 Effects of NSAIDs on kidney function 
NSAIDs are used widely. For example, it has been shown that more than 8 % of all 
persons in an open population are exposed to one or more NSAIDs (68). Due to their 
widespread use adverse reactions have become evident. Severe side-effects can occur on the 
gastrointestinal tract, the liver, and the kidney (12, 22, 93). On the kidney, NSAIDs can cause 
several clinical syndromes (11, 25, 27, 29, 30, 48, 77, 80, 81, 83, 114). A distinction can be 
made between chronic and acute effects. 
After chronic use of NSAIDs analgesic nephropathy can occur which is characterized 
by interstitial nephritis and papillary necrosis (25, 48, 114). The mechanism by which NSAIDs 
cause chronic nephrotoxicity is not known. As a result of inhibition of the prostaglandin 
synthesis, NSAIDs can change blood flow from the renal medulla to the cortex, causing 
medullary ischemia. This might be the initiating factor in the development of papillary necrosis. 
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Several more or less acute clinical features can be observed after using NSAIDs, e.g. 
disturbances of water and sodium balance with or without renal insufficiency and acute 
interstitial nephritis (11, 25, 27, 48, 80). 
Renal function reduction is most likely to occur in patients in which kidney function is 
more dependent on the adrenergic and renin-angiotensin system: patients with congestive heart 
failure, volume depletion, cirrhosis, shock states, preexisting renal disease and possibly advanced 
age. The increased norepinephrine and angiotensin Π levels in these patients result in renal 
vasoconstriction and a simultaneous increase in the synthesis of vasodilatory prostaglandins. As 
shown in figure 1.3, prostaglandins like PGE,, which is the most abundant prostaglandin in the 
kidney, cause vasodilation, an increase in renal blood flow and glomerular filtration rate, 
secretion of renin, sodium, and water diuresis (11, 80). In patients at risk, kidney function is 
largely dependent on prostaglandins and an inhibition of prostaglandin synthesis by NSAIDs 
leads to an enhanced renal vasoconstriction in combination with a diminished renal blood flow 
(36, 41, 43). 
Inhibition of the prostaglandin synthesis also results in a decrease in renin release 
which leads to a decrease in aldosterone release and an increase in potassium plasma levels (43, 
46). However, a direct action of prostaglandins and/or NSAIDs on potassium reabsorption or 
secretion is also possible. 
Many reports with contradictory results about the effects of NSAIDs on sodium and 
water balance have been published (4, 3, 13, 26, 28, 32, 58, 83, 110). Usually, NSAIDs are 
associated with water and salt retention. The mechanism of the effects on sodium excretion is 
not clear. They may be related to an aldosterone like effect, to redistribution of renal medullary 
blood flow, or to a direct antinatriuretic effect of the NSAIDs or of the prostaglandin synthesis 
inhibition. Water retention is probably the result of an enhanced effect of the antidiuretic 
hormone caused by prostaglandin synthesis inhibition and as a secondary effect of the salt 
retention. 
The clinical features of interstitial nephritis are massive proteinuria and renal 
insufficiency (13, 44, 70). The mechanism by which NSAIDs cause interstitial nephritis is 
unknown. A direct toxic effect or an influence on the lipo-oxygenase pathway is possible. 
133 Importance of NSAID pharmacokinetics: accumulation 
The pharmacokinetics of NSAIDs are important regarding their action and side-effects. 
Brune and coworkers showed in a large series of experiments that acidic NSAIDs reach higher 
concentrations in inflamed than in most other tissues throughout the body (16, 17, 18, 47, 89, 
90, 91). Because of this accumulation, NSAIDs are able to exert their action directly on the 
place where it is necessary. Accumulation is also seen in organs influenced by NSAIDs, 
stomach, liver, small intestine and kidney. High coocentratioiis of NSAIDs in these tissues can 
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exert a direct effect which might lead to the observed side-effects. 
NSAIDs can accumulate in the kidney as a result of the excretion process. The renal 
handling of NSAIDs probably involves glomerular filtration, active secretion, and passive 
reabsorption (10, 96, 97). Active secretion of NSAIDs can lead to concentration of drag in the 
kidney (42, 109). Practically all NSAIDs are weak acids and, therefore, are probably secreted by 
the organic anion transporter described in section 2.3 (SS). An indication for this is the finding 
that SA and indomethacin interfere with the transport of PAH (39, 108, 118). As a result of 
active uptake of drug into the cells across the BLM and facilitated transport down the 
electrochemical gradient out of the cells across the BBM, high intracellular drug conceatrations 
can be reached. For example, it has been shown that PAH can reach concentrations in the 
kidney more than 20 times higher than the plasma concentration (42). 
Another mechanism by which NSAIDs might accumulate in the kidney is passive back-
diffusion. Diffusion results from a high concentration gradient between tubular fluid and plasma. 
Luminal NSAID concentrations are higher than the plasma levels due to extensive water 
reabsorption and active NSAID secretion. Because urine is usually acidic, NSAIDs are non-
ionized and can pass the tubular cell membrane. As a result of this diffusion, intracellular drug 
concentrations will reach higher values than corresponding plasma concentrations. This 
concentration difference is the driving force for the diffusion of NSAIDs from cell into blood. 
The accumulation in the tubular cells, therefore, will be proportional to the concentration 
difference between urine and blood. Because the processes involved are passive, it is not likely 
that the resulting accumulation reaches high values. 
1.3.4 Drug interactions 
Adverse reactions can also occur as a result of interactions of NSAIDs with other 
drags (12, 14). Pharmacokinetic drag interactions can occur at several levels, such as renal 
handling of drags (excretion and reabsorption) and protein binding. 
NSAIDs can interact with other drugs at the level of renal handling by either 
competing for active tubular secretion or by changes in reabsorption. Most NSAIDs are organic 
acids and, therefore, subject to active secretion by the kidney. They will compete for transport 
with other anionic drugs. This type of interaction can have important clinical consequences. For 
example, the administration of an NSAID can lead to an mcreased plasma level of methotrexate, 
a cytostatic drag. This interaction is probably a result of competitie» for active secretion and 
can be fatal (71, 102, 104). The plasma level of NSAIDs can be also increased by this type of 
interaction. Probenecid, which has a high affinity for the organic anion transporter can compete 
with the secretion of NSAIDs. This leads to an increased NSAID plasma level and a prolonged 
half-life (96). 
Reabsorption can also be a source of drug interactions. NSAIDs are reabsorbed 
25 
passively, the extent of which is dependent on the tubular load, urinary flow and pH. An 
increase in the urinary pH leads to a decrease in reabsorption and, therefore, an increase in 
excretion. Such an increase in pH is observed when anti-acids, taken to ease gastric irritation, 
are used (12, 81). This type of drug interaction is used clinically in salicylate poisoning. 
Administration of sodium bicarbonate causes an increase in urinary pH, which enhances 
salicylate excretion. 
All NSAJDs bind highly to plasma proteins and interactions can occur with other 
highly bound drugs (12, 14). NSATOs might displace these drugs or they might be displaced by 
these drugs from plasma protein. This displacement can lead to changes in free and total plasma 
concentration, metabolism and excretion. The classical example of this type of interaction is the 
displacement of coumarin anticoagulants by phenylbutazone. 
Pharmacodynamic interactions can, for instance, occur at the level of prostaglandin 
synthesis. This type of interaction is related to patient factors, especially patients in which renal 
function is dependent on prostaglandin synthesis are susceptible. Drags which stimulate the 
prostaglandin synthesis, such as angiotensin-converting enzyme inhibitors, mteract with NSAJDs 
(4). The effects of diuretics, which increase water and salt excretion, can be also influenced by 
NSAIDs (59, 60, 65, 66, 113). NSATOs can reduce their effects by a direct interaction on renal 
tubular handling of salt and water or by an indirect interaction via prostaglandins (113). A 
pharmacokinetic interaction is also a possible mechanism for the effects of NSAIDs on diuretic 
efficacy (113). 
1.4. STEREOSELECTIVITY 
The 2-aiylpropionic acids are an important group of NSAIDs. These drugs possess one 
asymmetric carbon atom and can therefore occur as the S(+)- or the R(-)-eiiantiomer. Only the 
S-enantiomer appears to be pharmacologically active as determined by inhibition of the 
prostaglandin synthesis (3, 23, 106). Although the R-enantiomer has little or no anti-
inflammatory activity, most of the 2-arylpropionic acids are marketed as racemates. Only 
naproxen is marketed as the pharmacologically active S-enantiomer. The fact that these drugs 
are stereoisomers is often neglected and can lead to a misinterpretation of pharmacokinetics and 
drug disposition (6, 7, 33). In addition, little is known about the contribution of the separate 
enantiomers to the side-effects of NSAIDs. Because many enzymatic reactions are stereospecific, 
it is important to study both enantiomers separately. 
It has been shown that the pharmacokinetics of both stereoisomers of the 2-
arylpropionic drugs are distinct (45, 52, 53, 54, 55, 67, 86). If administered as the racemate, the 
S-enantiomer is predominant in plasma, because its half-life is longer due to the stereoselectively 
different disposition. The pharmacologically inactive R-enantiomer is inverted to the active S-
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Figure 1.4. Possible mechanisms for the stereoselective inversion of R-ibuprofen (R-IBUP) to S-
ibuprofen (S-IBUP), the pharmacologically active enantiomer. 
enantíomer (9, SO, 62, 63, 74, 76). Inversion from the S-enantiomer to the R-enantiomer does 
not occur. Figure 1.4 shows a possible mechanism for the inversion of R-ibuprofen to S-
ibuprofen (63, 78). The first step is the stereospecific metabolism of R-ibuprofen to R-ibuprofen-
CoA by acyl-CoA synthetase. S-ibuprofen is not a substrate for this enzyme. R-ibuprofen-CoA 
is racemized to S-ibuprofen-CoA by racemase, a nonstereospecific enzyme. The CoA thioesters 
of both stereoisomers are cleaved by an hydrolase to R- and S-ibuprofen. In this way R-
ibuprofen can be inverted to its enantiomer while the inversion of S-ibuprofen does not occur. 
The liver appears to be the major organ of enantiomeric inversion. Kidney, diaphragm, hing, 
muscle, smooth muscle, fat and small intestines are at least SO times less active in inverting the 
R-enantiomer as compared to the liver (62, 63). Because of this stereoinvemon, it is difficult to 
determine in in vivo experiments whether renal handling of these drugs is stereoselective. 
Chiral NSAIDs bind highly to plasma proteins in a stereospecific manner (34, 51, 61, 
100). This leads to different free drug concentrations of both enantiomers. Because the rate by 
which a drug is filtered through the kidney is dependent on the unbound drag concentration, the 
stereospecific plasma protein binding of the 2-arylpropionic acids can lead to differences in renal 
handling. However, these differences will probably be small because active secretion and passive 
reabsorption are the most important processes in renal handling of NSAIDs. Glomerular filtration 
contributes little to the excretion. 
The different three-dimensional structure of the stereoisomers might have an effect on 
the way these substrates are secreted by the proximal tubular cells. Their affinity for the carrier 
systems can differ or one of the enantiomers might not be a substrate for the carrier. As a 
result, accumulation of both stereoisomers could be different which could lead to differences in 
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effects on renal function. However, such a stereoselective renal pharmacokinetic behaviour does 
not seem very likely. Studies with chiral compounds have shown that examples of a 
stereoselective renal clearance are few and in those few cases, the differences were not large 
(21, 116). 
1.5 CONCLUDING REMARKS AND OBJECTIVES 
Although NSAIDs are used widely already for a long time, the mechanisms by which 
they exert effects on kidney function are not completely understood. Inhibition of the 
prostaglandin synthesis is important, but this alone cannot explain the effects on kidney function. 
The way these drugs are handled by the kidney is probably also important It has been shown 
that they accumulate in the kidney, probably as a result of active secretion. Passive reabsorption 
might also contribute to accumulation. As a result of accumulation, NSAIDs might exert a direct 
or indirect effect on kidney function. Obviously, it is important to know to what extent these 
drags accumulate in the kidney. 
Renal handling is also important because it is a potential source of drug interactions. 
NSAIDs are probably secreted via a carrier-mediated process. As a result, their clearance or the 
clearance of the interacting drug could be influenced. 
Thus far, not much attention has been given to the fact that many NSAIDs exist as 
racemates. Except for naproxen, all other chiral NSAIDs are marketed as racemates. Only the S-
enantiomer is pharmacologically active, and (he specific contribution of both enantiomers to the 
side-effects is unknown. It is evident that а рторег understanding of the effects of both 
enantiomers on kidney function as well as the renal handling could be important, clinically as 
well as scientifically. 
Phannacodynamically NSAIDs do not differ very much. However, considerable 
differences exist in their pharmacokinetic behaviour, which can lead to differences in renal side-
effects. Therefore, characterization of renal disposition and effects of NSAIDs might contribute 
to a more rational use of these drugs possible. The objectives of the studies described in this 
thesis can be summarized as: 
I characterization of renal effects of NSAIDs. 
II characterization of renal transport, especially accumulation, of NSAIDs. 
ΠΙ determination of the contribution of enantiomers to renal effects and transport of chiral 
NSAIDs. 
28 
1.6 REFERENCES 
1. Abramson S., Edelson H., Kaplan N.B., Given W., Korchak RM., and Weissmann G.: Differing 
effects of non-steroidal anti-inflammatory agents on neutrophil function in vitro and in vivo. Arthritis 
Rheum. 25: 37A (1982). 
2. Abramson S., Korchak H., Ludewig R., Edelson H., Haines K., Levin RX, Herman R., Rider L., 
Rimmel S., and Weissmann G.: Modes of action of aspirin-like drugs. Proc. Nad. Acad. Sci. 82: 
7227 - 7231 (1985). 
3. Adams S.S., Bresloff P., and Mason CG.: Pharmacological differences between the optical isomers 
of iboprofen: evidence fot metabolic inversion of the (-)-isomer. J. Pharm. Phannac. 28: 256 - 257 
(1976). 
4. AUon M., Pasque C.B., and Rodriguez M.: Interaction of Captopril and iboprofen on glomenilar and 
tubular function in humans. Am. J. Physiol. 259: F233 - F238 (1990). 
5. Anderson R.J., Bed T., McDonald K.M., and Schrier R.W.: Prostaglandins: effects on Hood 
pressure, renal blood flow, sodium, and water excretion. Kidney Int IO. 205 - 215 (1976). 
6. Ariens EJ.: Stereochemistry, a basis for sophisticated nonsense in pharmacokinetics and clinical 
pharmacology. Eur. J. Clin. Pharmacol. 26: 663 - 668 (1984). 
7. Aliens E J., Wuis E.W., and Veringa EJ.: Stereoselectivity of bioactive Xenobiotics: a pre-pastenr 
attitude in medicinal chemistry, pharmacokinetics and clinical pharmacology. Biochem. Pharmacol. 
37: 9 - 18 (1988). 
8. Aronson P.S.: The renal proximal tubule: a model for diveisity of anion exchangers and stilbene-
sensitive anion transporters. Anna Rev. PhysioL 51: 419 - 441 (1989). 
9. ВаіШе T.A., Adams W.J., Kaiser D.G., Olanoff L.S., Halstead G.W., HaipootHan H., and Van 
Giessen G.J.: Mechanistic studies of the metabolic chiral inversion of (RHboprofen in humans. J. 
Pharmacol. Exp. Tber. 249: 517 - 523 (1989). 
10. Bekersky I., Rshman L., Kaplan S.A., and Colbum W.A.: Renal clearance of salicylic add and 
salicyluric acid in the rat and in the isolated perfused rat kidney. J. Pharmacol. Exp. Tber. 212: 309 
- 314 (1980). 
11. Blacksbear J.L., Napier J.S., Davidman M., and Stillman M.T.: Renal complications of nonsteroidal 
antiinflammatoiy drags: identification and monitoring of those at risk. Sem. in Arthritis and Rheum. 
14: 163 - 175 (1985). 
12. Boyton CS., Dick CF., and Mayor GJL: NSAIDs: an overview. J. Clin. PhannacoL 28: 512 · 517 
(1988). 
13. Brater D.C., Anderson S., Baird В., and Campbell W.B.: Effects of ibuprofen, naproxen, and 
sulindac on prostaglandins in men. Kidney Int. 27: 6 6 - 7 3 (1985). 
14. Brater D.C.: Clinical phaimacology of NSAIDs. J. Clin. Pharmacol. 28: 518 - 523 (1988). 
15. Brezin J.H., Katz S.M, Schwartz A.B., and Chinitz J-L: Reversible renal failure and nephrotic 
syndrome associated with nonsteroidal anti-inflammatory drags. N. Engl. J. Med. 301: 1271 - 1273 
(1979). 
29 
16. Brune К., Ciaf P., and Glatt M.: Inhibition of prostaglandin synthesis in vivo by nonsteroid anti­
inflammatory drags: evidence for the importance of pharmacokinetics. Agents Actions 6: 159 - 164 
(1976). 
17. Brune К.: The importance of phaimacokinetics for the acton of nonsteroid anti-inflammatory drugs. 
Gin. Pharmacokinetics. Proc. Int Symposium at Salzgitter - Ringelheim. Ritschel W.A. (ed), 
Stuttgart - New Yoric 96 - 104 (1977). 
18. Brune К., Rainsford K.D., and Schweitzer Α.: Biodistribution of mild analgesics. Br. J. clin. 
Phaimac. 10: 279S - 284S (1980). 
19. Brune К., and Lanz R.: Mode of action of peripheral analgesics. Drag Res. 34: 1060 - 1065 (1984). 
20. Burckhardt G., and Ullrich K.J.: Organic anion tranport across the contralumina] membrane -
dependence on sodium. Kidney Int. 36: 370 - 377 (1989). 
21. Campbell D.B.: Stereoselectivity in clinical phaimacokinetics and drag development Eur. J. Drag 
Metab. PhaimacoJdn. 15: 109 • 125 (1990). 
22. Carson J.L., and Strom B.L.: The gastrointestinal side effects of the nonsteroidal anti-inflammatory 
drags. J. Clin. Pharmacol. 28: 554 - 559 (1988). 
23. Cerletti C, Manarini S., Colombo M, and Tavani Α.: The (+)-enantiomer is responsible for the 
antiplatelet and anti-inflammatory activity of (±)-indobufen. J. Pharm. PharmacoL 42: 885 - 887 
(1990). 
24. Charten J-Y., Besseghir K., and Roch-Ramel F.: Salicylic acid permeability properties of the rabbit 
cortical collecting duct. Am. J. Physiol. 259: F613 - F618 (1990). 
25. Clive D.M., and Stoff J.S.: Renal syndromes associated with nonsteroidal antiinflammatory drags. N. 
Engl. J. Med. 310: 563 - 572 (1984). 
26. Cordova H.R., Kokko J.P., Marver D.: Chronic indomethacin increases rabbit cortical collecting 
tubule Na*-K*-ATPase activity. Am. J. Physiol. 256: F570 - F576 (1989). 
27. Deventer van S.J.H., and Statius van Eps L.W.: Acute nierfunctiestooniissen door niet-steroïdale 
anti-inflammatoire fannaca. Ned. Tijdschr. Geneeskd. 130: 721 - 725 (1986). 
28. Dunn M.J., and Hood V.L.: Prostaglandins and the kidney. Am. J. Physiol. 233: F169 - F184 
(1977). 
29. Dunn M.J., and Zambraski EJ.: Renal effects of drags that inhibit Prostaglandin synthesis. Kidney 
Int. 18: 609 - 622 (1980). 
30. Dunn MJ., Simonson M., Davidson E.W., Schaischmidt LA., and Sedor JJt.: Nonsteroidal anti-
inflammatory drugs and renal function. J. Clin. Pharmacol. 28: 524 - 529 (1988). 
31. Edelson H.S., Kaplan H.B., Korchak KM., and Weissmann G.: Differing effects of non-steroidal 
anti-inflammatory agents on neutrophil functions. Clin. Res. 30: 469A (1982). 
32. Eriksson L-O., Beermann В., and Kallner M.: Renal function and tubular transport effects of 
sulindac and naproxen in chronic heart failure. Clin. Pharmacol. Ther. 42: 646 - 654 (1987). 
33. Evans A.M., Nation R.L., Sansom L.N., Bochner F., and Somogyi A.A.: Stereoselective drag 
disposition: potential for misinterpretation of drag disposition data. Br. J. clin. Phaimac. 26: 771 -
780 (1988). 
34. Evans A.M., Nation R.L., Sansom L R , Bochner F., and Somogyi A.A.: Stereoselective plasma 
protein binding of ibuprofen enantiomeis. Eur. J. Clin. Pharmacol. 36: 283 - 290 (1989). 
30 
35. Famaey J.P.: Recent developments about non-steroidal anti-inflammatory drags and their mode of 
action. Gen. Phaimac. 9: 155 - 162 (1978). 
36. Fawaz-Estrup F., and Ho G.: Reversible acute renal failure induced by indomethacin. Arch. Intern. 
Med. 141: 1670 - 1671 (1981). 
37. Ferreira S.H., Moneada S., and Vane J.R.: Indomethacin and aspirin abolish prostaglandin release 
from the spleen. Nature 231: 237 - 239 (1971). 
38. Ferreira S.H., and Vane J.R.: Aspirin and Prostaglandins. In: Prostaglandins. Ramwell P.W. (ed). 
Plenum Press, New York, vol. 2: 1 - 47 (1974). 
39. Ferner В., Martin M., and Roch-Ramel F.: Effects of p-aminohippurate and pyrazinoaie on the renal 
excretion of salicylate in the rat: a micropuncture study. J. Pharmacol Exp. Ther. 224: 451 - 458 
(1983). 
40. Flower R.J.: Drugs which inhibit prostaglandin biosynthesis. Pharmacol. Rev. 26: 33 · 67 (1974). 
41. Fong HJ., and Cohen A.H.: Ibuprofen-induced acute renal failure with acute tubular necrosis. Am. 
J. Nephrol. 2: 28 - 31 (1982). 
42. Foster R.P., and Copenhaver J.H.: Intracellular accumulation as an active process in a mammalian 
renal transport system in vitro. Am. J. Physiol. 186: 167 - 171 (1956). 
43. Caller M., FoUcert V.W., and Schlondorf D.: Reversible acute renal insufficiency and hypedcalemia 
following indomethacin therapy. JAMA, July 10: 154 - 155 (1981). 
44. Gary N.E., Dodelson R., and Eisinger R.P.: Indomethacin-associated acute renal failure. Am. J. 
Med., 2: 135 - 136 (1980). 
45. Geisslinger G., Schuster O-, Stock K.-P., Loew D., Bach G.L., and Brune К.: Pharmacokinetics of 
S(+)- and R(-)-ibuprofen in volunteers and first clinical experience of S(+)-ibuprofen in rheumatoid 
arthritis. Eur. J. Clin. Pharmacol. 38: 493 - 497 (1990). 
46. Goldszer R.C., Coodley EX., Rosner MJ., Simons W.M., and Schwartz A3.: Hypedcalemia 
associated with indomethacin. Arch. Intern. Med. 141: 802 - 804 (1981). 
47. Graf P., Glatt M., and Brune К.: Acidic nonsteroid anti-inflammatory drugs accumulating in 
inflamed tissue. Experientia 31: 951 - 953 (1975). 
48. Henrich W.L.: Southwestern internal medicine conference: analgesic nephropathy. Am. J. Med. Sci. 
295: 561 - 568 (1988). 
49. Hess E.V., and Tangnijkul Y.: A rational approach to NSAID therapy. Rational Drag Therapy 20: 1 
- 7 (1986). 
50. Him A.J., and Caldwell J.: The metabolic chiral inversion of 2-агу1рторіошс acids - a novel route 
with pharmacological consequences. J. Pharm. Pharmacol 35: 693 - 704 (1983). 
51. Iwakawa S., Spahn H., Benet L.Z., and Lin E.T.: Stereoselective binding of the glucuronide 
conjugates of caiprofen enantiomers to human serum albumin. Biochem. Pharmacol. 39: 949 -953 
(1990). 
52. Jamali F.: Pharmacokinetics of enantiomers of dural non-steroidal anti-inflammatory drugs. Eur. J. 
Drug Metab. Pharmacokin. 13: 1 - 9 (1988a). 
53. Jamali F., Berry B.W., Tehrani M.R., and Russell A.S.: Stereoselective Pharmacokinetics of 
Flurbiprofen in humans and rats. J. Pharmac. Sci 77: 666 - 669 (1988b). 
31 
54. Jamali F., Russell A.S., Foster R.T., and Lemko С: Ketoprofen pharmacokinetics in humans: 
evidence of enantiomeric inversion and lack of interaction. J. Pharmac. Sci. 79: 460 - 461 (1990). 
55. Jansen H.M.L., Rüssel F.G.M., Wouterse A.C., Gribnau F.W.J., and van Ginneken CAM.: Renal 
handling of indomethadn: isolated membrane vesicles of proximal tubular cells as an in vitro model 
system for transport. Neth. J. Med. 35: 137 - 142 (1989). 
56. Junqueira L.C., Cameiro J., and Contopoulos A.N.: Basic histology. Lange Medical Publications, Los 
Altos: 356 (1975). 
57. Kantor H.S., and Hampton M: Indomethacin in submicromolar concentrations inhibits cyclic AMP-
dependent protein kinase. Nature 276: 841 - 842 (1978). 
58. Kaojaiem S., Chennavasin P., Anderson S., and Bieter D.C.: Nephron site of effect of nonsteroidal 
anti-inflammatory drugs on solute excretion in humans. Am. J. Physiol. 244: F134 - F139 (1983). 
59. Kirchner K.A.: Role of medullaiy plasma flow in the attenuated furosemide response in 
indomethacin-treated rats. J. PharmacoL Exp. Ther. 249: 757 - 761 (1989). 
60. Kirchner K.A., Martin C.J., and Bower JX>.: Prostaglandin E, but not Ij restores furosemide 
response in indomethacin-tieated rats. Am. J. Physiol. 250: F980 - F985 (1986). 
61. Knadler MP., Brater D.C., and Hall S.D.: Plasma protein binding of flurbiprofen: enantioselectivity 
and influence of pathophysiological status. J. PharmacoL Exp. Ther. 249: 378 -385 (1989). 
62. Knadler MP., and Hall S.D.: Stereoselective arylpropionyl-CoA thiœster formation in vitro. 
Chirality 2: 67 - 73 (1990). 
63. Kmhinidd R.D., Williams KM., and Day R.O.: Chini inversion of 2-aiylpropiorac add non-
steroidal anti-inflammatory drugs - 1. Biochem. Pharmacol. 38: 4389 - 4395 (1989). 
64. Kmhinidd RJ)., Day R.O., Graham G.G., and Williams K-M..: Stereoselective disposition of 
Ibuprofen and flurbiprofen in rats. Chirality 2: 134 - 140 (1990). 
65. Koopmans Ρ J*., Thien Th., and Gribnau F.WJ.: Influence of non-steroidal anti-inflammatory drugs 
on diuretic treatment of mild to moderate essential hypertension. Br. med. J. 289: 1942 - 1944 
(1984). 
66. Koopmans PP., Kateman W.GP.M, Tan Y., van Ginneken C.A-M., and Gribnau F.WJ.: Effects of 
indomethacin and suHndac on hydrochlorothiazide kinetics, din. Pharmac. Ther. 37: 625 - 628 
(1985). 
67. Lee EJ.D., Williams K, Day R-, Graham G., and Champion D.: Stereoselective disposition of 
Ibuprofen enantiomers in man. Br. J. din. Pharmac. 19: 669 - 674 (1985). 
68. Leu&ens KG., AmeUng C.B., Hekster Y.A., and Bakker Α.: Utilization patterns of non-steroidal 
anti-inflammatory drugs in an open Dutch population. Pharm. WeekbL [Sd.] 12: 97 - 103 (1990). 
69. Lombaidlno J.G.: Medicinal chemistry of aridic nonsteroidal anti-inflammatory drugs. In: 
Nonsteroidal anti-inflammatory drugs. Lombardino J.G. (ed). New York, John Wiley and Sons, 253 -
431 (1985). 
70. Lomvardias S., Finn V.W., Wadhwa ML., Koshy KM., and Heller M: Nephrotic syndrome 
associated with sulindac N. Engl. J. Med. 304: 424 (1981). 
71. Maiche A.G.: Acute renal failure due to concomitant action of methotrexate and indomethacin. 
Lancet, 1: 1390 (1986). 
32 
72. Matsuda К., Ohnishi К., Misaka E., and Yamazald M: Decrease of urinary prostaglandin E, and 
prostaglandin F l a excretion by nonsteroidal anti-inflammatory drugs in rats. Biochem. Pharmacol 
32: 1347 - 1352 (1983). 
73. McDougall P., Maikham Α., Cameron I., and Sweetman AJ.: The mechanism of inhibition of 
mitochondrial oxidative phosphorylation by the non-steroidal anti-inflammatoiy agent гііПипіяаІ 
Biochem. PharmacoL 32: 2595 - 2598 (1983). 
74. Meffin P.J., Sallustio B.C., Purdie Y.J., and Jones M.E.: Enantioselective disposition of 2-
aiylpropionic acid nonsteroidal anti-inflammatory drugs. 1. 2-phenylpiopiomc acid disposition. J. 
PharmacoL Exp. Tlier. 238: 280 - 287 (1986). 
75. M0ller J.V., and Sheikh MI.: Renal organic anion transport system: pharmacological, physiological, 
and biochemical aspects. Pharmacol. Rev. 34: 315 - 358 (1983). 
76. Müller S., Mayer J.M., Etter J-C, and Testa В.: Metabolic chiial inversion of Ibuprofen in isolated 
rat hepatocytes. Chirality 2: 74 - 78 (1990). 
77. Murray M.D., and Brater D.C.: Adverse effects of nonsteroidal anti-inflammatory drags on renal 
function. Ann. Int. Med. 112: 559 - 560 (1990). 
78. Nakamura Y., Yamaguchi T., Takahashi S., Hashimoto S., Iwatani K., and Nakagawa Y.: Optical 
isomeiization mechanism of R(-)-hydiatropic acid derivatives. J. Pharm. Dyn. 4: S-l (1981). 
79. Newcombe D.S.: Leukotrienes: regulation of biosynthesis, metabolism, and bioactivity. J. Clin. 
PharmacoL 28: 530 - 549 (1988). 
80. Oberle O.P., and Stahl R.A.K.: Akute Nebenwirkungen nicht-steroidaler Antiphlogistika auf die 
Nieren. Dtsch. Med. Wschr. 115: 309- 314 (1990). 
81. O'Brien Vi M.: Pharmacology of nonsteroidal anti-inflammatory drugs. Am. J. Med. 2: 32 -39 
(1983). 
82. Ochs RR., Greenblatt DJ., Matlis R., and Weinbrenner J.: Interaction of ibuprofen with the H,-
receptor antagonists ranitidine and Cimetidine. Clin. Pharmacol. Ther. 38: 648 - 651 (1985). 
83. Onne MX.: Non-steroidal anti-inflammatory drugs and the kidney. Br. Med. J. 292: 1621 - 1622 
(1986). 
84. Partsch G., Schwarzer С, and Eberi R.: The effects of ibuprofen and diclofenac on the Chemotaxis 
and adenosine triphosphate level of polymorphonuclear cells in vitro. J. Rheum. 17: 583 - 588 
(1990). 
85. Passmore ΑΡ., Copeland S., and Johnston G.D.: The effects of ibuprofen and indomethacin on 
renal function in the presence and absence of frusemide in healthy volunteers on a restricted sodium 
diet. Br. J. clin. PhaimacoL 29: 311 - 319 (1990). 
86. Pedrazzini S., De Angelis M, Muciaccia W.Z., Sacchi С, and Forgione Α.: Stereochemical 
phannacokinetics of the 2-aiylpropionic acid non-steroidal antiinflammatory drug flunoxaprofen in 
rats and in man. Drug Res. 38: 1170 - 1175 (1988). 
87. Potter R.S.: Factors determining efficacy of NSAIDs. Drug Intell. Clin. Pharmacy 18: 42 - 51 
(1984). 
88. Pritchard J.B.: Coupled transpon of p-aminohippurate by rat kidney basolateral membrane vesicles. 
Am. J. PhysioL 255: F597 - F604 (1988). 
33 
89. Putney J.W., and Borzelleca J.F.: Active accumulation of '4C-salicylic acid by rat kidney cortex in 
vitro. J. Phaimacol. Exp. Ther. 186: 600 - 608 (1973). 
90. Rainsford K.D., Schweitzer Α., and Brane K.: Autoradiographic and biochemical observations on the 
distribution of non-steroid anti-inflammatory drugs. Arch. int. Phaimacodyn 250: 180 - 194 (1981). 
91. Rainsford KJD., Schweitzer Α., and Brane K.: Distribution of the acetyl compared with the salicyl 
moiety of acetylsalicylic acid. Biochem. Pharmacol. 32: 1301 - 1308 (1983). 
92. Rainsford K.D.: Aspirin and the salicylates. Butterwoth & Co. Ltd (publishers). The Thetford Press 
Ltd, Thetford, Norfolk (1984a). 
93. Rainsford K.D.: Side-effects of anti-inflammatoiy analgesic drugs: renal, hepatic and other systems. 
Trends Pharmacol. Sci. 5: 205 - 208 (1984b). 
94. Roch-Ramel F., Roth L., Amow J., and Weiner I.M.: Salicylate excretion in the rat; free flow 
micropuncture experiments. J. Pharmacol. Exp. Ther. 207: 737 - 746 (1978). 
95. Ross CR., and Holohan P.D.: Transport of organic anions and calions in isolated renal plasma 
membranes. Ann. Rev. Phaimacol. Toxicol. 23: 65 - 85 (1983). 
96. Runkel R., Mroszczak E., Chaplin M., Sevelius H., and Segre E.: Naproxen-probenecid interaction. 
Clin. Pharmacol. Ther. 24: 706 - 713 (1978). 
97. Rüssel F.G.M, van der Linden P.E.M., Vermeulen W.G., Heijn M, van Os C.H., van Ginneken 
C.A.M.: Na* and H* gradient-dependent transport of p-aminohippurate in membrane vesicles from 
dog kidney cortex. Biochem. Pharmacol. 37: 2639 - 2649 (1988). 
98. Schild L., and Roch-Ramel F.: Transport of salicylate in proximal tubule (S, segment) isolated from 
rabbit kidney. Am. J. Physiol. 254: F554 - F561 (1988). 
99. Shimada H., Moewes В., and Burckhardt G.: Indirect coupling to Na* of p-aminohippuric acid 
uptake into rat renal basolateral membrane vesicles. Am. J. Physiol. 253: F795 - F801 (1987). 
100. Siebler D., and Kinawi Α.: Bindung von razemischem Indoprofen und seiner Enantiomeren an 
Humanserumalbumin. Drag Res. 39: 659 - 660 (1989). 
101. Siegel M.I., McConnel R.T., and Porter N.A.: Aspirin-like drugs inhibit arachidonic acid metabolism 
via lipoxygenase and cydo-oxygenase in rat neutrophils from carrageenin pleural exudates. Biochem. 
Biophys. Res. Commun. 92: 688 - 695 (1980). 
102. Singh R.R., Malaviya A.N., Pandey J.N., and Guleria J.S.: Fatal interaction between methotrexate 
and naproxen. Lancet 1: 1390 (1986). 
103. Somogyi Α.: New insights into the renal secretion of drags. Trends Pharmacol. Sci. 8: 354 - 357 
(1987). 
104. Thyss Α., Milano G., Kubar J., Namer M, and Schneider M.: Clinical and pharmacokinetic evidence 
of a life-threatening interaction between methotrexate and ketoprofen. Lancet 1: 256 - 258 (1986). 
105. Tokumitsu Y., Lee S., and Ui Michio: In vitro effects of nonsteroidal anti-inflammatory drugs on 
oxidative phosphorylation in rat liver mitochondria. Biochem. Pharmacol. 26: 2101 - 2106 (1977). 
106. Tomlinson R.V., Ringold H.J., Qureshi M.C., and Forchielli E.: Relationship between inhibition of 
prostaglandin synthesis and drug efficacy: support for the current theory on mode of action of 
aspirin-like drugs. Biochem. Biophys. Res. Commun. 46: 552 - 559 (1972). 
107. Ullrich KJ., and Rumrich G.: Contraluminal transport systems in the proximal renal tubule Involved 
in secretion of organic anions. Am. J. Physiol. 254: F453 - F462 (1988a). 
34 
108. Ullrich KJ., Rumrich G., and Klöss S.: Contraluminal para-aminohippuiale (PAH) transport in the 
proximal tubule of the rat kidney. PflUgeis Arch. 413: 134 - 146 (1988b). 
109. Van Ginneken C.A.M, and Rüssel F.G.M.: Saturable phannacokinetics in the renal excretion of 
drugs. Clin. Pharmacokin. 16: 38 - 54 (1989). 
110. Vieihapper H., Jörg J., and WaldhSusl W.: Effect of acetylsalicylic add and of indomethadn on 
diuresis in man: the role of cyclo-oxygenase inhibition. Clin. Sci. 67: S79 - S83 (1984). 
111. Wahl L.M., Olsen CE., Sandberg AX., and Mergenhagen S.E.: Prostaglandin regulation of 
macrophage collagenase production. Proc. Natl. Acad. Sd. 74: 49S5 - 4958 (1977). 
112. Walker L.A., and FrOlich J.C.: Renal prostaglandins and leukotnenes. Rev. Physiol. Biochem. 
Pharmacol. 107: 1 - 72 (1987). 
113. Webster J.: Interactions of NSATOs with diuretics and ß-blockeis mechanisms and clinical 
implications. Drugs 30: 32 - 41 (1985). 
114. Wegmttller E.: Nicht-steroidale Antiiheumatika und Nephrotoxizitat Dtsch. Med. Wschr. 110: 469 · 
472 (1985). 
115. Whitehouse M.W.: Some biochemical and phaimaccdogical properties of anti-inflammatory drags. 
Drag Res. 8: 321 - 429 (1965). 
116. Yamaguchi T., and Nakamura Y.: Stereoselective disposition of hydratropic add in rat. Drug Metab. 
Disp. 13: 614 - 619 (1985). 
117. Yoshida M., Ueda S., Soejima H., Tsumta K., and Dcegami K.: Effects of prostaglandin E, and I, on 
renal cortical and medullary blood flow in rabbits. Arch. int. Phaimacodyn. 282: 108 - 117 (1986). 
118. Zeeuw de D., Jacobson H.R., and Brater D.C.: Indomethadn secietioa in the isolated perfused 
proximal straight rabbit tubule. J. Clin. Invest 81: 1585 - 1592 (1988). 
35 

CHAPTER 2 
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2.1 ABSTRACT 
An isolated perfused rat kidney (IPK) preparation is described in which renal perfusion 
flow, perfusion pressure, urinary flow, urinary pH, and GFR are recorded continuously during 
the perfusion experiment The usefulness of this IPK system in studying the renal handling and 
the effects of nonsteroidal anti-inflammatory drugs (NSAIDs) is shown using salicyluric acid 
(SU), salicylic acid (SA), and naproxen (NA). Excretion of SU involves glomerular filtration, 
active secretion, and passive reabsorption. The excretion rates of SA and NA were both much 
lower than their filtration rate, indicating extensive reabsorption. All three drugs accumulate in 
the IPK but at different levels. SU accumulates much more than either SA or NA. The effects 
on renal function were diffferent for the three drugs studied. SU had no effect on kidney 
function. SA perfusate concentrations greater than 100 μ&ΊηΙ caused diuresis and natriuresis, 
while SA concentrations less than 100 μg/ml did not influence kidney function. NA perfusate 
concentrations ranging from 0.16 to 25 ц^ті caused a decrease in urinary flow and sodium 
excretion. Very high NA concentrations ( > 500 μg/ml) caused an increase in urinary flow and 
sodium excretion. We conclude that the IPK is a suitable preparation for characterizing and 
comparing renal handling and effects of NSAIDs. 
2.2 INTRODUCTION 
The isolated perfused rat kidney (IPK) was introduced by Weiss, Passow, and 
Rothstein (1959) for studying the regulation of renal blood flow. It is now often used to study 
physiological and biochemical aspects of renal function (Ross, 1978). It can also be used as a 
tool in drug disposition studies (Bekersky, 1983; Hall and Rowland, 1984; Lee et ai, 1986; Mc. 
Dougall and Wiegmann, 1988; Hon et al., 1988). The advantages of this preparation are 
obvious, since variables can be changed in a controlled manner and nervous and hormonal 
influences are eliminated. 
In this report we describe the use of an IPK preparation in studying renal disposition 
and effects of nonsteroidal anti-inflammatory drugs (NSAIDs). Salicylic acid (SA), its major 
metabolite salicyluric acid (SU), and naproxen (NA) were examined. 
Renal handling of drugs can involve several mechanisms. Drugs can be filtered through 
the glomerulus, they can be secreted actively by the tubular cells and they can be reabsorbed 
either by passive back-diffusion or active reabsorption. Due to their high lipophilicity, most 
NSAIDs are reabsorbed extensively by passive back-difffusion which depends on the urinary pH 
and flow. NSAIDs are probably also transported actively. It has been shown that SA is secreted 
actively by (he proximal tubular cells (Roch-Ramel et al., 1978). Tubular secretion may result in 
accumulation of drug in renal cells because active uptake from plasma into the cells across the 
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basolateral membrane is usually followed by (facilitated) diffusion across the brush-border 
membrane into the tubular lumen. Some NSAIDs have been shown to accumulate in the kidney 
(Brune et al., 1980). 
NSAIDs, such as SA and NA, are known to exert nephrotoxic action (Rainsford, 1984; 
Clive and Stoff, 1984). NSAIDs may damage the kidney leading to papillary necrosis and 
chronic interstitial nephritis (Rainsford, 1984). Inhibition of prostaglandin synthesis probably is 
the major mechanism by which NSAIDs exert their influence on the kidney (Dunn et al., 1988). 
However, the transport mechanisms and the accumulation of NSAIDs in tubular cells might also 
play a role in their nephrotoxicity (Brune et al., 1980). 
Contradictory reports on the influence of NSAIDs on renal function have been 
published. Most authors describe that SA causes diuresis and natriuresis (Zambraski et al., 1988a 
and 1988b; Quintanilla and Kessler, 1973), but also a reduction in water and salt excretion has 
been reported (Hetzel et al., 1959). Studies with NA also gave contradictory results. Dixey et al. 
(1987) reported that NA decreased sodium, chloride, and potassium excretion, while Brater et al. 
(1985) found no influence on renal function. 
Renal handling and effects on kidney function of NSAIDs appear to vary with different 
NSAIDs. Therefore characterization in a well defined system may increase our insight as to the 
manner in which NSAIDs develop their nephrotoxic action. In this report, we describe the 
usefulness of the IPK as such a system. 
2 J METHODS 
Materials 
Sodium pentobarbital was obtained from Aphanno (Ambem, The Netherlands). Heparin, 
insulin and aldosterone were from Organon (Oss, The Netherlands). Pluronic F-108 was 
purchased from BASF (Amhem, The Netherlands), lysine-vasopressin from Sandoz (Basel, 
Switzerland) and angiotensin Π from Beckmann (Palo Alto, Calif., USA). Syntbamin 14 was 
from Travenol (Thetford, Norfolk, England). Salicyluric acid, 3,4-dimethoxy benzoic acid and 
LiChrosorb RP-18 woe from Merck (Darmstadt, FRG). Sodium salicylate was obtained from 
O.P.G. (Utrecht, The Netherlands). Naproxen (S-(+)-6-methoxy-a-methyl-2-naphthaIeneacetic 
acid) was from Sigma (StXouis, Mo., USA). Ethoxy-naproxen was from Syntex Research (Palo 
Alto, Calif., USA). All other chemicals were of analytical grade and were purchased either from 
Sigma (St.Louis, Mo., USA) or Merck (Darmstadt, FRG). 
Isolated perfused rat kidney 
Kidneys were obtained from male Wistar rats, weighing 225 - 275 g and perfused in 
vitro as decribed in detail previously by Brink et al. (1983b). Briefly, after anesthesia with i.p. 
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pentobarbital (45 mg/100 g), furosemide was injected i.p. (1 mg/100 g) to prevent deterioraticm 
of the distal nephron (Brezis et al., 1984; Knepper, 1983). Heparin (125 units/100 g) was 
injected via the femoral vein. After opening the peritoneal cavity, the right kidney was exposed 
and freed from adhering tissue. After cannulation of the ureter, the right renal artery was 
cannulated via the mesenteric artery. The kidney was then excised and placed in a waterbath 
with a constant temperature (37.3° C). During the first 5 to 10 minutes of perfusion, the venous 
effluent was discarded to wash out the (i.p.) injected furosemide. After this period, the perfusion 
fluid was recirculated and the kidney was allowed to stabilize for 30 min. 
Figure 2.1 shows a schematic drawing of the perfusion system. The perfusate reservoir 
was placed in a waterbath of 37.3° С and was gassed with 95 % 0 2 / 5 % CO,. The perfusion 
flow could be regulated by roller pump 1. A filter (Millipore, 5 μιη роте radius) was 
incorporated in the system because this has been shown to prolong the viability of the IPK 
(Ross et al., 1973). 
/ρ Г . . . ••> ».' . • •<•••>• •'..•• •••'• . • ·. *· ...^. 
i u r i n e π 
spectro­
photometer U 
pH 
ЬиЬЫе flow 
meier 
water bath 
37.5 "С 
U V 
\ / 
GFR 
computer 
Figure 2d. Schematic figure of the IPK system. U = urinary cyanocobalamin concentration; V = 
urinary flow; Ρ = pressure transducer; RPF = renal perfusion flow; RPP = renal perfusion 
pressure; PT = perfusion temperature; Τ = thermometer. See text for further explanation. 
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After the oxygenator, the perfusate flowed through a small chamber in which possible 
air bubbles were trapped and in which the perfusate pressure was measured sing a pressure 
transducer (type CP01, CTC Inglewood, Calif., USA). The temperature of the perfusate (37.5° 
C) was controlled electronically using Peltier elements and it was measured just before the 
perfusate entered the kidney with a PT100 (thermistor). 
The perfusate contained cyanocobalamin for the determination of the glomerular 
filtration rate (GFR) (Brink and Siegers, 1979). Therefore the ureter cannula was connected to a 
micro flow-through cuvette in which the urinary cyanocobalamin concentration was measured 
colorimetrically. From the microcuvette, the urine was led through a pH meter and a bubble 
flowmeter to determine the urinary pH and flow (the bubble flowmeter was developed by Brink 
and Siegers (1979)). 
Renal perfusion flow, urinary flow, urinary pH, urinary cyanocobalamin concentration, 
GFR, and renal perfusion pressure were recorded continuously during the experiment and stored 
in a computer. 
The perfusion fluid had the following composition (mM, except where otherwise 
indicated): NaCl 114.0, KCl 5.2, CaCl, 1.8, MgCl, 1.0, NaHCO, 22.5, Νβ,ΗΡΟ, 0.84, ΚΗ,ΡΟ, 
0.28, glucose 5.0, urea 4.0, pluronic F108 25.0 (g/L), cyanocobalamin 0.014, glutathione 0.330, 
inositol 0.083, cysteine 0.50, glycine 2.30, Na-pyruvate 2.00, Na-acetate 1.22, Na-propionate 
0.208, inosine 1.00, alanine 5.00, glutamine 0.106, L-glutamine acid 2.00, a-ketoglutarate 1.15, 
ascorbic acid 0.01, Na-lactate 1.0, choline chloride 1.0 (mg/L), insulin 4 (IU/L), aldosterone 2.0 
fyig/L), lysine-vasopressin 0.01 (IU/L), and angiotensin Π 15.0 (ng/L). To this solution 1.0 % 
Synthamin 14, a mixture of 15 amino acids, was added. 
The pH of the perfusion fluid was 7.4. Pluronic F108 was added to the perfusate as a 
colloid osmotic agent and to increase perfusion fluid viscosity. Pluronic Fl 08 is a synthetic co­
polymer of poly-oxy-ethylene and poly-oxy-propylene. Tbe properties of pluronic Fl 08 are 
described in detail elsewhere (Brink, 1983a) The perfusion fluid was filtered before the 
experiment (Millipore, 0.22 ц т pore radius). 
Experimental design 
After isolation, the kidney was allowed to stabilize for 30 min. During this period no 
urine and perfusate samples were collected. Kidneys with a fractional water reabsorption 
([GFR - urinary flow] / GFR) of less than 93 % were excluded. The subsequent experimental 
time was 150 min, during which urine was collected over 10 min periods. The first 30 min 
were used as control values for renal function. In this control period total perfusate volume was 
500 ml. After this period a new perfusate reservoir was connected with a total perfusate volume 
of 150 ml, in which the drug was already dissolved. Perfusate samples (25 - 150 μΐ) were taken 
from the reservoir at the midpoint of the urine collection periods. Two additional perfusate 
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samples were taken. One, before perfusion with the drug and one at the end of the experiment. 
SA and NA were added to the perfusate as sodium salts, while SU was added as the 
acid. Addition of the drugs did not affect perfusate pH. 
At the end of the experiment the kidney was removed from the system, blotted, 
weighed, and frozen. Drug concentrations in the kidney and in the perfusate and urine samples 
were determined. 
To determine the volume which was lost by evaporation, total perfusate volume was 
determined at the end of the experiment by weighing the perfusate in the reservoir and in the 
perfusion system. This volume was less than 4 % of the total perfusate volume. 
Analytical methods 
Urine and perfusate samples were analyzed for sodium, potassium, chloride, glucose, 
magnesium, and calcium. Sodium and potassium were determined by flame photometry. Chloride 
was determined by electrochemical titration, magnesium by atomic absorption flame photometry. 
The RAPID STAT diagnostic kit of Lancer (Athy, Ireland) was used for calcium determination 
and the OLUCO-QUANT glucose kit from Boehringer (Mannheim, FRG) for glucose analysis. 
Perfusate and urine SU, SA and NA concentrations were determined by high-
performance liquid chromatography. Chromatography was performed on a stainless steel column 
(10 cm χ 4.6 mm ID) packed with LiChrosorb RP-18 (particle size 5 μιη). In (he analyses of 
SA and SU a mixture of 35 % methanol and 65 % potassium dihydrogen phosphate buffer 
0.1 % pH 2.0 was used as eluent. The elution rate was 1 ml/min and 3,4-dimethoxy benzoic 
acid (DMBA) was used as the internal standard. The compounds were detected by UV 
absorption at 237 nm. Under these conditions the retention times of SU, DMBA, and SA were 
5, 7, and 12 min, respectively. 
In the analysis of NA a mixture of 60 % methanol and 40 % potassium dihydrogen 
phosphate buffer 0.1 % pH 3.0 was used as eluent. The elution rate was 1 ml/min and ethoxy-
naproxen was used as the internal standard. The compounds were detected fluorometrically at an 
excitation wavelength of 235 nm and an emission wavelength of 350 nm. Under these 
conditions the retention times of ethoxy-naproxen and NA were 7 and 13 min, respectively. 
The extraction procedure from urine and perfusate samples and from the kidneys was 
similar for SU, SA, and NA. Urine samples in the SU experiments had to be diluted due to the 
large amounts of SU in the urine. At low perfusate concentration, the urine samples were 
diluted 10 times and at high SU concentrations 20 times. Depending on the drug used and its 
concentration, 0.01 to 10 μ£ internal standard was used in each sample, and 20 to 100 μΐ urine 
or perfusate were added. After addition of 50 μΐ 1.5 M HCl, distilled water was added to a 
total volume of 150 μ]. Di-ethyl ether (1.35 ml) was added, the mixture was vortexed for 10 
sec and centrifuged for 10 min at 2000 χ g. Ih the analyses of SA and SU the di-ethyl ether 
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layer was added to 0.5 ml 0.1 % potassium dihydrogen phosphate buffer pH 7.0 and was 
evaporated under a stream of dry filtered air on ice. In the NA determination, the di-ethyl ether 
layer was evaporated on ice until dryness and the residue was dissolved in 0.1 to 0.S ml 
methanol. After the mixture had been vortexed, 0.1 to 0.5 ml distilled water was added. In all 3 
drug analyses, an aliquot (10 - 20 μΐ) of the obtained solution was injected onto the column. 
Calibration was performed using peak area ratios of drug and internal standard after spiking 
samples of blank perfusate with various amounts of drug. Linear calibration curves were 
obtained in all cases (R2 > 0.989). 
Drug concentrations in the kidneys were determined in a similar way. The kidney was 
homogenized in S or 10 ml distilled water with a Polytron homogenizer (Braun Melsungen, 
FRG) on setting 10 for 2 times 60 sec. To 250 μΐ of this homogenate, 0.035 to 10 μg internal 
standard and 50 μΐ 6 M HCl were added. The mixture was vortexed, 1.2 ml di-ethyl ether was 
added and it was vortexed again for 60 sec. After centrifugation for 30 min at 6000 χ g, the di­
ethyl ether layer was removed and the extraction was repeated. The di-ethyl ether fractions were 
collected. In the analyses of SA and SU, 1 ml 0.1 % potassium dihydrogen phosphate buffer pH 
7.0 was added to the di-ethyl ether fractions. After the mixture was vortexed, it was centrifuged 
for 30 min at 6000 χ g. The di-ethyl ether layer was discarded and an aliquot of the obtained 
solution (10 μΐ) was injected onto the column. In the determination of NA, the di-ethyl ether 
fractions were evaporated on ice under a stream of dry filtered air. The residue was dissolved in 
0.25 to 1 ml methanol, 0.25 to 1 ml distilled water was added and the mixture was centrifuged 
for 30 min at 6000 χ g. An aliquot (10 - 20 μΐ) of the clear solution was injected onto the 
column. Calibration was performed using peak area ratios of drug and internal standard after 
spiking samples of blank kidney homogenates with various amounts of drug. Linear calibration 
curves were obtained in all cases (R2 > 0.982). 
Histological techniques 
Kidneys were perfused for 1 min with Bouin's fixative solution which was injected 
into the bubble chamber. The Sidneys were removed from the perfusion system, cut into 3 parts 
and fixed in Bouin's for at least 24 hours. After embedding the kidneys in paraplast, 2 μιη 
sections were cut The sections were stained with methamine silver (MS) and periodic acid 
Schiff (PAS) and were examined by light microscopy. 
A kidney which was perfused for 150 min without drug and a kidney which was not 
perfused, were used as controls. 
Statistics 
Average values are expressed as mean ± standard deviation (SD). Statistical differences 
between means were established using Student's t-test. 
44 
2.4 RESULTS 
Kidney function 
Control experiments were performed with perfusate that did not contain SU, SA, or 
NA. Kidney function was monitored by determination of urinary flow, urinary pH, GFR, and 
fractional excretion of sodium, chloride, potassium, glucose, magnesium, and calcium. Table 2.1 
lists the mean functional parameters of 12 control perfusion experiments. Kidney function 
decreased in the course of the experiment as can be seen from this table. The mean perfusate 
flow (N = 12) was 16 ± 3 ml/min and the mean pressure (N ж 12) was 87 ± 6 mm Hg. 
Table 2.1. Functional parameters of control IPK experiment? 
Time Urinary Urinary Fractional excretion1· 
flow pH GFR Na CI К Glucose Mg Ca 
(min) (μΙΜίη) (μΐ/min) (%) (%) (%) (%) (%) (%) 
cO-clO· 2(τ±6 
cl0-c20 
C20-C30 
OMO 
10-20 
20-30 
30-40 
40-50 
50-60 
60-70 
70-80 
80-90 
90-100 
25±5 
24±5 
23±4 
24±5 
23±5 
22±5 
21±4 
20±5 
20±5 
20±5 
19±5 
20±6 
100-110 2Qt7 
110-120 20±8 
5.9±0.2 
5.8±0.2 
5.8Ю.2 
5.7±0.2 
5.8±0.2 
5.8±0.2 
5.8-K).2 
5.8±0.2 
5.8±0.2 
5.8Ю.2 
5.8±0.3 
5.8±0.3 
5.8±0.3 
5.9Ü0.3 
5.9±0.3 
440±80 
410±70 
390±60 
380±60 
390±60 
370150 
340±50 
320І4О 
310±50 
30O±4O 
280150 
260±50 
25ОІ50 
230±50 
210150 
2.6±0.6 
2.6±0.6 
2.6±0J 
2.5±0J 
2.510.5 
2.6±0.7 
2.610.7 
2.6±0.7 
2.6Ю.7 
2.6±0.8 
2.8±0.8 
3.0±0.9 
3.4ІІ.0 
3.811.3 
4.511.7 
3.1 Ю.8 
3.2Ю.8 
3.3 Ю.7 
3.3 Ю.7 
3.4Ю.7 
3.511.0 
3.711.0 
3.610.9 
3.610.9 
3.7 Ю.9 
3.811.0 
4.011.0 
4.411.2 
4.911.5 
5.611.8 
35111 
38113 
41114 
43115 
45116 
48119 
48119 
46119 
43116 
39115 
39115 
39115 
40115 
40115 
42116 
2.410.3 
2.4 Ю.4 
2.4 Ю.4 
2.510.6 
2.8 Ю.8 
3.010.9 
3.211.1 
3.411.2 
3.711.7 
4 12 
5 13 
6 13 
7 14 
8 15 
10 15 
4417 
4819 
4919 
4819 
4819 
47110 
44110 
4219 
3919 
3619 
3318 
3217 
3017 
3017 
3117 
4.311.3 
4.711.4 
4.611.3 
4.511.2 
4.611.3 
4.711 JS 
4.611.4 
4.411.5 
4.411.6 
4.311.7 
4.411.8 
4.611.9 
5 ±2 
6 13 
7 13 
* Mean values are presented of 12 experiments. 
* Fractional excretion = (urinary flow * urinary concentration) I (GFR * perfusate concentration). 
' с = control period. 
* Time at which the new (150 ml) perfusate reservoir is connected. 
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Table 2.2. Fractional clearance and kidney to perfusate ratio of SU, SA, and NA 
Experiment Dose η Drag cone, range Cl/GFR' K/P raüo" 
in perfusate 
(mg) ^g/ml) 
3 
6 
15 
30 
45 
60 
6 
4 
4 
4 
4 
4 
21 
41 
97 
190 
310 
400 
- 4 
- 11 
- 37 
- 115 
- 230 
- 300 
8.3 
5.9 
3.0 
1.2 
0.90 
0.58 
±0.9 
± 1.5 
±0.5 
±0 .2 
±0.1 
±0.04 
21 
20 
7.2 
3.3 
1.9 
2.0 
± 5 
± 4 
± 1.0 
±0.8 
±0 .2 
±0 .2 
3 
6 
15 
30 
45 
60 
4 
4 
4 
5 
6 
5 
20 
40 
101 
215 
340 
430 
- 15 
- 30 
- 87 
- 165 
- 270 
- 350 
0.041 ± 0.008 
0.052 ± 0.017 
0.08 ±0.03 
0.07 ±0.02 
0.09 ±0.04 
0.12 ±0.04 
1.5 ±0.3 
1.5 ±0 .2 
0.97 ± 0.04 
0.87 ± 0.13 
0.92 ±0.18 
0.91 ± 0.19 
0.003754 
0.0375 4 
0.375 4 
3.75 4 
100 4 
0.026-
0.26 -
2.3 -
25 -
640 -
0.012 
0.16 
1.5 
21 
520 
0.042 ± 0.010 
0.047 ±0.011 
0.037 ± 0.004 
0.033 ± 0.003 
0.061 ± 0.017 
3.4 ±0.7 
2.9 ±0.4 
2.7 ±0.3 
1.28 ± 0.06 
0.96 ± 0.06 
" Cl/GFR = Clearance per GFR. Mean values of the period 30 - 120 min are 
presented. 
* K/P ratio = Udney-to-perfusate ratio ( μg drug per g kidney divided 
by the perfusate concentration in \ig/ml). Values are determined at the 
end of the experiments (120 min). 
SU 
SA 
NA 
Renal handling 
Several doses SU, SA, and NA were given to the IPK. The drug amounts in the urine 
and perfusate samples and in the kidneys were measured. The drug excretion rate was 
determined as a function of time. Time was corrected for the lag-time which was introduced by 
the system used. The cause of this lag-time is the volume (140 μΐ) of the ureter cannula, 
microcuvette, and bubble flowmeter. The drug clearance was calculated by dividing the excretion 
rate by the perfusate concentration at the midpoint of each urine sampling period (calculated by 
log-linear interpolation). 
Table 22 shows the fractional clearance after addition of several doses SU, SA, and 
NA to the IPK. The first 3 urine samples of each experiment were excluded from kinetic 
analysis because these samples were taken in the distribution phase of the drugs. Table 2.2 also 
shows the kidney to perfusate ratio. This ratio is the amount ^g ) of drug per g kidney found in 
the kidney at the end of the experiment divided by the perfusate concentration Qig/ml). 
Effects on kidney function 
To determine the influence of SU, SA, and NA on kidney function, functional 
parameters were monitored. SU had no influence on kidney function, irrespective of the dose 
used. SA perfusate concentrations less than 100 μgƒml (doses less than IS mg) also did not 
affect renal function. SA perfusate concentrations ranging from 160 to 450 μg/ml (doses 30 to 
60 mg) and NA perfusate concentrations ranging from 320 to 640 μgƒml (dose 100 mg) caused 
an increase in urinary flow and fractional excretion of sodium, chloride, potassium, glucose, and 
calcium. NA perfusate concentrations ranging from 0.16 to 25 μg/ml (doses 0.0375 to 3.75 mg) 
caused a decrease in urinary flow, GFR, and fractional excretion of sodium, chloride, potassium, 
and calcium. To illustrate the different effects of SA and NA on kidney function, table 2.3 
shows the functional parameters after the addition of 3 mg SA, 60 mg SA, 3.75 mg NA, and 
100 mg NA to the IPK. Mean values of the parameters in the time period 30 - 120 min after 
drug addition are presented. These values are normalized to the control period cO - c30 by 
dividing them by the values of the corresponding parameters in the control period. 
Histology 
In order to determine whether perfusion influenced kidney structure and whether SA 
and NA caused any structural damage to the IPK, several kidneys were examined histologically. 
A nonperfiised left kidney was compared with a control right kidney which was perfused for 
150 min without drug. The perfused kidney was swollen and had wide arterial branches 
compared to the nonperfiised kidney. No differences could be detected in kidneys perfused for 
30 min and kidneys perfused for ISO min. Addition of 60 mg SA or 3.7S mg NA for 120 min 
(after a 30 min control period) did not lead to (qualitative) structural alterations in cell structure 
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Table 2.3. Normalized effects of SA and NA on kidney function' 
Urinary Urinary GFR Fractional excretion 
flow pH Na CI К Glucose Mg Ca 
(μΐ/mm) (μΐ/πιίη) % % % % % % 
Control 0.84 ± 0.11 1.00 ± 0.03 0.67 ± 0.08 1.2 ± 0.2 1.3 ± 0.2 1.1 ± 0.3 2.5 ± 1.0 0.75 ± 0.10 1.1 ± 0.2 
SA (3 mg) 0.83 ±0.17 1.02 ±0.04 0.69 ± 0.07 1.2 ± 0 . 4 1.2 ± 0 . 4 1.0 ± 0 . 4 2.5 ± 0.4 0.86 ± 0.11 1.6 ±0.5 
SA (60 mg) 1.31 ± 0.24" 1.05 ± 0.04* 0.68 ± 0.15 2.3 ± 0.8" 2.4 ± 0.6" 1.7 ± 0.2" 5 ± 2 " 0.92 ± 0.20 2.6 ± 0.7"* 
NA (3.75 mg) 0.58 ± 0.10" 0.983 ± 0.013 0.53 ± 0.09' 0.72 ± 0.19*"0.79 ± 0.19"0.70 ± 0.19" 2.5 ± 0.7 0.48 ± 0.07"* 0.78 ± 0.14" 
NA(lOOmg) 1.35 ±0.30* 1.02 ±0.03 0.62 ± 0.05 2.9 ± 0.8" 4.3 ± 1.0"'4.2 ± 1 . 7 " 5.3 ± 1.1'" 0.97 ± 0.24 5.5 ± 1 . 1 " ' 
• Mean values of the period 30 - 120 min are presented of control (N = 12) and 3 mg SA (Ν = 4), 60 mg SA (Ν = 5), 
3.75 mg ΝΑ (Ν = 4), and 100 mg ΝΑ (Ν = 4) experiments. The drug concentration ranges in the perfusate, reached after 
addition of the different doses, are listed in table 22. Values are normalized by dividing them by the mean values of the 
control period cO - c30. FE = fractional excretion. 'P < 0.05 vs. control; "P < 0.01 vs. control; '"P < 0.001 vs. control. 
A à. 
В 
Figure 2.2. Histological sections of kidneys perfused for 120 min with SA (60 mg). Figures 22a 
and 22c are coupes stained with methamine silver (x 80) and figure 22b is a coupe stained with 
periodic acid Schiff (x 130). 
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Figure 2.2. (continued) 
and appearance as compared to kidneys perfused without drug. Figure 2.2 shows light 
microscope pictures of a kidney that was perfused with 60 mg SA for 120 min. As can be seen 
in this figure, glomeruli appear normal (figure 2.2a). Proximal tubuli and thick ascending limb 
(TAL) of Henle's loop have vacuohzed cytoplasm (figures 2.2a and 2.2b). Besides proximal 
tubuli with flattened brash border membranes, there are groups of tubuli with normal brash 
border membranes and wide lumina (figure 2.2c). 
2.5 DISCUSSION 
The IPK preparation described in this paper was essentially based on that developed by 
Brink et al. (1983b). The perfusion fluid contained pluronic F108 as a colloid osmotic agent. 
Due to pluronic F108, the perfusate viscosity was high and relatively low renal perfusion flow 
rates (12 - 20 ml/min) were needed, as compared to preparations which contain albumin. In the 
latter preparations, high renal perfusion flow rates (35 - 45 ml/min) are needed to obtain a 
perfusion pressure of about 90 mm Hg due to a low viscosity of the perfusate as compared to 
blood with a normal hematocrit (Maack, 1986). 
As can be seen in table 2.1, the kidney function decreased in the course of the 
experiment. This decrease is also seen in other IPK preparations (Newton and Hook, 1978; 
Maack, 1980). 
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SU fractional clearance was much higher than that of SA and NA (table 2.2). At low 
perfusate concentrations values are much higher than 1, indicating that the excretion rate is 
much higher than the rate of filtration. Therefore SU must be secreted actively. Increasing the 
concentration results in saturation of the active secretion and a decrease in the fractional 
clearance. At higher concentrations the fractional clearance becomes less than 1, indicating 
reabsorption. The reabsorption is probably passive and dependent on the tubular load, urinary 
flow, and urinary pH. Active reabsorption, however, cannot be excluded, although it seems 
unlikely as there were no indications of saturable reabsorption over the wide concentration range 
studied. Thus besides glomerular filtration, SU is actively secreted and (probably passively) 
reabsorbed in the IPK. This is also seen in vivo in dogs (Knoefel et al., 1962). As described 
elsewhere, the pharmacokinetic parameters of SU excretion are similar to those obtained in vivo 
(Cox et al., 1989). Fractional clearance of SA and NA are much less than 1. Both drugs must 
therefore be extensively reabsorbed. Saturation of an active secretion is probably masked by a 
more extensive reabsorption and a less extensive secretion as compared to SU. 
The kidney-to-perfusate ratio was highest for all 3 drugs at low perfusate 
concentrations and decreased with increasing perfusate concentration (table 2.2). The kidney-to-
perfusate ratio values were higher than 1 at low perfusate concentrations, indicating that SU, 
SA, and NA accumulate in the IPK. This is probably the result of tubular transport, either 
active secretion or reabsorption. SU that is excreted at high rates due to active tubular secretion, 
accumulates extensively. Saturation of the active secretion results in a decrease in the fractional 
clearance and in the kidney-to-perfusate ratio. Accumulation of SU has been predicted on basis 
of pharmacokinetic analysis (Rüssel et al., 1987). Accumulation of SA and NA is much less 
pronounced. It has been shown that SA accumulates in the kidneys of rats after SA 
administration in vivo (Rainsford et al., 1983; Brune et al., 1980). 
From table 2.3 it is clear that SU, SA, and NA exert quite different effects on renal 
function. SU, the major metabolite of SA which had no anti-inflammatory activity, had also no 
influence on the functioning of the IPK although it showed the highest accumulation. SA 
perfusate concentrations less than 100 μg/ml also did not affect kidney function. While 
concentrations greater than 100 μg/ml caused diuresis and natriuresis in the IPK. This is in 
agreement with observations made in vivo (Quintanilla and Kessler, 1973; Zambraski et al., 
1988a and 1988b). NA perfusate concentrations ranging from 0.16 to 25 μg/ml caused a 
reduction in urinary flow and electrolyte excretion. These are effects which are often associated 
with NSAIDs and might be caused by a reduction of the prostaglandin synthesis (Clive and 
Stoff, 1984; Dunn et al., 1988). NA is a much more potent inhibitor of the prostaglandin 
synthesis than SA, which might explain why low NA concentrations have an influence on 
kidney function while low SA concentrations have no influence. Voy high NA perfusate 
concentrations ( > 500 μgAnl) caused diuresis and natriuresis in the IPK. These concentrations 
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however are much higher than those used therapeutically ( < 120 μ^πιΐ) (Runkel et al., 1973). 
The different effects of NA on kidney function that have been reported might be caused by the 
different study protocols used and by different NA doses (Brater et al., 1985; Dixey et al., 
1987). The decrease in excretion of sodium, chloride, and potassium seen after addition of low 
doses NA to the IPK is quantitatively similar to the decrease reported by Dixey et al. (1987) 
after administration of NA to men. In the IPK we see a decrease in GFR as compared to 
control experiments while Dixey et al. (1987) did not find a change in creatinine clearance. 
The TAL of Henle's loop is especially susceptible to structural damage such as 
vacuolization, cellular disruption, and nuclear pyknosis during perfusion (Alcorn et al., 1981). 
This is probably the result of the high metabolic activity in the TAL. Perfusion might result in 
anoxia, especially in the region of the TAL. Lowering the metabolic activity in the TAL by 
addition of furosemide results in a less extensive structural damage (Brezis et al., 1984). 
Addition of amino acids to the perfusate also results in a much more normal appearance of the 
TAL, although some residual abnormalities such as mitochondrial swelling were still present 
(Epstein et al., 1982). 
We used furosemide during the surgical procedure to prevent deterioration of the distal 
region of the tubule. During perfusion, however, no furosemide could be used because it may 
have interfered with the renal handling and effects of NSATOs. This might explain the cellular 
vacuolization seen in our preparation as compared to the preparation in which furosemide was 
added (Brezis et al., 1984). Although SA and NA had an influence on many functional 
parameters of the IPK, they did not cause structural alterations as compared to control kidneys. 
In our IPK preparation SU, SA, and NA had quite different characteristics. SU was 
cleared very fast from the perfusate and accumulated highly in the kidney. SA and NA were 
eliminated very slowly from the perfusate and accumulated slightly. SU and low SA 
concentrations ( S 100 μg/ml) did not affect kidney function. High SA concentrations ( > 100 
μg/ml) caused diuresis and natriuresis. NA concentrations ranging from 0.16 to 25 \4lvai caused 
a decrease in urinary flow and salt excretion, while very high NA concentrations ( > 500 μg/ml) 
caused an increase. Similar characteristics of these drugs have been reported in vivo. We 
conchide that our IPK preparation is a valuable model for characterizing and comparing renal 
transport mechanisms and effects of NSATOs. 
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PART Π 
ISOLATED PERFUSED RAT KIDNEY: 
SALICYLURIC ACID, SALICYLIC ACID AND INDOMETHACIN 
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CHAPTER 3 
RENAL HANDLING OF SALICYLURIC ACID IN 
THE ISOLATED PERFUSED RAT KIDNEY: 
EVIDENCE FOR ACCUMULATION IN TUBULAR CELLS1 
P.G.F. Cox, W.M. Moons, F.G.M. Rüssel and CA.M. van Ginneken 
1
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3.1 ABSTRACT 
The renal handling of salicyluric acid (SU) was studied over a broad concentration 
range (0 - 400 Ц^т!) in the isolated perfused rat kidney (IPK). The accumulation of SU was 
determined by difference calculations between the SU dose given and the SU amount present in 
the perfusate and excreted into (he urine. SU accumulates highly in the IPK and this 
accumulation is concentration dependent. At low perfusate concentrations (5 to 20 μg/ml) there 
is a sharp increase in the accumulation (100 to 400 μg/ml), while at higher concentrations (20 
to 100 μg/ml) a small increase (400 to 500 μ^πιΐ) is seen. The largest part of the accumulation 
is probably caused by accumulation of SU in the tubular cells. This is a result of the active 
uptake of SU over the basolateral membrane followed by facilitated diffusion over the brush 
border membrane. As a result of the saturation of the active SU uptake, accumulation reaches a 
maximal value. Excretion of SU in the IPK involves glomerular filtration, active secretion and 
reabsorption. Reabsorption is probably a passive process, dependent on the urinary flow and pH. 
The apparent Michaelis-Menten constant of the excretion (K,-) is 18.7 ± 1 . 8 μgƒml and the 
maximum transport capacity (TM) is 69.8 ± 1 . 4 μg/mш. The pharmacokinetic parameters of the 
excretion of SU were in good agreement with previously reported in vivo values. 
33, INTRODUCTION 
Nonsteroidal anti-inflammatoiy drugs (NSAIDs) play an important role in the treatment 
of rheumatologk disorders. They can have a number of severe side-effects on the gastro­
intestinal tract, the liver, and the kidney (Rainsford, 1984). Effects of NSAIDs on the kidney 
can vary from acute renal failure to papillary necrosis (Rainsfoid, 1984). The mechanism of 
these effects is not clear, but inhibition of the prostaglandin synthesis is probably an important 
factor (Dunn et al., 1988). The effects might be related to the transport of NSAIDs through the 
tubular cells and a possible retention and accumulation within the cells. High concentrations of 
NSAIDs in the kidney could have a direct damaging effect on the tubular cells or could affect 
the electrolyte transpon. 
Salicyluric acid (SU) is the major metabolite (glycine conjugate) of salicylic acid (SA), 
a classical NSATO. The kidney is an important site of SU formation (Bekersky et al., 1980a). 
SU is eliminated by the kidney via glomerular filtration and active tubular secretion. The initial 
step in the secretion process is active uptake of SU at the basolateral membrane, followed by 
facilitated diffusion across the brush-border membrane. As a consequence of this process, SU 
might accumulate in the tubular cells (Rüssel et al., 1987; Bekersky et al., 1980b). Besides 
glomerular filtration and active secretion, SU can also be reabsorbed. Dependent on the tubular 
load, urinary flow, and urinary pH, a net reabsoiption can be observed (Knoefel et al., 1962). 
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The aim of the present investigation was to study the renal handling of SU and the 
possible effects of SU on renal function in the isolated perfused rat kidney (IPK). We also tried 
to quantify the accumulation of SU in the IPK. 
33 METHODS 
Materials 
Sodium pentobarbital was obtained nom Apharmo (Arnhem, The Netherlands). Heparin, 
insulin and aldosterone were from Organon (Oss, The Netherlands). Pluronic F-108 was 
purchased from BASF (Arnhem, The Netherlands), lysine-vasopressin from Sandoz (Basel, 
Switzerland) and angiotensin Π from Beckmann (Palo Alto, USA). Synthamin 14 was from 
Travenol (Thetford, Norfolk, England). Salicyluric acid, 3,4-dimethoxy benzoic acid and 
LiChrosorb RP-18 were from Merck (Darmstadt, FRO). All other chemicals were of analytical 
grade and were purchased from Sigma (StXouis, Mo., USA) and from Merck (Darmstadt, FRO). 
IPK experiment 
Male Wistar rats, weighing 225-275 g, were used in all experiments. After anesthesia 
with i.p. pentobarbital (45 mg/100 g), ñirosemide was injected i.p. (1 mg/100 g) to prevent 
deterioration of the distal nephron (Brezis et al., 1984; Knepper, 1983). Heparin (125 units/lOO 
g) was injected via the femoral vein. After opening the peritoneal cavity, the right kidney was 
exposed and freed from adhering tissue. After cannulation of the ureter, the right renal artery 
was cannulated via the mesenteric artery. The kidney was then excised and placed in a bath 
with a constant temperature of 37.5o С. The temperature was controlled electronically using 
Peltier elements. Renal perfusion was maintained by a roller pump and renal pressure was 
measured with a pressure transducer. The perfusion fluid had the following composition (mM, 
except indicated otherwise): NaCl 114.0, KCl 5.2, CaCl, 1.8, MgCl, 1.0, NaHCO, 22.5, 
Νβ,ΗΡΟ« 0.84, KHJP01 0.28, glucose 5.0, urea 4.0, pluronic F108 25.0 g/L, cyanocobalamin 
0.014, glutathione 0.330, inositol 0.083, cysteine 0.50, glycine 2.30, Na-pyruvate 2.00, Na-
acetate 1.22, Na-propionate 0.208, inosine 1.00, alanine 5.00, glutamine 0.106, L-glutamine acid 
2.00, a-ketoglutarate 1.15, ascorbic acid 0.01, Na-lactate 1.0, choline chloride 1.0 mg/L, insulin 
4 IU/L, aldosterone 2.0 μg/L, lysine-vasopressin 0.01 lU/L, and angiotensin Π 15.0 ng/L. To 
this solution 1.0 % Synthamin 14, a mixture of 15 amino acids, was added. 
The perfusion fluids were filtered before and during the experiment (Millipore 0.22 and 
5.0 \im pore radius, respectively). The solution was oxygenated with a flow-through oxygenator 
using 95 % 02 and 5 % CO,. Glomerular filtration rate (GFR) was detennined instantaneously 
and continuously, using cyanocobalamin as a marker, as described in detail elsewhere (Brink 
and Siegers, 1979). In short, the ureter cannula was connected to a micro flow-through cuvette 
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in which the urinary cyanocobalamin concentration was measured colorimetrically. From the 
micro-cuvette the urine was led through a bubble flowmeter to determine the urine flow. 
Experimental design 
After isolation, the kidney was allowed to stabilize for 30 min. During this period the 
i.p. injected furosemide was completely washed out and no urine or perfusate samples were 
taken. Kidneys with a fractional water reabsorption of less than 93 % were excluded. The 
subsequent experimental time was ISO min, during which urine was collected over 10 min 
periods. The first 30 min were used as control values for renal function. In this control period 
total perfusate volume was 500 ml. After this period a new perfusate reservoir was connected 
with a total perfusate volume of ISO ml, in which SU was already dissolved. Perfusate samples 
(0.1 ml) were taken from the perfusate reservoir at the midpoint of the urine collection periods. 
Two additional perfusate samples were taken. One, before perfusion with SU and one at the end 
of the experiment 
At the end of the experiment the kidney was removed from the system, blotted, 
weighed, and frozen. SU concentrations in the kidney, in the perfusate samples, and in die urine 
samples were determined. 
To correct for evaporation and loss by urine production during the experiment, total 
perfusate volume was determined at the end of the experiment by weighing the perfusate in the 
reservoir and the perfusate in the perfusion system. 
Analytical methods 
Urine samples and perfusate were analyzed for sodium, potassium, chloride, glucose, 
magnesium, calcium, and SU. Sodium and potassium were determined by flame photometry. 
Chloride was determined by electrochemical titration, magnesium by atomic absorption flame 
photometry. The RAPID STAT diagnostic kit of Lancer (Athy, Ireland) was used for calcium 
determination and the GLUCO-QUANT glucose kit from Boehringer (Mannheim, FRG) was 
used for glucose analysis. 
Perfusate and urine SU concentration were determined by high-performance liquid 
chromatography (HPLC). Chromatography was performed σα a stainless steel column (10 cm χ 
4.6 mm Ш) packed with LiChrosorb RP-18 (particle size S цт) using as eluent a mixture of 35 
% methanol and 65 % potassium dihydrogen phosphate buffer 0.1 % pH 2.0. The elution rate 
was 1 ml/min and 3,4-dimethoxy benzoic acid (DMBA) was used as the internal standard. The 
compounds were detected by UV absorption at 237 nm. Under these conditions the retentirai 
times of SU and DMBA were 5 and 7 min, respectively. 
Urine samples were diluted 10 times with perfusate at low SU concentrations and 20 
times at high SU concentrations. Depending on the SU concentration, 2 to 10 μg DMBA was 
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used in each sample, and SO to 100 μΐ diluted urine or perfusate was added. After addition of 
50 μΐ 1.5 N HCl, distilled water was added to a total volume of 150 μΐ. Di-ethyl ether (1.35 
ml) was added, the mixture was voitexed for 10 sec and centrifuged f от 10 min at 2000 g. The 
di-ethyl ether layer was added to 0.5 ml 0.1 % potassium dihydrogen phosphate buffer pH 7.0 
and was evaporated under a stream of dry Altered air on ice. An aliquot (10 μΐ) of the obtained 
solution was injected onto the column. Calibration was performed using peak area ratios of SU 
and DMBA after spiking samples of blank perfusate with various amounts of SU. Linear 
calibration curves were obtained in all cases (correlation coefficient > 0.994). 
SU concentrations in the kidneys were determined in a similar way. The kidney was 
homogenized in 10 ml distilled water with a Polytron homogenizer on setting 10 for 2 times 60 
sec. To 250 μΐ of this homogenate, 10 μg DMBA and 50 μΐ 6 N HCl were added. The mixture 
was voitexed, 1.2 ml di-ethyl ether was added and it was voitexed again for 60 sec. After 
centrifugation for 30 min at 6000 g, the di-ethyl ether layer was removed and the extraction 
was repeated. The di-ethyl ether fractions were collected and 1 ml 0.1 % potassium dihydrogen 
phosphate buffer pH 7.0 was added. After the mixture was vortexed, it was centrifuged for 30 
min at 6000 g. The di-ethyl ether layer was discarded and an aliquot of the obtained solution 
(10 μΐ) was injected onto the column. Calibration was performed using peak area ratios of SU 
and DMBA after spiking samples of blank kidney homogenates with various amounts of SU. 
Linear calibration curves were obtained in all cases (correlation coefficient > 0.990). 
Kinetic analysis 
SU excretion rate as a function of time was determined. The excretion rate curve was 
corrected for the extra lag-time mtroduced by the system used. The cause of the extra lag-time 
is the volume of the ureter cannula, microcuvette, and bubble flowmeter. This volume is 140 μΐ. 
The excretion rate «uves were fitted to a bi-exponential function. Perfusate 
concentration as a function of time was fitted to a mono-exponential function. Total perfusate 
volume decreased throughout the experiment because of urine production and evaporation ( < 6 
%). Assuming that the decrease in volume was linear with the experimental time, the perfusate 
volume could be calculated at any time of the experiment. The total amount of SU in the 
kidney at any time of the experiment was calculated using equation 1. The perfusate 
concentration function (C (t)) and the excretion rate function (O (t) * С (t)) used in this 
equation were the fitted mono - and bi-exponential functions. 
A(t) - Cp(0)*V(0) - Cp(t)*V(t) - Jo^trC^Odt (1) 
Where: A, amount in kidney ^g) ; t, time (min); С , concentration in perfusate ^g/ml); V, 
perfusate volume (ml); С (0)*V(0), dose ^g); (5 , urine flow rate (μΐ/min); С , concentration 
in urine (jlg/ml). 
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Data handling 
Fits of the perfusate concentration data and the urinary excretion rate data for 
calculation of the SU accumulation were performed using the computer program NONLIN 
(Metzler et al., 1974). All data were reciprocally weighted. The tubular titration curve (plot of 
the urinary excretion rate data versus the perfusate concentration data) was fitted to a Michaelis-
Menten equation with NONLIN. AU data were equally weighted. 
Statistical differences between means were established using student's t-test. Average 
values are expressed as mean ± SD. 
3.4 RESULTS 
Kidney function 
Several SU doses were given to the IPK leading to SU concentrations in the perfusate 
ranging from S μg/ml to 400 μg/ml. With each dose at least 4 IPK experiments were 
perfonned. 
Renal function was monitored by determination of the GFR, urinary flow, urinary pH, 
fractional excretion of glucose, sodium, chloride, potassium, calcium, and magnesium. None of 
these parameters changed significantly as compared to control experiments, irrespective of the 
SU dose used. To illustrate this, table 3.1 shows these parameters of control experiments and of 
experiments in which the highest SU dose (60 mg) was given to the IPK. The decrease in 
kidney function seen in the course of the experiments was also seen in the control experiments 
and was not caused by SU. The mean perfusate flow was 16.7 ± 1 . 4 ml/min and the mean 
pressure was 84 ± 7 mm Hg. 
Renal handling of SU 
Although SU can be converted to SA, which has been shown in the IPK (Bekersky et 
al., 1980a), in our IPK experiments only trace amounts of SA could be detected after the 
addition of SU to the kidney. 
SU was eliminated very rapidly from the perfusate. Figure 3.1 shows the mean 
perfusate concentration and the corresponding excretion rate data as a function of time after the 
addition of 6 SU doses to the IPK. All SU doses gave log-linear concentration time curves. The 
urinary excretion rate increased rapidly after the addition of SU, whereafter there was a gradual 
decrease. Increasing the SU dose given to the IPK from 3 to 6 mg and from 6 to 15 mg did 
lead to an increase in excretion rates. Increasing the SU dose above IS mg, did not lead to 
higher excretion rates. The slope of decline in the perfusate concentration curves and in the 
excretion rate curves decreased at higher SU doses. This can be explained by saturation of 
active secretion, which causes a lower SU clearance at higher perfusate concentrations. 
63 
Table 3.1. Comparison of kidney function in control experiments and experiments with 60 mg 
SV 
Parameter Experiment Time (min) 
0 - 3 0 Stf- 60 6 0 - 9 0 90 -120 120 - 150 
Urinary flow 
(ц тіп) 
GFR 
(μΐ/niin) 
Urinary pH 
FE glucose 
(%) 
FE sodium 
(%) 
FE chloride 
(%) 
FE potassium 
(%) 
FE calcium 
(%) 
FE magnesium 
(%) 
-
SU 
-
SU 
-
SU 
-
su 
-
su 
-
su 
-
su 
-
su 
-
su 
25 ± 5 
25 ± 4 
430 ± 80 
460 ± 3 0 
5.8 
5.9 
2.5 
2.8 
2.6 
2.1 
3.2 
2.7 
38 
27 
4.5 
4.0 
47 
45 
±0.2 
±0.1 
±0.4 
±0.5 
±0.6 
± 0 . 4 
± 0 . 8 
±0.6 
± 1 3 
± 8 
± 1 . 4 
± 0 . 4 
± 9 
± 6 
24 ± 5 
2 6 ± 6 
400 ± 7 0 
4 4 0 ± 4 0 
5.7 
5.9 
2.9 
3.3 
2.5 
2.3 
3.4 
3.1 
45 
32 
4.6 
4.3 
48 
42 
± 0 . 2 
± 0 . 2 
± 0 . 8 
± 0 . 6 
± 0 . 6 
± 1.1 
± 0 . 8 
± 1.2 
± 17 
± 10 
± 1 . 4 
± 1 . 4 
± 10 
± 6 
22 ± 5 
24 ± 5 
340 ± 5 0 
370 ± 30 
5.8 
6.1 
3.7 
4.5 
2.6 
2.8 
3.6 
3.6 
46 
34 
4.5 
6 
41 
43 
± 0 . 2 
± 0 . 2 
± 1.5 
± 0 . 9 
±0.7 
± 1.8 
± 0 . 9 
± 1.7 
± 18 
± 8 
± 1.5 
± 2 
± 9 
± 8 
21 ± 5 
24 ± 4 
290 ± 5 0 
3 4 0 ± 4 0 
5.8 
6.1 
6 
6.3 
2.8 
3 
3.8 
4.0 
39 
34 
4.4 
7 
34 
41 
± 0 . 3 
± 0 . 3 
± 3 
±1.0 
±0.8 
± 2 
± 1.0 
± 1.9 
± 15 
± 6 
± 1.8 
± 3 
± 8 
± 8 
21 ± 7 
27 ± 4 
240 ± 5 0 
290 ± 4 0 
5.9 
6.2 
10 
9.6 
3.9 
5 
5.0 
6 
41 
35 
6 
10 
30 
43 
± 0 . 3 
± 0 . 4 
± 6 
±1.1 
± 1.4 
± 3 
±1.6 
± 3 
± 1 5 
± 9 
± 3 
± 4 
± 7 
± 14 
* Mean values of 3 urine 10 min periods are given, control (Ν = 12) and SU 60 mg (Ν = 4). FE 
= fractional excretion. 
* Time at which the reservoir is switched to perfusate with or without 60 mg SU. 
Figure 3.2 shows the titration curve of SU in the IPK. This figure is composed of 26 
experiments in which 6 SU doses (3, 6, 15, 30, 45, and 60 mg) were added to the perfusate. At 
low perfusate concentrations, the excretion rate was much higher than the rate of filtration, 
which is typical for a drag which is actively secreted. Because the excretion rate becomes lower 
than the filtered amount at perfusate concentrations higher than 180 μgƒml, SU must also be 
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Figure 3.1. Mean perfiisate SU concentration (left panel) and mean renal excretion rate (right 
panel) as a function of time after the addition of 6 SU doses to the IPK: 3, 6, 15, 30, 45, and 60 
mg. For the dose 3 mg: η = б. For the other doses: η = 4. 
reabsorbed. Ibis reabsorption is probably passive and dependent on the tubular load, urinary 
flow and urinary pH. 
Excretion of SU involves glomerular filtration, active secretion, and passive 
reabsorption. When the active secretion was saturated, a rise in the SU perfusate concentration 
resulted in higher filtered SU amounts, but not in higher excretion rates (figure 3.2). Therefore 
the rise in the filtered SU amount must be completely reabsorbed. Because the excretion rates 
remain nearly constant at increasing perfusate concentrations, it is likely that the filtered SU 
amount is equal to the SU amount which is reabsorbed. The kinetics of the SU excretion can 
therefore be described as an active secretion process only. Active secretion can be described 
using a Michaelis-Menten equation. Therefore the tubular titration curve was fitted to a 
Mkhaelis-Menten equation using the computer program NONLIN (figure 3.2). The apparent 
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Figure 3.2. Tubular titration curve of SU, showing the total excretion rate and the rate of 
filtration of SU as a function of the perfusate concentration. The solid line represents the fit of 
the data to a Michaelis-Menten equation. GF represents the clearance by glomerular filtration 
and is calculated by: GFR * SU perfusate concentration. 
Michaelis-Menten constant (Kr) was 18.7 ±1.8 pg/ml and the maximum transport capacity (TM) 
was 69.8 ± 1 . 4 μ^ιηίη. The goodness of fit was evaluated through the deviations between the 
observed and model-predicted values as R2 « 1 - £(dev)72Xobs)2, where ЦоЬв)1 is the corrected 
sum of squared observations and Z(dev)2 the sum of squared deviations. The goodness of fît 
was: R2 = 0.905. 
Accumulation of SU 
In order to determine the amount of SU in the kidney, the perfusate concentration 
curve of each IPK experiment was fitted to a mono-exponential function. The excretion rate 
curve was fitted to a bi-exponential function. Total SU amount in the kidney was calculated 
using equation 1. Figure 3.3 shows the SU amount per g kidney as a function of time after 
addition of 3 doses (3, 6 and IS mg) to the IPK. The SU amount in the kidney increased 
rapidly after SU addition and decreased slowly during the experiment. SU accumulation after a 
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Figure 3.3. Amount SU per g kidney as a function of time after the addition ofSSU doses to the 
IPK: 3, 6, and 15 mg. For the doses 6 and 15 mg: η = 4. For the dose of 3 mg: η = 6. 
dose of 3 mg was significantly lower than the accumulation reached after the addition of 6 and 
15 mg (Ρ < O.OS). Raising the dose from 6 to 15 mg, did lead to slightly higher accumulation 
but the difference did not reach the 5 % level of statistical significance. 
In order to verify the method used to calculate the SU amounts in the kidney, the 
calculated amounts at the end of the experiment were compared with the amounts found in the 
kidneys after analysis of the SU concentrations in the kidneys (table 3.2). The amounts 
determined with both methods are equal and support the method used to calculate the amount 
SU in the kidney at any time during the experiment. At higher doses (¿ 30 mg) the 
accumulation could not be determined accurately because of the relatively low amount of SU in 
the kidney compared with the SU dose given. 
Figure 3.4 shows the SU accumulation expressed as the kidney to perfusate ratio as a 
function of the perfusate concentraticm. At low perfusate concentrations the relative accumulation 
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Table 3.2. Comparison of the calculated and measured amount of SU in the kidney 
SU dose' 
(mg) 
3 
6 
15 
30 
45 
60 
SU concentration 
fag/nû) 
5.6 ± 1.5 
12.3 ± 1.5 
45 ± 7 
133 ± 10 
241 ± 10 
306 ± 15 
SU / g kidney" 
(μΕ/Ε) 
ПО ± 4 0 
220 ± 70 
330 ± 70 
л 
-
-
SU found/g kidney0 
Oig/g) 
110 ± 20 
230 ± 2 0 
320 ± 20 
420 ± 6 0 
4 6 0 ± 4 0 
500 ± 5 0 
* η = 4 for all doses, except for dose 3 mg: η = 6. 
* Amount SU determined by equation 1 at time 120 min. 
' Amount SU found after analysis of the kidney at the end of the experiment. 
' At higher doses (30 - 60 mg), the SU amount could not be determined accurately 
because of the relatively low amount in the kidney compared with the dose given. 
was very high. Raising the perfusate concentration did lead to a sharp decrease in the kidney to 
perfusate ratio, whereafter there was only a small decrease. 
3.5 DISCUSSION 
SU is the major metabolite of SA. The kidney is an important site of SU formation. 
SU can also be converted to SA, which has been demonstrated in the IPK (Bekersky et al., 
1980a). The much lower SA amount found after addition of SU to our IPK preparation in 
comparison with the IPK preparation of Bekersky et al. (1980a) might be a result of the 
different composition of the perfusate solutions and the much lower perfusate volume used (60 
ml). In in vivo experiments using rats, also only trace amounts of SA could be detected in the 
blood after i.v. administration of SU (Nakamura et al., 1988). 
Despite pronounced accumulation, SU has no effect on the functional parameters of the 
IPK. 
The first part of the titration curve, shown in figure 3.2, is a typical titration curve of 
a drug which is actively secreted. At higher perfusate concentrations the excretion rate becomes 
much lower than the filtered amount, indicating that extensive reabsorption must take place. 
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Figure 3.4. The kidney to perfusate ratio (amount SU per g kidney per perfusate concentration) 
as a function of the perfusate concentration, after the addition of 3 SU doses to the IPK: 3, 6, 
and 15 mg. For the doses 6 and 15 mg: η = 4. For the dose of 3 mg: η = 6. 
Reabsorption of SU is also seen in clearance experiments in the dog (Knoefel et al., 1962). The 
reabsorption is dependent on tubular load, the urinary flow, and the urinary pH and is probably 
a passive process. Active reabsorption however cannot be excluded, although it seems unlikely 
because the reabsorption shows no saturation over the wide concentration range studied. If active 
secretion is saturated, an increase in the perfusate concentration results in an increase in 
reabsorption, while the secretion is not increased. As a result of this process net reabsorption is 
observed at high perfusate concentrations. At a somewhat lower urinary pH and a similar 
urinary flow as in the present study, net reabsorption was observed in SU clearance experiments 
in dogs at plasma concentrations greater than 100 μg/ml (Knoefel et ai, 1962). In our 
experiments net reabsorption is observed at perfusate concentrations greater than 180 μ&ΊηΙ. The 
difference is probably a result of the lower urinary pH and the lower tubular loading due to a 
lower filtered SU amount because of protein binding in the dog clearance experiments. No net 
reabsorption was seen in other IPK preparations, probably due to a high urinary flow (61 ± 21 
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μΐ/тш) and pH (6.7 ± 0.4) compared with the urinary flow and pH in our preparation 
(Bekersky et al., 1980b; Bekersky, 1983). 
The apparent Michaelis-Menten constant of the SU excretion is 18.7 ± 1.8 μg/mI. This 
value is in close accordance with the values found in dog (Rüssel et al., 1987). The maximum 
transport capacity (TM) is 69.8 ±1 .4 μ^πιίη. Assuming TM is a linear function of the tubular 
cell volume, TM can be compared with the TM value found in the dog. The tubular cell volume 
of a Wistar rat (225 - 275 g) kidney and a Beagle dog (12 - 17 kg) kidney can be estimated 
fremi literature (Pfaller and Rittinger, 1980; Dunnill and Halley, 1973) and is 340 μΐ and 30 ml, 
respectively. For rat kidney the ratio TM : tubular cell volume is 205 and for the dog kidney 
this ratio is 143 (Rüssel et al., 1987). The pharmacokinetic parameters found in the IPK are in 
good agreement with values found in the dog in vivo, so it is likely that a similar anion-canier 
is responsible for the active transport of SU in the dog and the rat kidney. 
SU is shown to be transported through the kidney by glomerular filtration and active 
tubular secretion (Rüssel et al., 1987; Bekersky et al., 1980b; Hekman and van Ginneken, 1983). 
The first step in the active secretion process is probably active uptake of SU at the basolateral 
membrane followed by facilitated diffusion across the brush border membrane. Active secretion 
of organic anions is usually associated with the accumulation and retention of the drag in the 
proximal tubular cells (Forster and Copenhaver, 1956). In the present study extensive 
accumulation of SU in the IPK is shown over a broad concentration range. High accumulation 
is seen in the IPK (figure 3.3) after the addition of 3, 6, and 15 mg SU to the IPK. The 
relative accumulation, expressed as the kidney to perfusate ratio, is highest at low 
concentrations. Kidney to perfusate ratio ranged from 6.3 at perfusate concentration of 76 μg/ml 
to 21 at perfusate concentrations of 5 μ^ιηΐ (figure 3.4). 'The kidney to perfusate ratios at low 
perfusate concentrations are higher than those seen in other IPK experiments, while the kidney 
to perfusate ratios at high perfusate concentrations are similar (Berkersky et al., 1980b; Bekersky 
and Olejnik, 1985). 
The accumulation of SU increases sharply at low perfusate concentrations (0 to 40 
μg/ml), whereafter there is a slow increase. This is probably caused by saturation of the 
secretion of SU. If the active secretion is saturated there is a maximal constant uptake over the 
basolateral membrane and a constant diffusion over the brush border membrane, resulting in a 
constant concentration and accumulation of SU in the tubular cells. Therefore the largest part of 
the accumulation is probably caused by the secretion process. Factors, such as binding of SU to 
plasma proteins, reabsorption, accumulation in an organell of the tubular cells, and accumulation 
in other parts of the kidney than the tubular cells only, might also play a role in the 
accumulation of SU. 
In summary, SU accumulates in great amounts in the kidney. This accumulation is 
dependent on the perfusate concentration. The largest part of the accumulation is probably 
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caused by the accumulation of SU in the tubular cells due to active secretion over the 
basolateral membrane and facilitated diffusion over the brush border membrane. Saturation of 
the active secretion leads to a maximal accumulation in the tubular cells. Despite high 
accumulation values, SU has no effect on the functional parameters of the IPK. Renal handling 
of SU involves filtration, active secretion and reabsorption. The pharmacokinetic parameters 
obtained in the IPK are in good agreement with those obtained in in vivo dog experiments. 
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CHAPTER 4 
RENAL HANDLING AND EFFECTS OF SALICYLIC ACID 
IN THE ISOLATED PERFUSED RAT KTONEY1 
P.G.F. Cox, W.M. Moons, F.O.M. Rüssel and СЛ.М. van Ginneken 
1
 Published in: Pharmacol. & Toxicol. 68, 322 - 328 (1991) 
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4.1 ABSTRACT 
The renal handling of salicylic acid (SA) and its effects on renal function were studied 
in the isolated perfused rat kidney (IPK). The renal handling of SA is dominated by 
reabsorption. Only a small fraction of the filtered SA is excreted into the urine. Reabsorption is 
a passive process and is dependent on urinary pH. Because of the extensive reabsorption, no 
decrease in perfusate concentration can be observed in the course of the IPK experiment. SA 
accumulated slightly in the IPK and this accumulation is concentration dependent Small 
amounts of SA were converted to salicyluric acid (SU), the glycine conjugate of SA. SA 
concentrations higher than 100 ц^ті caused an immediate increase in urinary flow and in 
fractional excretion of sodium, potassium, chloride, and calcium. Fractional excretion of glucose 
increased gradually. Glomerular nitration rate, renal perfusion flow, renal pressure, and fractional 
excretion of magnesium were not affected by SA. The effects were dependent on the SA 
concentration. Although SA is a classical nonsteroidal anti-inflammatory drug (NSAID), its 
influence on renal function appears to be different ñom other NSAIDs which are usually 
associated with a reduction in urinary flow and salt excretion. 
4.2 INTRODUCTION 
Nonsteroidal anti-inflammatory drugs (NSAIDs) can have several effects on the kidney, 
such as acute renal failure and papillary necrosis (Clive & Stoff 1984; Rainsford 1984a). The 
mechanism of these effects is not fully elucidated but inhibition of the prostaglandin synthesis 
plays an important role (Dunn et al. 1988). Important is probably also the way NSAIDs are 
transported and eliminated by the kidney. 
Salicylic acid (SA) is a classical NSAID. Renal handling of SA involves various 
transport mechanisms: glomerular filtration, active tubular secretion, passive reabsorption by non-
ionic and facilitated back-diffusion (Dalgaard-Mikkelsen 1951; Roch-Ramel et al. 1978; 
Bekersky et al. 1980b; Schild & Roch-Ramel 1988). Al high urinary flow and pH net secretion 
of SA can be observed, whereas under nonnal conditions net reabsorption is seen. Tubular 
secretion of SA probably involves active uptake of SA at the basolateral membrane followed by 
facilitated diffusion across the brash border membrane. As a consequence of this process, SA 
may accumulate in the tubular cells (Putney & Borzelleca 1973; Dunn et al. 1988). 
SA is converted to its major metabolite, salicyluric acid (SU), by a glycine conjugation 
pathway. The kidney is an important site of SU formation. Conversion of SA to SU has been 
demonstrated in the IPK (Bekersky et al. 1980a). This conversion is dependent on the ATP, 
glycine, and SA concentration. 
NSAIDs usually are associated with reduction in urinary flow and retention of sodium. 
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A possible mechanism is the inhibition of the prostaglandin synthesis resulting in a decrease in 
renal blood flow, glomerular filtration rate (GFR), water and salt excretion (Clive & Stoff 1984; 
Boynton et ai. 1988). However, also other mechanisms have been suggested (Vierhapper et al. 
1984; Anderson et al. 1987; Dixey et al. 1987). The effect of SA on renal function is not clear. 
SA is reported to decrease water and salt excretion (Hetzel et al. 1959; Rainsford 1984b), but 
also to increase water and salt excretion (Ramsay & Elliott 1967; QuintaniUa Sc Kessler 1973; 
Zambraski et al. 1988a; Zambraski et al. 1988b). 
Although much is known about the renal handling of SA in the ETC (Bekersky et al. 
1980a; Bekersky et al. 1980b), the effects of SA on renal function have not been studied 
previously in die IPK. The aim of the present study was to investigate these effects. We 
compared them with the effects of SA reported in in vivo experiments and with the effects of 
naproxen (another NSATO) in the IPK. In order to relate the effects with SA concentrations, we 
also studied renal handling of SA in our IPK preparation. In this way we were able to obtain a 
more complete insight in the pharmacological and toxicologkal properties of SA in the IPK. 
43 MATERIALS AND METHODS 
Chemicals 
Sodium pentobarbital was obtained from Apbarmo (Arnhem, The Netherlands). Heparin, 
insulin and aldosterone were from Organon (Oss, The Netherlands). Pluronic F-108 was 
purchased from BASF (Amhem, The Netherlands), lysine-vasopressin from Sandoz (Basel, 
Switzerland) and angiotensin Π from Beckmann (Palo Alto, Cal., USA). Synthamin 14 was from 
Travenol (Thetford, Norfolk, England). Salicyluric acid, 3,4-dimethoxy benzoic acid and 
LiChrosorb RP-18 were from Mock (Darmstadt, FRG). Sodium salicylate was obtained from 
O.P.G. (Utrecht, The Netherlands). All other chemicals were of analytical grade and were 
purchased either from Sigma (SLLouis, Mo., USA) or Merck (Darmstadt, FRG). 
IPK experiment 
The IPK experiments were performed as described in detail elsewhere (Cox et al. 
1990). In short, male Wistar rats (223-275 g) were used in all experiments. After anaesthesia 
with i.p. pentobarbital (45 mg/100 g), furosemide was injected i.p. (1 mg/100 g) to prevent 
deterioration of the distal nephron during the isolation procedure (Knepper 1983; Brezis et al. 
1984). Heparin (125 units/lOO g) was injected via the femoral vein. After opening the peritoneal 
cavity, the right kidney was exposed and freed from adhering tissue. After cannulation of the 
ureter, the right renal artery was cannulated via the mesenteric artery. The kidney was thai 
excised and placed in a bath with a constant temperature of 37.5° С The temperature was 
controlled electronically using Peltier elements. Renal perfusion was maintained by a roller 
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pump and renal pressure was measured with a pressure transducer. The perfusion fluid had the 
following composition (mM, except indicated otherwise): NaCl 114.0, KCl 5.2, СаС12 1.8, 
MgClj 1.0, ЫаНСОз 22.5, NajHPO, 0.84, ΚΗ,ΡΟ« 0.28, glucose 5.0, urea 4.0, pluronic F108 
25.0 g/1, cyanocobalamin 0.014, glutathione 0.330, inositol 0.083, cysteine 0.50, Na-pymvate 
2.00, Na-acetate 1.22, Na-propionate 0.208, inosine 1.00, alanine 5.00, glutamine 0.106, L-
glutamine acid 2.00, a-ketoglutarate 1.15, ascorbic acid 0.01, Na-lactate 1.0, choline chloride 1.0 
mg/1, insulin 4 Ш/1, aldosterone 2.0 μ ^ , lysine-vasopressin 0.01 ГОД, and angiotensin Π 15.0 
ng/1. To this solution 1.0 % Synthamin 14, a mixture of 15 amino acids (including glycine) was 
added. The pH of the solution was 7.4. Pluronic F108 was added as colloid osmotic agent and 
to increase perfusion fluid viscosity. Pluronic F108 is a synthetic co-polymer of poly-oxy-
ethylene and poly-oxy-propylene. Its properties are described in detail elsewhere (Brink 1983). 
The perfusion fluid was filtered before and during the experiment (Millipore 0.22 and 
5.0 |im pore radius, respectively). The solution was oxygenated with a flow-through oxygenator 
using 95 % 0 2 and 5 % COj. GFR was determined instantaneously and continuously, using 
cyanocobalamin as a marker, as described in detail elsewhere (Brink & Siegers 1979). In short, 
the ureter cannula was connected to a micro flow-through cuvette in which the urinary 
cyanocobalamin concentration was measured colorimetrically. From the micro-cuvette the urine 
was led through a bubble flowmeter to determine the urine flow. 
Experimental design 
After isolation, the kidney was allowed to stabilize for 30 min. During this period the 
i.p. injected furosemide was completely washed out and no urine and perfusate samples were 
taken. Kidneys with a fractional water reabsorption of less than 93 % at the beginning of the 
control period, were excluded. The subsequent experimental time was 150 min, during which 
urine was collected over 10 min periods. The first 30 min were used as control values for renal 
function. In this control period total perfusate volume was 500 ml. After this period a new 
perfusate reservoir was connected with a total perfusate volume of 150 ml and in which sodium 
salicylate was already dissolved. Perfusate samples (50 - 100 μΐ) were taken from the perfusate 
reservoir at the midpoint of the urine collection periods. Two additional perfusate samples were 
taken. One, before perfusion with SA and one at the end of the experiment. Addition of SA to 
the perfusate did not affect perfusate pH. 
At the end of the experiment the kidney was removed from the system, blotted, 
weighed and frozen. SA concentrations and (possible) SU concentrations in the kidney 
(expressed as amount per wet weight) and in the perfusate and urine samples were determined. 
SA excretion rate as a function of time was corrected for the extra lag-time, which was 
introduced by the urine volume in the ureter cannula, microcuvette and bubble flowmeter. This 
volume was 140 μΐ. 
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Average values are expressed as mean ± SD. Statistical differences between means 
were established using Student's t-test. A difference was considered significant if Ρ < 0.0S. 
Analytical methods 
Urine and perfusate samples were analyzed for sodium, potassium, chloride, glucose, 
magnesium, calcium, SA and SU. Sodium and potassium were determined by flame photometry. 
Chloride was determined by electrochemical titration, magnesium by atomic absorption flame 
photometry. The RAPID STAT diagnostic kit of Lancer (Athy, Ireland) was used for calcium 
determination and the GLUCO-QUANT glucose kit from Boehringer (Mannheim, FRG) for 
glucose analysis. 
Perfusate and urine SA and SU concentration were determined simultaneously by high-
performance liquid chromatography (HPLC). Chromatography was performed on a stainless steel 
column (10 cm χ 4.6 mm ID) packed with LiChrosorb RP-18 (particle size S μιη) using as 
eluent a mixture of 35 % methanol and 65 % potassium dihydrogen phosphate buffer 0.1 %, pH 
2.0. The elution rate was 1 ml/min and 3,4-dimethoxy benzoic acid (DMBA) was used as 
internal standard. The compounds were detected by UV absorption at 237 nm. The retention 
times of SU, DMBA, and SA under these conditions were 5, 7, and 12 min, respectively. 
Depending on the SA concentration, 5 to 10 μg DMBA was used in each sample, and 
20 to 100 μΐ urine or perfusate was added. After addition of 50 μΐ 1.5 M HCl, distilled water 
was added to a total volume of 150 μΐ. Di-ethyl ether (1.35 ml) was added, the mixture was 
voitexed for 10 sec and centrifuged for 10 min at 6000 χ g. The di-ethyl ether layer was added 
to 0.5 ml 0.1 % potassium dihydrogen phosphate buffer pH 7.0. After the mixture was vortexed, 
the di-ethyl ether layer was evaporated under a stream of dry filtered air on ice. An aliquot (10 
μΐ) of the obtained solution was injected onto the column. Calibration was performed, using 
peak area ratios of SA or SU and DMBA, after spiking samples of blank perfusate with various 
amounts of SA and SU. Linear calibration curves were obtained in all cases (R1 > 0.989). 
SA and SU concentrations in the kidney were determined in a similar way. Kidney 
was homogenized in 10 ml distilled water with a Polytron homogenizer on setting 10 for 2 
times 60 sec. To 250 μΐ of this homogenate, 10 μg DMBA and 50 μΐ 6 M HCl were added. 
The mixture was vortexed, 1.2 ml di-ethyl ether was added and it was vortexed again. After 
centrifugation for 30 min at 6000 χ g, the di-ethyl ether layer was removed and the extraction 
was repeated. The ether fractions were collected and 1 ml 0.1 % potassium dihydrogen 
phosphate buffer pH 7.0 was added. After the mixture had been vortexed, it was centrifuged for 
30 min at 6000 χ g. The ether layer was discarded and an aliquot of the obtained solution (10 
μΐ) was mjected onto the column. Calibration was performed using peak area ratios of SA and 
DMBA, and SU and DMBA after spiking samples of blank kidney homogenates with various 
amounts of SA and SU. Linear calibration curves were obtained in all cases (R1 > 0.990). 
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Histologie techniques 
Kidneys perfused for 150 min without drug and with 310 and 380 Ц^ті SA, were 
examined histologically. After 150 min perfusion, these kidneys were perfused for 1 min with 
Bouin's fixative solution. The kidneys were removed from the perfusion system, cut into three 
parts, and fixed in Bouin's for at least 24 hr. After embedding the kidneys in paraplast, 2 μπι 
sections were cut. ТЪе sections were stained with methamine silver and periodic acid Schiff and 
were examined by light microscopy. 
4.3 RESULTS 
SA kinetics 
Several SA doses were given to the IPK leading to concentrations in the perfusate 
ranging from 20 μgƒml to 400 μg/ml. Except for the highest concentrations ( > 300 Mg/ml), 
these are clinically relevant concentrations. 
SA was eliminated very slowly from the perfusate and no decrease in perfusate 
concentration was seen during the experimental time, as shown in figure 4.1. Figure 4.1 also 
perfusate cone (/jg/ml) 
500 
excretion ratel/jg/mm) 
60 Θ0 100 120 100 120 
time (mm) 
Figure 4.1. Mean perfusate SA concentration (left panel) and mean renal excretion rate (right 
panel) as a function of time. Six SA doses were used: 3, 6, IS, 30, 45, and 60 mg. For the doses 
3, 6, and 15 mg: η = 4. For the doses 30 and 60 mg: η = 5. For the dose 45 mg: η = 6. 
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Figure 4'.2. Tubular titration curve of SA. The total excretion rate (solid line) and the filtration 
rate (dotted line) of SA as a function of the perfusate concentration are shown. GF represents the 
clearance by glomerular filtration and is calculated by: GFR * perfusate concentration. 
shows the urinary excretion rates of SA. The excretion rate of SA was much lower than its 
filtration rate. This can be seen in the tubular titration curve shown in figure 4.2. In this figure 
the mean values of the excretion rates shown in figure 4.1 are plotted against the mean 
perfusate concentrations. The data of die first two urine samples of each experiment were 
omitted because these were taken in the distribution phase of SA. 
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It is known that the SA excretion is dependent on the urinary pH. A higher urinary pH 
leads to higher excretion rates caused by a decrease in non-ionic reabsorption. This was also 
seen in our IPK experiments (figure 4.3). The change in urinary pH occurred spontaneously. 
SA metabolism and accumulation 
The conversion of SA to SU, the glycine conjugate of SA, was also seen in our 
preparation. Only trace amounts of SU could be detected in the perfusate after addition of SA 
to the IPK. The amounts of SU excreted in the urine and the SU amounts present in the kidney 
could be determined after adding low amounts of SA to the IPK. Higher SA doses led to lower 
SU formation (table 4.1). No SU could be measured in the urine and in the kidney at SA 
concentrations higher than 100 μg/ml (dose > 15 mg). 
excretion rate (/jg/min) 
1.00-
0.80 
0.60 
0.40 
0.20 
0.00 
5.5 
SALICYLIC ACID /. 
3 mg 
6.0 6.5 
urinary pH 
Figure 43. Renal excretion rate as a function of urinary pH after the addition of 3 mg SA (pK. 
= 237) to the IPK (n = 4). 
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Table 4.1. SU amounts in the kidney and in the urine and SA amounts in the kidney 
SA 
dose 
(mg) 
3 
6 
15 
30 
45 
60 
η 
4 
4 
4 
5 
6 
5 
SA 
perfusate 
cone. 
(Mg/ml) 
17.3 ± 1.5 
35 ± 2 
93 ± 3 
190 ± 20 
310 ± 30 
380 ± 20 
SU 
in 
kidney 
^g/g) 
6 ± 3 
15 ± 2 
11 ± 4 
á 5" 
5 5" 
i s -
su 
in 
urine 
^ g ) 
23 ± 7 
17 ± 7 
16 ± 5 
¿S' 
¿ 8 * 
£ 8 · 
Total SU 
as % of 
SA dose 
(%) 
0.96 
0.53 
0.18 
S 0.043 
S 0.029 
á 0.022 
SA 
in 
kidney 
Oig/g) 
25 ± 4 
48 ± 7 
92 ± 3 
170 ± 30 
300 ± 4 0 
340 ± 80 
" SU amounts were below the detectable values. 
Table 4.1 also shows the amount of SA found in the kidney at the end of the IPK 
experiment. Figure 4.4 shows the kidney to perfusate (K/P) ratio as a function of the perfusate 
concentratioa At SA perfusate concentrations ranging from 20 to 40 μ&^ηΐ, this ratio was 
significantly higher as compared to concentrations above 40 μg/ml. 
Effects of SA on renal function 
Renal function was monitored by determination of the GFR, urinary flow, urinary pH, 
fractional excretion of glucose, sodium, chloride, potassium, calcium, and magnesium. As an 
illustration of the kidney function before SA addition, table 4.2 shows the renal functional 
parameters of the control period from experiments in which 380 μg/ml (dose 60 mg) SA was 
used. SA concentrations higher than 100 μ^ιηΐ (dose > 15 mg) had an effect on some of these 
parameters (figure 4.5). Urinary flow, water reabsorption, and fractional excretion of sodium, 
chloride, potassium, and calcium were all significantly different from the control period during 
the time interval 10 - 30 min of experiments in which SA concentrations higher than 100 μ^πιΐ 
(doses 30, 45, and 60 mg) were used (P < 0.05). The fractional excretion of glucose was 
significantly increased during the last 30 min of the experiments in which SA concentrations 
higher than 100 μg/ml (dose > 15 mg) were used as compared to the experiments in which 17.3 
μg/IIll (dose 3 mg) SA was used (P < 0.05). 
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Figure 4.4. KIP ratio as a function of the perfusate concentration. The KIP ratio is the SA 
amount fog) per g kidney divided by the perfusate concentration fog/ml). Six SA doses were 
added to the IPK: 3, 6, 15, 30, 45, and 60 mg. For the doses 3, 6, and 15 mg: η = 4. For the 
doses 30 and 60 mg: η = 5. For the dose 45 mg: η = 6. 
As can be seen in figure 4.5, high SA concentrations caused a pronounced increase in 
urinary flow. During the course of the experiment the urinary flow decreased again to 
approximately the same value as in the control period. The effect was dependent on the SA 
concentration. The highest concentration (380 pg/mj, dose 60 mg) resulted in the highest 
increase in urinary flow. Figure 4.5 also shows the GFR, water reabsorption, urinary pH, and 
fractional excretion of sodium, potassium, chloride, glucose, magnesium, and calcium as a 
function of time after addition of several SA amounts to the IPK. The GFR was not influenced 
by SA, although there was an apparent increase in the first 20 minutes after SA addition. This 
increase however, was probably an artefact The GFR was determined using cyanocobalamin as 
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Table 4.2. Renal functional parameters before SA additiotf 
Functional parameter 
GFR 
Urinary flow 
Water reabsorption 
Urinary pH 
FE glucose 
FE magnesium 
FE calcium 
FE potassium 
FE sodium 
ЕЕ chloride 
(μΐ/min) 
(μΐ/min) 
(%) 
(%) 
(*) 
(%) 
(%) 
(%) 
(%) 
460 
30 
93.4 
5.89 
2.8 
51 
5.5 
40 
3.0 
4.0 
± 
± 
± 
± 
± 
± 
± 
± 
± 
± 
50 
4 
0.6 
0.13 
0.6 
6 
1.8 
13 
0.6 
0.8 
* Mean values of the control period from experiments in 
which 60 mg SA was added to the IPK are presented (N = 
5). FE = fractional excretion. 
a marker. The cyanocobalamin concentration in the urine was measured by UV spectroscopy. In 
the first 20 minutes after addition of high SA doses to the IPK the urinary flow increased 
sharply and the cyanocobalamin concentration decreased. The increase in urinary flow was 
measured immediately after SA addition, while the decrease in the cyanocobalamin concentration 
was measured a few minutes later. This was because of the time the urine needed to flow from 
the kidney to the micro-UV cuvette. The GFR is calculated by: (urinary flow * urinary 
cyanocobalamin concentration) / perfusate cyanocobalamin concentration. Therefore the GFR 
appeared to increase immediately after addition of SA. 
The urinary pH decreased slightly after the addition of SA to the IPK, whereafter there 
was an increase. Fractional excretions of sodium, potassium, chloride, and calcium increased 
rapidly and this increase was dependent on the SA concentration. Fractional excretion of 
magnesium was unaffected immediately añer SA addition but decreased slightly in the course of 
the experiment. This decrease was also seen in control experiments and was not dependent on 
the SA concentration used. Fractional excretion of glucose increased gradually and this increase 
was dependent on the SA concentration. 
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FRACTIONAL EXCRETION 
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Figure 4.5. Effects of SA on renal function. GFR, urinary flow, urinary pH, water reabsorption, 
and fractional excretion (%) of sodium, potassium, chloride, glucose, magnesium, and calcium 
are shown. Renal function values are normalized for the mean value of the control period. After 
the control period, SA was added to the IPK on time t = 0 min. The effects after the following 4 
SA doses are shown: 3 mg (m), 30 mg (о), 45 mg (л), and 60 mg (π). For dose 3 mg: η = 4. 
For doses 30 and 60 mg: η = 5. For dose 45 mg: η = 6. 
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SA concentrations less than 100 μg/ml (doses 3, 6, and 15 mg) did not cause a change 
in renal function as compared to control experiments. In the course of control experiments 
kidney function decreased slowly. The same decrease was also seen in experiments with low SA 
concentrations (figure 4.5, SA dose 3 mg). The mean flow of all SA experiments (n = 28) was 
16.5 ± 2.8 ml/min and the mean renal pressure was 83 ± 7 mm Hg. 
To determine whether SA caused any structural damage to the tubular cells, the 
kidneys at the end of the IPK experiments in which high SA concentrations (310 and 380 
μg/ml, doses 45 and 60 mg) were used, were examined histologically. The cell structure and 
appearance of these kidney preparations did not differ qualitatively from the preparations of 
kidneys which were perfused for 150 min and which were not exposed to SA. 
4.5 DISCUSSION 
Renal handling of SA involves various transport mechanisms: glomerular filtration, 
active tubular secretion, passive and probably facilitated back-diffusion (Dalgaard-Mikkelsen 
1951; Roch-Ramel et al. 1978; Bekersky et al. 1980b; Schild & Roch-Ramel 1988). Passive 
reabsorption is caused by non-ionic back-diffusion and is therefore dependent on the urinary 
flow and pH. A rise in urinary pH results in a decrease in reabsorption and an increase in the 
SA excretion as is also seen in our IPK preparation (figure 4.3). Active reabsorption, however, 
can not be excluded although it seems unlikely as there were no indications of saturable 
reabsorption over the wide concentration range studied. 
The excretion rate of SA in the IPK was linear with the perfusate concentration and 
was considerably lower than the rate of glomerular filtration, indicating extensive reabsorption. 
Only 4 to 9 % of the filtered SA amounts were excreted in the urine. As a result, no decrease 
in the perfusate concentration could be detected in the course of the experiments (figure 4.1). 
SA is partly metabolized to SU in the IPK. Formation of SU from SA is dependent on 
the SA, glycine, and ATP concentrations. The glycine concentration in the perfusate was 1.17 
mM. Only trace amounts of SU could be detected in the perfusate after addition of SA. This 
was also seen in other IPK preparations with glycine concentrations of 1 and 2 mM (Bekersky 
et al. 1980a). In contrast to Bekersky et al. (1980a), we found SU in the urine and in the 
kidney after using low SA concentrations (table 4.1). Raising the SA concentration above 100 
pg/ml (dose > 15 mg) resulted in an absolute decrease in SU formation. This might be caused 
by a toxic effect of SA on the tubular cells. It is known that SA can inhibit the oxidative 
phosphorylation, thereby leading to a decline in the cellular ATP concentration (Rainsford 
1984b). Lowering the ATP amounts in the cells might lead to decreasing SU formation. 
In several reports it is suggested that SA accumulates in the kidney (Putney & 
Borzelleca 1973; Brune et al. 1980). In the IPK we see that the K/P ratio is higher than 1 at 
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low perfusate concentrations, indicating that SA accumulates. However, the accumulation of SA 
in the IPK does not reach high values (table 4.1). The K/P ratio decreases between the SA 
perfusate concentrations 40 μg/ml and 100 μg/ml, whereafter it remains nearly constant (figure 
4.4). This can be explained if SA is susceptible to tubular transport, either active secretion or 
mediated reabsorption. As a result of uptake into the cells, SA might accumulate in the tubular 
cells. Saturation of the transport mechanism would result in a decrease in the K/P ratio, as seen 
in our IPK experiments. Increasing the SA perfusate concentration above values at which the 
transport mechanism is saturated, would lead to a K/P ratio that is independent of the perfusate 
concentration. 
Accumulation may also be caused by the extensive passive reabsorption of SA. But an 
increase in the SA perfusate concentration would then lead to an increase in accumulation. 
Accumulation would probably be linear with the perfusate concentration, and could not explain 
the course of the K/P ratio as a function of the perfusate concentration. 
Another possible explanation of the course of the K/P ratio as a function of the 
perfusate concentration might be a toxic effect of SA on the tubular cells. This possibility seems 
unlikely, because SA concentrations between 40 and 100 pg/ml did not cause any effect on 
renal function while the K/P ratio decreased strongest in this concentration range. However, 
active transport of SA might be more sensitive than other tubular functions. 
In the IPK preparations of Bekersky et ai. (1980b) lower K/P ratio's were observed. 
They found K/P ratio's which were much less than 1 even at low SA perfusate concentrations. 
This difference probably is a result of different IPK preparations. Bekersky et al. used a 
perfusate medium which contained albumin and a much higher glycine concentration than our 
perfusate medium, leading to a higher SU formation. A higher SU formation in the tubular cells 
might result in lower SA amounts in the cells. 
Some functions of the IPK were affected immediately after the addition of SA. These 
effects were dependent on the SA concentration used. Low SA concentrations ( á 100 Hg/ml) 
had no effect on renal function, while SA concentrations higher than 100 μg/ml did affect some 
renal functions. GFR, renal perfusion flow, and renal pressure were not affected by SA. The 
urinary flow and the fractional excretions of sodium, chloride, potassium, and calcium increased 
sharply after the addition of SA and this increase was dependent on the SA concentration. 
Fractional excretion of magnesium was not influenced by SA. The fractional excretion of 
glucose also did not change immediately after SA addition but the excretion increased gradually 
and this increase was dependent on the SA concentration. This increase of glucose excretion 
might be caused by inhibition of the oxidative phosphorylation by SA resulting in a decrease in 
the cellular ATP concentration. It has been shown that high SA concentrations (400 μg/ml) 
result in a 50 % reduction of the ATP concentration in the cortex of dog kidney (Quintanilla & 
Kessler 1973). An even higher reduction of cellular ATP concentrations is reported after 
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addition of high SA concentrations (276 μξ/πύ) to kidney cells of monkeys (Tonnessen et al. 
1989). A decrease of the ATP concentration probably affects the Na*-K*-ATP-ase and can result 
in a decrease in the sodium coupled reabsorption of glucose. The ATP decrease is probably 
dependent on the SA concentration and would lead to a gradual increase in the fractional 
excretion of glucose, as seen in our experiments. 
The increase in urinary flow and fractional excretion of sodium, potassium, chloride, 
and calcium seen immediately after addition of SA to the IPK while the fractional excretion of 
glucose is not affected immediately, indicates an effect of SA on the distal tubule. The excretion 
of magnesium is unaffected by SA. Magnesium is transported mainly in the ascending limb of 
the loop of Henle, presumably the thick ascending limb (Sutton & Dirks 1986). Therefore it 
seems unlikely that SA has an effect on the ascending limb of the loop of Henle. 
Similar effects of SA as seen in our IPK preparations have been observed in vivo. 
High SA concentrations (200 to 250 μκ/οαΐ) did not lead to a change in GFR and in renal blood 
flow, but did lead to diuresis and natriuresis in sodium-restricted dogs (Zambraski et al. 1988a) 
and in normal miniature swine (Zambraski et al. 1988b). 
As described in detail elsewhere (Cox et al. 1990), in the IPK relatively low 
concentrations of naproxen (0.16 to 23 μg/ml) caused a decrease in urinary flow and electrolyte 
excretion. Relatively high naproxen concentrations ( > SOO μg/ml) resulted in an increase in 
urinary flow and electrolyte excretion. High naproxen doses and high SA doses cause the same, 
probably toxic, effects on kidney function. The effects on kidney function observed with low 
naproxen doses, might be caused by the inhibition of the prostaglandin synthesis. The much less 
potent inhibitory action on the prostaglandin synsthesis of SA as compared to other NSAIDs, 
might explain why low SA doses have no influence on kidney function. The effects of low SA 
doses on the kidney function are therefore different from the effects of other NSAIDs. 
In conclusion, SA excretion is low due to extensive non-ionic back-diffusion. SA is 
partly metabolized to SU and it accumulates slightly in the IPK. SA perfusate concentrations 
greater than 100 μg/ml cause an increase in urinary flow and fractional excretion of sodium, 
potassium, chloride, glucose, and calcium. SA perfusate concentrations less than 100 μgДnl did 
not affect kidney function. The effects of (low concentrations) SA on the function of the IPK 
are different from the effects on kidney function of other NSAIDs, which are usually associated 
with a reduction in urinary flow and excretion of sodium. 
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CHAPTER 5 
INDOMETHACIN: RENAL HANDLING AND EFFECTS 
IN THE ISOLATED PERFUSED RAT KIDNEY1 
Peter G.F. Cox, Miek M. Moons, Frans G.M. Rüssel and Cees A.M. van Ginneken 
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5.1 ABSTRACT 
We investigated renal handling and effects of indomethacin on renal function in the 
isolated perfused rat kidney (IPK). Indomethacin concentrations less then 2.S * IO3 μg/ml did 
not influence renal function, while higher concentrations caused a decrease in urinary flow and 
electrolyte excretion. The presence of 133 ng/ml prostaglandin E, (PGE,) in the perfusate fully 
opposed these effects on kidney function. Only a small fraction of the filtered indomethacin is 
excreted into the urine, indicating extensive reabsorption of the compound. This is probably a 
passive process, dependent on the tubular load, urinary pH, and urinary flow. Indomethacin 
accumulates extensively in the IPK, causing a kidney to perfusate ratio between S and 9. 
Accumulation decreased with increasing perfusate concentration. This can be explained by active 
secretion: increasing the perfusate concentration leads to a saturation of the active secretion and 
a decrease in the relative accumulation. We conclude that indomethacin accumulates extensively 
in the IPK, that it affects kidney function and that this influence is probably caused by the 
inhibition of PGE, synthesis. 
5.2 INTRODUCTION 
Nonsteroidal anti-inflammatory drugs (NSAIDs) belong to the most widely distributed 
and most frequently used drugs. Their effects on renal function are well known, but have not 
been completely characterized. NSAIDs are usually associated with a reduction in urinary flow 
and electrolyte excretion [1, 2]. These actions seem to be mediated by the inhibition of 
prostaglandin synthesis, but the involvement of other mechanisms has also beai suggested [3, 4, 
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Indomethacin is one of the most potent NSAIDs and is often used as a standard 
against which the many recently introduced NSAIDs are evaluated. It is a very strong inhibitor 
of prostaglandin synthesis and can also exert a nephrotoxic action. It is reported to decrease 
urinary flow and sodium excretion [4, 5], and to increase serum electrolytes [6]. However, there 
are also reports of no influence on electrolyte excretion [7, 8]. Many studies in which the 
effects of indomethacin on renal function are investigated are in vivo studies. We have shown 
that it is possible to characterize the influence on kidney function of different NSAIDs using the 
isolated perfused rat kidney (IPK) as an in vitro model [9]. 
In vivo, indomethacin is excreted into the urine unchanged, as glucuronide conjugate or 
as inactive metabolites and their glucuronides [10]. Indomethacin is a weak organic acid and its 
renal handling involves glomerular filtration, passive reabsorption, and active secretion. It is 
secreted actively at the basolateral membrane, partly by a sodium coupled anion transport 
process and partly by an anion exchanger [11]. At the brash-border membrane transport occurs 
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probably by facilitated diffusion [12]. Active transport across the basolateral membrane and 
passive transport across the brush-border membrane might lead to accumulation in the proximal 
tubular cells. Accumulation of indomethacin has been observed using autoradiographic methods 
[13, 14]. High intracellular concentrations might play an important role in the nephrotoxic action 
of indomethacin because of the inhibition of prostaglandin synthesis or a direct damaging effect 
on the tubular cells. 
The aim of the present investigation was to study the effects of indomethacin on 
kidney function using the IPK as an in vitro model. The influence on these effects of 
prostaglandin E, (PGEJ, the most abundant prostaglandin in the kidney, was studied. We also 
investigated whether indomethacin accumulates in the IPK. 
S3 METHODS 
Materials 
Sodium pentobarbital was obtained from Apharmo (Arnhem, The Netherlands). Heparin, 
insulin and aldosterone were from Organon (Oss, The Netherlands). Pluronic F-108 was 
purchased from BASF (Arnhem, The Netherlands), lysine-vasopressin from Sandoz (Basel, 
Switzerland) and angiotensin Π from Beckmann (Palo Alto, Ca., USA). Synthamin 14 was from 
Travenol (Thetford, Norfolk, England). LiChrosorb RP-18 was from Merck (Dannstadt, FRG). 
Indomethacin (l-[p-chlorobenzoyl]-5-methoxy-2-methyl-indole-3-acetic acid), indole-3-acetic acid 
and PGEj were from Sigma (Stlouis, Mo., USA). All other chemicals were of analytical grade 
and were purchased either from Sigma (StXouis, Mo., USA) or Merck (Darmstadt, FRG). 
IPK experiment 
The IPK experiments were performed as described in detail elsewhere [9]. In short, 
male Wistar rats (225-275 g) were used in all experiments. After anesthesia with i.p. 
pentobarbital (450 mg/kg), furosemide was injected i.p. (10 mg/kg) to prevent deterioration of 
the distal nephron [15, 16]. Heparin (1250 U/kg) was injected via the femoral vein. After 
cannulation of the ureter, the right renal artery was cannulated via the mesenteric artery. The 
kidney was then excised and placed in a bath with a constant temperature of 37.5° C. The 
temperature was controlled electronically using Peltier elements. Renal perfusion was maintained 
by a roller pump and renal pressure was measured with a pressure transducer. The perfusion 
fluid had the following composition (mmol/1, except indicated otherwise): NaCl 114.0, KCl 5.2, 
CaCl, 1.8, MgCl, 1.0, NaHCO, 22.5, NajHPO, 0.84, KHjPO, 0.28, glucose 5.0, urea 4.0, 
pluronic F108 25.0 gA, cyanocobalamin 0.014, glutathione 0.330, inositol 0.083, cysteine 0.50, 
glycine 2.30, Na-pyruvate 2.00, Na-acetate 1.22, Na-propionate 0.208, inosine 1.00, alanine 5.00, 
glutamine 0.106, L-glutamine acid 2.00, a-ketoglutarate 1.15, ascorbic acid 0.01, Na-lactate 1.0, 
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choline chloride 1.0 mg/1, insulin 4 IU/1, aldosterone 2.0 μ ^ , lysine-vasopressin 0.01 Ш/1, and 
angiotensin Π 15.0 ng/1. To this solution 1.0 % Synthamin 14, a mixture of 15 amino acids, 
was added. 
Glomerular filtration rate (GFR) was determined instantaneously and continuously, 
using cyanocobalamin as a marker, as described in detail elsewhere [17]. In short, the ureter 
cannula was connected to a micro flow-through cuvette in which the urinary cyanocobalamin 
concentration was measured colorimetrically. From the micro-cuvette the urine was led through a 
bubble flowmeter to determine the urinary flow. 
Experimental design 
After isolation, the kidney was allowed to stabilize for 30 min. During this period the 
i.p. injected furosemide was completely washed out and no urine or perfusate samples were 
taken. Kidneys with a fractional water reabsorption of less than 93 % were excluded. The 
subsequent experimental time was 150 min, during which urine was collected over 10 min 
periods. The first 30 min were used as control values for renal function. In this control period 
total perfusate volume was 500 ml. After this period a new perfusate reservoir was connected 
with a total perfusate volume of 150 ml, in which indomethacin was already dissolved. Perfusate 
samples (50 - 150 μΐ) were taken from the perfusate reservoir at the midpoint of the urine 
collection periods. Two additional perfusate samples were taken. One, before perfusion with 
drug and one at the end of the experiment. 
At the end of the experiment the kidney was removed from the system, blotted, 
weighed and frozen. Indomethacin concentrations in the kidney, in the perfusate samples, and in 
the urine samples were determined. 
To correct for evaporation and loss by urine production during the experiment, total 
perfusate volume was determined at the end of the experiment by weighing the perfusate in the 
reservoir and the perfusate in the perfusion system. 
In experiments in which the influence of PGE, was studied, the kidneys were perfused 
with PGE, from the moment of isolation. 
Average values are expressed as mean ± SD. Statistical differences between means 
were established using Student's t-test. A difference was considered significant if ρ < 0.05. 
Analytical methods 
Urine samples and perfusate were analyzed for sodium, potassium, chloride, glucose, 
magnesium, calcium, and indomethacin. Sodium and potassium were determined by flame 
photometry. Chloride was determined by electrochemical titration, magnesium by atomic 
absorption flame photometry. The RAPID STAT diagnostic kit of Lancer (Athy, Ireland) was 
used for calcium determination and the GLUCO-QUANT glucose kit from Boehringer 
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(Mannheim, FRG) for glucose analysis. 
Perfusate and urine indomethacin concentrations were determined by a high-
performance liquid chromatographic method which is a modification of the method described by 
Bernstein and Evans, 1982 [18]. The method is based on the deacylation of indomethacin by 
sodium hydroxide to deschlorobenzoyl-indomethacin. Indomethacin is deacylated because 
deschlorobenzoyl-indomethacin can be detected fluorimetrically, while indomethacin can not. 
Chromatography was performed on a stainless steel column (10 cm χ 4.6 mm Ш) 
packed with LiChrosorb RP-18 (particle size S μπι) using as eluent a mixture of 30 % methanol 
and 70 % potassium dihydrogen phosphate buffer (0.1 %, pH 3.0). The elution rate was 1 
ml/min and indole-3-acetic acid was used as the internal standard. The compounds were detected 
fluorimetrically at an excitation wavelength of 288 nm and an emission wavelength of 390 nm. 
Under these conditions the retention times of indole-3-acetic acid and indomethacin were 11 and 
16 min, respectively. 
Depending on the drug concentration, 0.1 to 0.3 μg indole-3-acetic acid was used in 
each sample, and SO to 120 μΐ urine or perfusate was added. After addition of 50 μΐ 1.5 mol/l 
HCl, distilled water was added to a total volume of 150 or 170 μΐ. Di-ethyl ether (1.2 ml) was 
added, the mixture was vortexed for 10 sec and centrifuged for 10 min at 6000 χ g. The di­
ethyl ether layer was evaporated under a stream of dry filtered air on ice. After the extraction 
of indomethacin from urine от perfusate, indomethacin was deacylated to deschlorobenzoyl-
indomethacin by the addition of 200 μΐ 0.1 mol/l NaOH. After the mixture was vortexed, it was 
allowed to stand for 15 min at room temperature. The solution was neutralized with 50 μΐ 0.4 
mol/l HCl, vortexed and 75 to 250 μΐ methanol was added. An aliquot (50 μΐ) of the obtained 
solution was injected onto the column. Calibration was performed using peak area ratios of 
indomethacin and indole-3-acetic acid after spiking samples of blank perfusate with various 
amounts of indomethacin. Linear calibration curves were obtained in all cases (R1 > 0.980). 
Indomethacin concentrations in the kidneys were determined in a similar way. The 
kidney was homogenized in 5 ml distilled water with a Polytron homogenizer on setting 10 for 
2 times 60 sec. To 300 μΐ of the homogenate, 0.6 to 2 μg mdole-3-acetic acid and 50 μΐ 6 
mol/l HCl were added. The mixture was vortexed, 12 ml di-ethyl ether was added and it was 
vortexed again for 60 sec. After centrifugation for 30 min at 6000 χ g, the di-ethyl ether layer 
was removed and the extraction was repeated. The di-ethyl ether fractions were collected and 
evaporated under a stream of dry filtered air on ice. After this extraction, indomethacin was 
deacylated by addition of 200 μΐ 0.03 mol/l NaOH. The mixture was vortexed and allowed to 
stand for 15 min at room temperature. After neutralization of the solution with 50 μΐ 0.12 mol/l 
HCl, 250 μΐ methanol was added. An aliquot of the resulting clear solution (50 μΐ) was mjected 
onto the column. Calibration was performed using peak area ratios of indomethacin and indole-
3-acetic acid aña spiking samples of blank kidney bomogenates with various amounts of 
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indomethacin. Linear calibration curves were obtained in all cases (R1 > 0.989). 
The limit of detection for the determination of indomethacin was 0.123 μg per ml 
urine, perfusate, or kidney homogenate analyzed. 
5.4 RESULTS 
Renal handling 
A very broad concentration range of indomethacin was studied. Doses ranging from 
373 to 0.00373 μg were given to the IPK. Only the kinetic data of the doses 373 and 37.3 μg 
could be determined and are listed in table 3.1. Lower doses led to perfusate and urine 
concentrations below the detectie» limit of the analytical method. 
Table 5.1. Kinetic data of indomethacin' 
Dose Perfusate Filtration Excretion FE* Cumulative Amount in K/P 
concentrationb rate"* rate' amount in kidney 
urine 
ftig) Qig/ml) Qigfnúa) ^g/min) (%) ^ g ) ^g/g) 
37.5 0.18±0.08 0.066±0.012 0.0036±0.0003 3.5 0.41± 0.19 1.8±0.2 8.8±0.9 
375 2.43±0.12 0.78 ±0.10 0.021 ±0.017 2.7 2.4 ± 0.3 12 ±3 5.2±0.5 
375* 1.98 ±0.42 0.6 ±0.3 0.030 ±0.006* 5.0 3.3 ± 0.7 10.7±0.9 6.3 ±1.5 
375' 2.25±0.18 0.76 ±0.19 0.042 ±0.007" 5.5 4.6 ± 1.0' 11.8±1.3 6.5±2.2 
• N = 4 for all doses. ' Ρ < 0.05 vs. experiments in which no PGE, was added; " Ρ < 0.01 vs. 
experiments in which no PGE, was added. 
* Mean values of the period 0 -120 min are presented. 
' Mean values of the period 30 -120 min are presented. 
' Filtration rate of indomethacin = GFR χ perfusate concentration. 
' FE = fractional excretion = 700 χ excretion rate I filtration rate. 
'Perfusate contained 133 nglml PGE,. 
' Perfusate contained 133 ng/ml PGE,. 
97 
Urinary excretion rates remained practically constant after their maximal values were 
reached (usually within the first 30 min after addition). The excretion rates were much less than 
the filtration rates of indomethacin, indicating extensive reabsorption. As a result, practically no 
decrease in perfusate concentration could be observed during the course of the experiments. 
At the end of the experiment (he indomethacin amount in the kidney was determined. 
The kidney to perfusate ratio (K/P) ratio is the amount (Jig) per g kidney divided by the 
perfusate concentration measured at the end of the experiment. A K/P ratio greater than one 
indicated accumulation of the drug in the kidney. As shown in table 5.1, indomethacin 
accumulates extensively in the IPK and in a concentration-dependent manner. 
The excretion rate and amount of indomethacin excreted into the urine increased by the 
addition of PGE, to the perfusate (table 5.1). Perfusate concentration, fíltration rate, and K/P 
ratio were not influenced by PGE,. 
Effect on kidney function 
Kidney function was monitored by determination of the GFR, urinary flow, urinary pH, 
fractional excretion of glucose, sodium, chloride, potassium, calcium, and magnesium. 
Indomethacin caused a reduction in urinary flow and electrolyte excretion. To illustrate this, 
table 5.2 shows the functional parameters of control experiments and of experiments in which 
375 μg drug was added to the IPK. The change in renal function mainly occurred during the 
first 30 minutes after drug addition. 
Figure 5.1 shows the effects of different indomethacin concentrations on kidney 
function. In this figure the normalized values of the functional parameters are shown. 
Normalization was performed by dividing the mean parameter value of the period 30 to 120 
min by the mean parameter value of the control period cO - c30. Perfusate concentrations of 2.5 
* 10"' and 2.5 * 10* μg/ml did not affect kidney function, whereas higher concentrations 
resulted in a decrease in urinary flow and electrolyte excretion and in an increase in water 
reabsorption. GFR and glucose excretion were also decreased but with most concentrations this 
decrease was not significant as compared to control experiments. Urinary pH was not 
influenced. 
Because indomethacin is a strong inhibitor of prostaglandin synthesis, we examined the 
effect of adding PGE, to perfusate prior to drug administration. PGE, concentrations of 13.3 
ng/ml partly opposed the effects of indomethacin on kidney function. Addition of 133 ng/ml 
PGE, to the perfusate fully opposed the changes in renal function, as can be seen in figure 5.1. 
Kidney function, as compared to control experiments, was not affected by PGE,. 
Indomethacin did not influence perfusion flow and perfusion pressure. The mean 
perfusion flow of all indomethacin experiments (N = 32) was 16.5 ± 1 . 6 ml/min and the mean 
perfusion pressure was 83 ± 9 mm Hg. 
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Table 5.2. Kidney function of control experiments and experiments with 375 μg indomethaciif 
Parameter Exp 
Urinary flow (μΐ/mm) • 
GFR (μΐ/min) 
Urinary pH 
FE of glucose 
FE of sodium 
FE of chloride 
FE of potassium 
FE of calcium 
FE of magnesium 
cO - c30 
25 ± 5 
[ 26 ± 2 
430 ± 8 0 
[ 490±50 
5.8 ± 0.2 
[ 5.6 ± 0.3 
2.5 ± 0.4 
[ 2.6 ± 0.2 
2.6 ± 0.6 
[ 2.6 ± 0.3 
3.2 ± 0.8 
[ 2.6 ± 0.5 
38 ± 13 
[ 43 ± 17 
4.5 ± 1.4 
[ 3.5 ± 0.6 
47 ± 9 
[ 41 ± 3 
O"- 30 
24 ± 5 
19 ± 3 
400 ± 7 0 
400 ± 5 0 
5.7 ± 0.2 
5.6 ± 0.3 
2.9 ± 0.8 
2.7 ± 0.3 
2.5 ± 0.6 
1.9 ± 0.3* 
3.4 ± 0.8 
2.5 ± 0.5* 
45 ± 17 
46 ± 19 
4.6 ± 1.4 
3.1 ± 0.6· 
48 ± 10 
35 ± Г 
Time (min) 
3 0 - 6 0 
22 ± 5 
15 ± 2 " " 
340 ± 5 0 
330 ± 30 
5.8 ± 0.2 
5.6 ± 0.2 
3.7 ± 1.5 
2.9 ± 0.4 
2.6 ± 0.7 
1.5 ± 0.1" 
3.6 ± 0.9 
1.7 ± 0.3"" 
46 ± 18 
30 ± 17 
4.5 ± 1.5 
2.1 ± 0 . 4 ~ 
41 ± 9 
26 ± 4 -
6 0 - 9 0 
21 ± 5 
14 ± 2 " · 
290 ± 5 0 
300 ± 2 0 
5.8 ± 0.3 
5.8 ± 0.2 
6 ± 3 
3.6 ± 0.7" 
2.8 ± 0.8 
1.3 ± 0.1"* 
3.8 ± 1.0 
1.5 ± О-г"" 
39 ± 15 
23 ± 14 
4.4 ± 1.8 
1.4 ± 0.3"· 
34 ± 8 
20 ± 6 " 
90 - 120 
21 ± 7 
13 ± 2 " 
240±50 
270 ± 3 0 
5.9 ± 0.3 
5.8 ± 0.2 
10 ± 6 
5.1 ± 0.9' 
3.9 ± 1.4 
1.2 ± 0.2"· 
5.0 ± 1.6 
1.4 ± 0.4"· 
41 ± 15 
20 ± 1Г 
6 ± 3 
1.3 ± 0.3"· 
30 ± 7 
17 ± 6 " 
" Mean values of three urine 10 - min periods are given. - = control experiments (N =12) and I 
= indomethacin 375 \ig experiments (N = 4). FE = fractional excretion, с = control period. ' Ρ 
< 0.05, " Ρ < 0.01, and "' Ρ < 0.001 vs. control experiments. 
* Time at which the reservoir is switched to perfusate with or without 375 μg indomethacin. 
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Figure 5.1. Effect of indomethacin on GFR, urinary flow, water reabsorption, urinary pH and 
fractional excretions of glucose, sodium, potassium, chloride, calcium, and magnesium. 
Normalized parameter values are shown. Normalization is performed by dividing the mean 
parameter value of the period 30 to 120 min by the mean parameter value of the control period 
cO - сЗО. С = normalized parameter value of control experiments (N = 12). For all 
concentrations: N = 4. Only perfusate concentrations of the two highest doses could be 
determined, the other concentrations were below the detection limit of the analytical method and 
are determined by dividing the dose by total perfusate volume. Open circles represent experiments 
with perfusate containing 133 nglml PGE2. ' Ρ < 0.05, " Ρ < 0.01, and "' Ρ < 0.001 vs. control 
experiments. 
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SS DISCUSSION 
Only a small portion of the filtered indomethacin amounts were excreted into the urine 
(table 5.1). Therefore, indomethacin must be reabsorbed extensively, probably in a passive 
manner and, therefore, dependent on the tubular load, urinary flow, and urinary pH. The 
presence of PGE, in the perfusate resulted in a significant increase in the excretion rate and 
excreted amount of indomethacin. Indomethacin caused a decrease in urinary flow (figure 5.1). 
PGE, opposed this effect, leading to a higher urinary flow. This resulted in a lower 
indomethacin concentration in the lumen and therefore caused a lower passive reabsorption. This 
explains the increase in excretion rate and excreted amounts of indomethacin observed with 
perfusate that contained PGE,. 
Indomethacin is secreted actively by the kidney. At the basolateral membrane, it is 
transported actively from the blood into the proximal tubular cells. More than one transporter is 
involved in the active secretion. Part of the secretion occurs by a sodium coupled anion 
transporter and another part occurs by an anion exchanger [11]. Transport from the cells to the 
lumen, across the brush-border membrane occurs probably by facilitated diffusion [12]. As a 
consequence of these transport processes, indomethacin might accumulate in the cells. Rainsford 
et al. [14] have demonstrated that indomethacin accumulates in the kidney. In the IPK we 
observed extensive accumulation, which was much higher than the accumulation described by 
Rainsford et al. [14]. This might be explained by the higher concentration used by than. As can 
be seen in table 5.1, the K/P decreases with increasing perfusate concentration. This can be 
explained by active secretion. Increasing the perfusate concentration results in saturation of the 
active secretion and, therefore, in a decrease in relative accumulation. Rainsford et al. [14] 
observed high accumulation in the cortex, while accumulation in the medulla was much less. 
This agrees with the idea that active secretion is the cause of the accumulation. Rainsford et al. 
[14], however, suggested that the accumulation was caused by passive reabsorption. Beside 
secretion, the reabsorption probably also contributes to the concentration of indomethacin in the 
tubular cells. 
Many in vivo studies have been performed in which the effects of indomethacin on 
kidney function were investigated. The results of these studies however are inconsistant. In some 
studies, indomethacin caused a decrease in urinary flow and electrolyte excretion [4, 5], while in 
other studies no influence on urinary flow and electrolyte excretion was observed [7, 8]. The 
IPK is a good in vitro model for studying the effects of NSAIDs on kidney function [9]. In the 
IPK indomethacin caused a decrease in urinary flow and excretion of electrolytes. These effects 
are usually associated with NSAIDs [1]. 
Because indomethacin is a strong inhibitor of prostaglandin synthesis, we investigated 
the influence of PGE, on the effects of indomethacin. The presence of 133 ng/ml PGE, in the 
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perfusate fully opposed the effects (figure S.l). The influence of indomethacin on kidney 
function, therefore, is probably caused by the reduction of the PGE, amount in the kidney. 
However, other mechanisms cannot be ruled out. PGE, might counteract the effects of some 
agent that causes water and electrolyte reteniion. Cyclooxygenase products other than PGE, are 
also affected by indomethacin and they could also play a role in the effects of indomethacin on 
renal function. 
From figure 5.1 the lowest indomethacin concentration at which an effect on kidney 
function is observed can be estimated. This concentration is about 2 * 103 μg/ml. Porter [19] 
reported that 50 % of the PGE, production in ifaeumatoid synovial organ cultures is inhibited by 
2.5 * ΙΟ3 μ&ιΐηΐ indomethacin. This value lies in the same range as the lowest concentration at 
which an effect on the function of the IPK is seen and supports the idea that the inhibition of 
the prostaglandin synthesis is the cause of the effects on kidney function. 
Flower et al. [20] reported that 6 * 102 μg/ml indomethacin caused a 50 % inhibition 
of (isolated) prostaglandin synthetase. This concentration is about 30 times higher than the 
lowest concentration at which we observe an effect on kidney function. This difference might be 
explained by the accumulation of indomethacin in the tubular cells. 
Although it is known that PGE, can cause vasoconstriction in the IPK, resulting in a 
short lasting increase in perfusion pressure [21, 22], the presence of PGE, in our perfusate did 
not influence kidney function as compared to control experiments. Because in our experiments 
the kidneys were perfused with PGE, from the moment of isolation, no increase in perfusion 
pressure was seen. However, if PGE, is added to the perfusate after the stabilization period, we 
also observed a transient rise in the perfusion pressure. 
In conclusion, indomethacin is highly reabsorbed in the IPK; it accumulates extensively 
in a concentration-dependent manner, probably caused by active tubular secretion; indomethacin 
affects kidney function and this influence is probably caused by the inhibition of PGE, 
synthesis. 
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PARTin 
ISOLATED PERFUSED RAT KIDNEY AND CHIRAL NSAIDs: 
NAPROXEN AND IBUPROFEN 
105 

CHAPTER 6 
RENAL DISPOSITION AND EFFECTS OF 
NAPROXEN AND ITS I-ENANTIOMER 
IN THE ISOLATED PERFUSED RAT KIDNEY1 
P.G.F. Cox, W.M. Moons, F.G.M. Rüssel and СЛ.М. van Ginneken 
1
 Published In: J. Phannacol Exp. Ther. 2SS, 491 - 496 (1990) 
107 

6.1 ABSTRACT 
Renal handling, metabolism, and effects on kidney function of naproxen and its 1-
enantiomer were examined in the isolated perfused rat kidney (IPK). Urinary excretion rate of 
naproxen was much lower than the filtration rate, indicating extensive reabsorption. Naproxen is 
accumulated considerably in the IPK. This accumulation is concentration dependent and is 
probably the result of active secretie« of naproxen. Considerable amounts of desmethyl-naproxen 
were formed in the IPK. The kinetic behavior of the 1-enantiomer of naproxen did not differ 
from naproxen. Addition of 37J to 3750 μg naproxen caused a decrease in urinary flow, GFR, 
and fractional excretion of sodium, chloride, potassium, magnesium, and calcium. The presence 
of prostaglandin E, (PGE,) in the perfusate fully opposed the effects of naproxen on kidney 
function. Addition of 373 μg 1-enantiomer of naproxen did not influence kidney function. 
Addition of very high doses (PIO 9 μg) of naproxen and its 1-enantiomer to the IPK caused 
diuresis and increased the fractional excretion of sodium, chloride, potassium, glucose, and 
calcium. We conclude that die pharmacokinetic behavior and the metabolism of naproxen in the 
IPK is probably not stereoselective; that relatively low doses of naproxen exert a specific, 
stereoselective effect on kidney function caused by inhibition of the PGE, synthesis; and that 
high doses of naproxen exert a nonstereoselective effect on kidney function. 
6Λ INTRODUCTION 
Nonsteroidal anti-inflammatory drugs (NSAIDs) are widely used in medicine. They are 
known to exert nephrotoxic action (Clive and Stoff, 1984). The mechanism of which is 
incompletely understood. Besides inhibition of the prostaglandin synthesis, direct tubular effects 
of NSAIDs have been proposed (Famaey, 1978; Dixey et al., 1988; Dunn et al., 1988). The 
renal handling of NSAIDs probably also plays an important role (Brune and Lanz, 1984). 
NSAIDs are usually associated with salt and water retention. The effects of naproxen 
(d-(+)-6-methoxy-a-methyl-2-naphtaleneacetic acid: d-NA) on kidney function are not clear. 
Eriksson et al. (1987) reported that naproxen decreased sodium, chloride, and water excretion. 
Dixey et al. (1987) described a decrease in sodium, chloride, and potassium excretion and no 
decrease in water excretion, while Brater et al. (1985) reported no influence on the electrolyte 
and water excretion by naproxen. 
Renal handling of naproxen probably involves glomerular filtration, active secretion, 
and passive reabsorption (Runkel et al., 1978). As a result of active secretion, drugs can 
accumulate in the proximal tubular cells (Cox et al., 1989). Due to high intracellular 
concentrations, naproxen might exert a damaging effect 
Only a small fraction of naproxen is excreted unchanged in vivo (Upton et al., 1980). 
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The major metabolite of naproxen is desmethyl-naproxen (DMN). Glucuronide conjugates of 
naproxen and DMN are also formed. Recently, desmethyl-naproxensulfate (DMNS) has been 
identified as another metabolite of naproxen (Kiang et al., 1989). 
Of the 2 - arylpropionic acid NSAIDs, naproxen is the only compound commercially 
available as the d - enantiomer, the others are being marketed as the racemates. The d -
enantiomer has anti-inflammatory activity, while the 1 - enantiomer has not (Hutt and Caldwell, 
1983; Jamali, 1988). This correlates with the much more potent inhibition of the PGE, synthesis 
by the d-enantiomer, than by the I-enantiomer (Tomlinson et al., 1972). Chiral inversion of 
naproxen is observed and always involves conversion of the inactive l-enantiomer to the 
pharmacologically active d-enantiomer (Goto et al., 1982). It is known that naproxen can exert 
nephrotoxic action. The influence of the I-enantiomer of naproxen however has not yet been 
investigated. 
In this study we examined the renal handling and the effects on kidney function of 
naproxen and its l-enantiomer in the isolated perfused rat kidney (ДОС). 
63 METHODS 
Materials 
Sodium pentobarbital was obtained from Aphaimo (Amhem, The Netherlands). Heparin, 
insulin and aldosterone were from Organon (Oss, The Netherlands). Pluronic F-108 was 
purchased from BASF (Amhem, The Netherlands), lysine-vasopressin from Sandoz (Basel, 
Switzerland) and angiotensin Π from Beckmann (Palo Alto, Ca., USA). Synthamin 14 was from 
Travenol (Thetford, Norfolk, England). LiChrosorb RP-18 was from Merck (Dannstadt, FRG). 
Naproxen (d-(+)-6-methoxy-a-methyl-2-naphtaleneacetic acid : d-NA), l-(-)-6-methoxy-a-methyl-
2-naphtaleneacetic acid (1-NA) and PGE, were from Sigma (St.Louis, Mo., USA). 
Ethoxynaproxen and desmethyl-naproxen (DMN) were from Syntex Research (Palo Alto, Ca., 
USA). All other chemicals were of analytical grade and were purchased either from Sigma 
(StLouis, Mo., USA) or Merck (Darmstadt, FRG). 
EPK experiment 
The IPK experiments were performed as described in detail elsewhere (Cox et al., 
1990). In short, male Wistar rats (225-275 g) were used in all experiments. After anesthesia 
with i.p. pentobarbital (45 mg/100 g), furosemide was injected i.p. (1 mg/100 g) to prevent 
deterioration of the distal nephron (Brezis et al., 1984; Knepper, 1983). Heparin (125 U/100 g) 
was injected via the femoral vein. After opening the peritoneal cavity, the right kidney was 
exposed and freed from adhering tissue. After cannulation of the ureter, the right renal artery 
was cannulated via the mesenteric artery. The kidney was then excised and placed in a fluid 
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bath with a constant temperature of 37.5° C. The temperature was controlled electronically using 
Peltier elements. Renal perfusion was maintained by a roller pump and renal pressure was 
measured with a pressure transducer. The perfusion fluid had the following composition (mM, 
except indicated otherwise): NaCl 114.0, KCl 5.2, CaQ, 1.8, MgCl, 1.0, NaHCO, 22.5, 
Na,HP04 0.84, KHjPO^ 0.28, glucose 5.0, urea 4.0, pluronic F108 25.0 g/1, cyanocobalamin 
0.014, glutathione 0.330, inositol 0.083, cysteine 0.50, glycine 2.30, Na-pyruvate 2.00, Na-
acetate 1.22, Na-propionate 0.208, inosine 1.00, alanine 5.00, ghilamine 0.106, L-glutamine acid 
2.00, a-ketoglutarate 1.15, ascorbic acid 0.01, Na-lactate 1.0, choline chloride 1.0 mg/1, insulin 4 
Ш/1, aldosterone 2.0 μg/l, lysine-vasopressin 0.01 Ш/1, and angiotensin Π 15.0 ng/1. To this 
solution 1.0 % Synthamin 14, a mixture of 15 amino acids, was added. 
The perfusion fluids were Altered before and during the experiment (Millipore 0.22 and 
5.0 μτη pore radius, respectively). The solution was oxygenated with a flow-through oxygenator 
using 95 % 0 2 and 5 % C02. Glomerular nitration rate (GFR) was determined instantaneously 
and continuously, using cyanocobalamin as a marker, as described in detail elsewhere (Brink 
and Siegers, 1979). In short, the ureter cannula was connected to a micro flow-through cuvette 
in which the urinary cyanocobalamin concentration was measured colorimetrically. From the 
micro-cuvette the urine was led through a bubble flowmeter to determine the urine flow. 
Experimental design 
After isolation, the kidney was allowed to stabilize for 30 min. During this period the 
i.p. injected furosemide was completely washed out and no urine or perfusate samples were 
taken. Kidneys with a fractional water reabsorption of less than 93 % were excluded. The 
subsequent experimental time was 150 min, during which urine was collected over 10 min 
periods. The first 30 min were used as control values for renal function. In this control period 
total perfusate volume was 500 ml. After this period a new perfusate reservoir was connected 
with a total perfusate volume of 150 ml, in which naproxen or its 1-enantiomer were already 
dissolved. Both enantiomers were added as the salt. Perfusate samples (50 - 150 μΐ) were taken 
from the reservoir at the midpoint of the urine collection periods. Two additional perfusate 
samples were taken. One, before perfusion with drug and one at the end of the experiment. 
At the end of the experiment the kidney was removed from the system, blotted, 
weighed and frozen. Naproxen or 1-NA, and DMN concentrations in the kidney, in the perfusate 
samples, and in the urine samples were determined. 
To correct for evaporation and loss by urine production during the experiment, total 
perfusate volume was determined at the end of the experiment by weighing the perfusate in the 
reservoir and the perfusate in the perfusion system. 
The excretion rate as a function of time was corrected for the extra lag-time, which 
was introduced by the urine volume in the ureter cannula, the microcuvette and the bubble 
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flowmeter. This volume was 140 μΐ. 
Average values are expressed as mean ± SD. Statistical differences between means 
were established using Student's t-test. A difference was considered significant if ρ < 0.05. 
Analytical methods 
Urine samples and perfusate were analyzed for sodium, potassium, chloride, glucose, 
magnesium, calcium, d-NA or 1-NA, and DMN. Sodium and potassium were determined by 
flame photometry. Chloride was determined by electrochemical titration, magnesium by atomic 
absorption flame photometry. The RAPID STAT diagnostic kit of Lancer (Athy, Ireland) was 
used for calcium determination and the GLUCO-QUANT glucose kit from Boehiinger 
(Mannheim, FRO) for glucose analysis. 
Perfusate and urine d-NA, 1-NA, and DMN concentrations were determined by a 
nonstereoselective high-performance liquid chromatographic method which is a modification of 
the method described by van Loenhout et al. (1982). Chromatography was performed on a 
stainless steel column (10 cm χ 4.6 mm Ш) packed with LiChrosorb RP-18 (particle size S |im) 
using as eluent a mixture of 60 % methanol and 40 % potassium dihydrogen phosphate buffer 
(0.1 %, pH 3.0). The elution rate was 1 ml/min and ethoxynaproxen was used as the intonai 
standard. The compounds were detected fluorimetrically at an excitation wavelength of 235 nm 
and an emission wavelength of 350 nm. Under these conditions the retention times of DMN, d-
NA or 1-NA, and ethoxynaproxen were 3, 7, and 13 min, respectively. 
Urine and perfusate samples from experiments in which the highest d-NA and 1-NA 
doses ( f lO 9 μg) were given, were diluted 25 times with perfusate. Depending on the drug 
concentration, 0.01 to 0.25 μg ethoxynaproxen was used in each sample, and 20 to 100 μΐ urine 
or perfusate was added. After addition of 50 μΐ 1.5 M HCl, distilled water was added to a 
total volume of ISO μΐ. Di-ethyl ether (1.35 ml) was added, the mixture was vortexed for 10 
sec and centrifuged for 10 min at 6000 χ g. The di-ethyl ether layer was evaporated under a 
stream of dry filtered air on ice. After addition of 0.2 to 1 ml methanol, the mixture was 
vortexed and 0.2 to 1 ml distilled water was added. An aliquot (10 to 20 μΐ) of the obtained 
solution was injected onto the column. Calibration was performed using peak area ratios of d-
NA, 1-NA or DMN and ethoxynaproxen after spiking samples of blank perfusate with various 
amounts of d-NA or 1-NA and DMN. Linear calibration curves were obtained in all cases (R1 > 
0.989). 
d-NA, 1-NA, and DMN concentrations in the kidneys were determined in a similar 
way. The kidney was homogenized in 5 to 10 ml distilled water with a Polytron homogenizer 
on setting 10 for 2 times 60 sec. The homogenate from experiments in which the highest 
naproxen dose was given to the IPK was diluted 25 times with homogenate from control 
kidneys. To 250 μΐ of the homogenate, 0.0Э5 to 1 μg ethoxynaproxen and 50 μΐ 6 M HCl were 
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added. The mixture was vortexed, 1.2 ml di-ethyl ether was added and it was vortexed again for 
60 sec. After centrifugation for 30 min at 6000 χ g, the di-ethyl ether layer was removed and 
the extraction was repeated. The di-ethyl ether fractions were collected and evaporated under a 
stream of dry filtered air on ice. After addition of 0.25 to 1 ml methanol, the mixture was 
vortexed and 0.23 to 1 ml distilled water was added. The solution was vortexed again and 
centrifuged for 30 min at 6000 χ g. An aliquot of the obtained clear solution (20 to 40 μΐ) was 
injected onto the column. Calibration was performed using peak area ratios of d-NA, 1-NA or 
DMN and ethoxynaproxen after spiking samples of blank kidney homogenates with various 
amounts of d-NA or 1-NA and DMN. Linear calibration curves were obtained in all cases (R2 > 
0.982). 
The limit of detection for the determinations of d-NA and 1-NA was 0.004 μg per ml 
fluid injected onto the column and for the determinations of DMN 0.01 μg per ml fluid. 
p e r f u s a t e concentration (/jg/ml) 
t i-D—о—о—•—α—α—α—о—о—α—о—α-α 1 KF/jg 
excretion rate(jug/min) 
110' 
110" 
110° 
110-': 
Δ - й — ΰ _ Δ _ Δ _ Λ _ Α _ Λ — л — а — й — д — а - л 37510'/ ig 
11Ο­
110' 
N A P R O X E N 
-о—о 110е /ug 
110" ; 
Ι,ΙΟ-'Ξ 
-о—О—о—о—О—ι 
о—о-о-о—о-»« 37510'yug uQ-i / 
- м 37510'/ig 
ПО"
1 
-
Δ
-
Δ
- Δ - Δ - - ΰ - Δ 37510>9 
- 0 - 0 _ 0 _ o _ 0 _ 0 _ 0 3 7 5 , 0 2 ^ 
37510>g 
3 75/ig 
0 20 ¿0 60 80 100 120 
i * - - * - * - * ^ » ^ - » - » - » 375 
ι 
1.10-4 
/jg 
0 21Ö ¡ 0 60 80 1Ò0 120 
t i m e (mm) 
Figure 6.1. Mean perfusate naproxen concentration {left panel) and mean renal excretion rate 
(right, panel) as a function of time. For each dose: N =4. 
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6.4 RESULTS 
Renal handling 
A broad naproxen concentration range was examined (2.S * 10* to 650 m^ml). 
Samples of experiments in which the naproxen perfusate concentration was greater than 2.S * 
IO3 μg/ml were analysed for d-NA or 1-NA. As can be seen in figure 6.1 only a small decrease 
in perfusate concentration was seen during the experiment. Urinary excretion rates remained 
practically constant after their maximal values were reached. Table 6.1 shows the mean values 
of the perfusate concentrations, the mean excretion rate data, and the mean filtered naproxen 
amounts. The excretion rate was much lower than the rate of filtration, indicating extensive 
reabsorption. Addition of 373 or IMO9 μg of 1-NA to the IPK resulted in the same perfusate 
concentrations and excretion rate data as naproxen. 
Table 6.1. Mean perfusate concentrations, excretion rates and filtration rates of naproxen' 
Dose 
d-NA 
(μ«) 
то
5 
3750 
375 
37.5 
3.75 
Perfusate 
concentration 
(Mg/ml) 
560 ± 2 0 
22.4 ±0.7 
1.88 ±0.19 
0.21 ±0.02 
0.019 ± 0.002 
Filtration 
rate of d-NAb 
Qig/min) 
180 ± 6 0 
6.9 ± 1.6 
0.56 ± 0.14 
57*10J ± 12*ισ3 
5.7*10-' ± 1.7*10J 
Excretion rate 
of d-NA excretion0 
(pg/min) 
9.2 ± 0.6 
0.22 ± 0.05 
0.021 ± 0.004 
3.0*^ ± ο.3*ισ3 
ОЗИЮ* ± 0.04*10-3 
Fractional 
(*) 
5.1 
3.1 
3.8 
5.3 
3.7 
" Mean values of the period 30 - ¡20 min are presented. N = 4 for all doses. 
* Filtration rate of d-NA = GFR * perfusate concentration. 
' Fractional excretion (%) = 100 + excretion rate I filtration rate. 
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Table 6.2. Amount DMN in per/usate, urine, and kidney and amount naproxen or its l-enantiomer 
in urine and kidney 
NA 
dose 
<M) 
mo
5 
3750 
375 
37.5 
3.75 
375· 
375' 
IMO5 
375 
dfl 
d 
d 
d 
d 
d 
d 
d 
1 
1 
NA 
in 
urine 
(ЦЯ) 
1000 ±200 
26 ± 5 
2.4 ± 0 . 2 
0.341 ± 0.015 
0.022± 0.004 
2.2 ± 0 . 3 
3.1 ± 0.5 
900 ±300 
2.3 ±0.5 
NA 
in 
kidney 
Oig/g) 
534 ± 26 
28 ± 2 
4.4 ± 0.6 
0.54 ± 0.03 
0.054± 0.005 
4.1 ± 0.3 
4.0 ± 0.4 
560 ± 23 
5.7 ± 1.0 
DMN 
in 
perfusate 
(Mg) 
1300± 190 
190 ± 3 0 
35 ± 15 
_b 
_b 
49 ± 9 
41 ± 7 
1600± 170 
38 ± 3 
DMN 
in 
urine 
<W) 
20 ± 4 
2.9 ± 0.5 
1.1 ± 0.5 
0.13 ±0.03 
0.018± 0.015 
0.86 ± 0.24 
0.6 ±0.3 
16 ± 5 
0.9 ±0.3 
DMN Total DMN as 
in % of NA dose 
kidney 
0ig/g) 
34 ± 7 
2.1 ± 0 . 4 
1.7 ± 0.4 
0.25± 0.04 
0.09± 0.04 
2.5 ± 0.4 
2.3 ± 0.6 
35 ± 5 
1.7 ± 0.3 
(%) 
1.5 
5.3 
10 
-
-
14 
12 
1.7 
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' N = 4 for all doses. 
* amounts were to low and could not be determined. 
' perfusion fluid contained 133 ng/ml PGE,. 
' perfusion fluid contained 133 ng/ml PGE,. 
At the end of the experiments the d-NA or 1-NA amount in the kidneys was 
determined (table 6.2). The kidney to perfusate (K/P) ratio is the amount ^g ) per g kidney 
divided by the perfusate concentration. As can be seen in figure 6.2, this ratio was dependent 
on the perfusate concentration. Increasing the perfusate concentratimi resulted in a lower K/P 
ratio. At low perfusate concentration the ratio was higher than 1. This means that naproxen 
accumulated in the IPK. Addition of 1-NA to the IPK did not lead to different accumulation 
values. 
Considerable amounts of DMN were formed in the IPK. DMN could be determined in 
the perfusate and urine samples and in the kidney, as can be seen in table 6.2. The DMN 
amounts formed, expressed as percentage of the added dose increased with decreasing dose. No 
difference in DMN formation could be seen between the two enantiomers. 
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Figure 62. Kidney to perfusate rano as a function of the perfusate concentration. The kidney to 
perfusate ratio is the naproxen amount (μ8) per gram kidney divided by the perfusate 
concentration (\iglml). 
Effects on kidney function 
Kidney function was monitored by determination of urinary flow, urinary pH, GFR, 
and fractional excretion of sodium, chloride, potassium, glucose, calcium, and magnesium. As an 
illustration of the kidney function of the IPK, table 6.3 shows the functional parameters of the 
control period of control experiments. Kidney functicm decreased slowly in the course of the 
control experiments (table 6.4a, first column). 
Naproxen doses above 3.7S μg affected kidney function. The change in renal function 
mainly occured during the first 30 minutes after drug addition. After this period, renal function 
remained practically stabile. As can be seen in table 6.4a, low naproxen doses (0.0375 to 0.375 
μg) did not influence kidney function as compared to control experiments. Higher doses (3.75 to 
3750 μg) resulted in a decrease in the urinary flow, GFR, and fractional excretion of sodium, 
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Table 6.3. Renal functional parameters of the control period" 
Functional parameter 
GFR 
Urinary flow 
Water reabsorption 
Urinary pH 
FE sodium 
FE chloride 
FE potassium 
FE glucose 
FE magnesium 
FE calcium 
(μΐ/min) 
(μΐ/тш) 
(%) 
(%) 
(%) 
(%) 
(%) 
{%) 
(%) 
430 
25 
94.1 
5.8 
2.6 
3.2 
38 
2.5 
47 
4.5 
± 8 0 
± 5 
± 0.5 
± 0.2 
± 0.6 
± 0.8 
± 13 
± 0.4 
± 9 
± 1.4 
" Mean values of the control period from control expertinents 
are presented (N = 12). FE = fractional excretion. 
potassium, chloride, magnesium, and calcium. Fractional excretion of glucose was not affected. 
Doses above 37.5 μg resulted in significant changes as compared to control experiments. 
Increasing the naproxen dose from 375 μg to 3750 μg did not lead to a greater decrease in 
urinary flow, GFR, and fractional excretion of electrolytes. 
Addition of 375 μ£ of the 1-enantiomer of naproxen to the IPK did not cause an effect 
on kidney function (table 6.4b). 
Because naproxen reduces the PGE, synthesis, we examined whether PGE, could 
influence the effects of naproxen on kidney function. The presence of 13.3 ng/ml PGE, in the 
perfusate did not influence the effects of naproxen. However, a ten times higher concentration of 
PGE, in the perfusate (133 ng/ml) fully opposed the effects of naproxen on kidney function 
(table 6.4b). 
No statistical significant differences in renal handling were observed after the addition 
of PGE, to the perfusate (table 6.2). Kidney function, as compared to control experiments, was 
not affected by PGE,. 
In contrast to the effects seen with low naproxen doses, very high doses (IMO5 μg) of 
naproxen or its 1-enantiomer caused an increase in the urinary flow and in the fractional 
excretion of sodium, potassium, chloride, glucose, and calcium (table 6.4b). GFR and fractional 
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Table 6.4a. Normalized effects of naproxen on kidney function' 
Control d-NA 
Dose ^g) - 0.0375 0.375 3.75 37.5 375 3750 
Urinary flow 0.84±0.11 0.81±0.04 0.88±0.05 0.71±0.12 0.65±0.09" 0.57±0.06"· 0.58±0.10" 
(μΐ/πύη) 
UrinaiypH 1.00±0.03 0.97±0.03 1.023±0.014 1.02±0.02 1.03±0.02 1.01±0.03 0.983±0.013 
GFR 0.67 ±0.08 0.69 ±0.072 0.68 ±0.03 0.61 ±0.03' 0.54 ±0.10* 0.52±0.03"· 0.53 ±0.09* 
(μΐ/πΰη) 
FE Na 12 ±0.2 0.94±0.09 1.20±0.11 1.0 ±0.2 0.89±0.1Г 0.76^.09*" 0.72*0.04"* 
(%) 
FE К 1.1 ±0.3 0.98±0.15 1.19±0.12 1.2 ±0.4 0.82±0.10· 0.71±0.14" 0.70±0.19" 
(%) 
FE α 1.3 ±0.2 1.2 ±0.3 1.36±0.08 1.0 ±0.2 0.83±0.10*" 0.82*0.08"* 0.79±0.19" 
(%) 
FE gluc 2.5 ±1.0 2.4 ±0.4 3.4 ±0.6 3.1 ±1.3 3.1 ±0.5 2.7 ±0.5 2.5 ±0.7 
(%) 
FE Mg 0.75±0.10 0.68±0.06 0.70±0.05 0.70±0.07 0.55±0.04"' 0.49±0.07'" 0.48±0.06"· 
(%) 
FE Ca 1.1 ±0.2 0.88±0.16 1.1 ±0.3 1.0 ±0.4 0.9 ±0.2 0.75±0.15" 0.78±0.14" 
(%) 
" Mean values of the period 30 - 120 min are presented, control (N = 12) and naproxen 
experiments (N = 4). Values are normalized to the mean values of the control period cO - c30. 
FE = fractional excretion. 'P < 0.05 vs. control; "P < 0.01 vs. control; "'P < 0.001 vs. control. 
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Table 6.4b. Normalized effects of naproxen and its l-enantiomer on kidney function' 
Control NA 
Dose Oig) - IMO5 m o 5 375 375b 375' 375 
d/1 d 1 d d d 1 
Urinaiy flow 0.84:10.11 1.4 ±0.3' 1.4 ±0.3" 0.57±0.06~ 0.51 ±0.03"" 0.72 ±0.09 0.77±0.0б 
(μΐ/πώι) 
UrinaiypH 1.00±0.03 1.02±0.03 1.057±0.016~1.01 ±0.03 1.01 ±0.02 1.00 ±0.01 1.01±0.02 
GFR 0.67 ±0.08 0.62 ±0.05 0.66 ±0.03 0.52±0.03~ 0.57 ±0.04" 0.59 ±0.08 0.65±0.07 
(μΐ/πύη) 
FE Na 12 ±0.2 2.9 ±0.8" 3.0 ±1.1" 0.76±0.09~ 0.60 ±0.08·" 1.1 ±0.1 1.0 ±0.2 
(%) 
Р Е К 1.1 ±0.3 4.2 ±1.7" 2.4 ±0.5" 0.71 ±0.14" 0.52 ±0.05"· 12 ±0.2 1.2 ±0.6 
(%) 
FE α 1.3 ±0.2 4.2 ±1.0"* 3.5 ±0.9"· 0.82М.08"· 0.71 ±0.10"" 1.21 ±0.18 1.2 ±0.3 
(*) 
FE glue 2.5 ±1.0 5.3 ±1.1*" 5.3 ±0.9"· 2.7 ±0.5 2.1 ±0.3 3.1 ±0.7 3.1 ±1.4 
(%) 
FE Mg 0.75 ±0.10 1.0 ±0.2 0.67 ±0.10 0.49 ±0.07"· 0.61 ±0.07* 0.66 ±0.07 0.68±0.07 
FE Ca 1.1 ±0.2 5.5 ±1.0*" 3.4 ±0.8*" 0.75±0.15" 0.58 ±0.10*" 1.03 ±0.13 1.1 ±0.4 
(*) 
* Mean values of the period 30 - 120 min are presented, control (N = 12) and naproxen and Ι­
ΝΑ experiments (N = 4). Values are normalized to the mean values of the control period cO -
c30. FE = fractional excretion. 'P < 0.05 vs. control; "P < 0.01 vs. control; "'P < 0.001 vs. 
control. 
* Perfusate contained 13 J ng PGE, Imi. 
' Perfusate contained 133 ng PGE2 Imi. 
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excretion of magnesium were not affected as compared to control experiments. 
Perfusion flow and perfusion pressure were not affected by addition of naproxen or Ι­
ΝΑ. The mean perfusion flow of all naproxen and 1-NA experiments (N - 44) was 18 ± 2 
ml/min and the mean perfusate pressure was 91 ±7 mm Hg. 
6.5 DISCUSSION 
Only a small fraction of the Altered naproxen amount was excreted into the urine 
(table 6.1). This means that naproxen must be reabsorbed extensively. Reabsorption is probably 
a passive process, dependent on the urinary flow and pH. Because no saturation of the 
reabsorption can be detected in the broad concentration range studied, active reabsorption seems 
unlikely. However, this possibility cannot be excluded. 
Besides filtration and reabsorption, naproxen is probably also actively secreted. An 
indication for the active secretion of naproxen is the reduction of the naproxen clearance by 
probenecid, which blocks the tubular secretion of organic anions (Runkel et al., 1978). Active 
secretion cannot be deduced from our excretion rate data, probably because of the extensive 
reabsorption. As a result of active uptake of naproxen across the basolateral membrane and 
facilitated diffusion across the brush-border membrane, naproxen can accumulate in the tubular 
cells. In the IPK naproxen accumulates considerably. At low naproxen perfusate concentrations 
the КУР ratio is highest (flg. 6.2). Increasing the naproxen perfusate concentration results in a 
decrease in the K/P ratio. This decrease can be explained by saturation of active secretion of 
naproxen. Reabsorption could also result in accumulation of naproxen. However, accumulation 
would probably be linear with the perfusate concentration and could not explain the course of 
the K/P ratio as a function of the perfusate concentration. 
Addition of 1-NA to the IPK did not lead to different perfusate concentrations, 
excretion rate data or accumulation values compared with addition of naproxen. This indicates 
nonstereoselective pharmacokinetics in the IPK. Goto et al. (1982) reported a greater half-life for 
naproxen than for its l-enantiomer in vivo. This was at least partly caused by the stereoselective 
inversion of 1-NA to naproxen, which probably does not occur in the IPK or only to a small 
extent. Other nonrenal factors probably also play an important role in the different half-lives of 
both enantiomers. 
The major metabolite of naproxen is DMN. About 30 % of the naproxen dose is 
excreted as DMN or its glucuronide in vivo (Runkel et al., 1973; Runkel et al., 1978). 
Metabolism predominantly occurs in the liver, but in the IPK also large amounts of DMN are 
formed (table 6.1). No difference in demethylation could be seen between the d - and 1-
enantiomers. These observations indicate that the kidney is an important site of demethylation 
and that this demethylation is a nonstereoselective process. 
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The effects of naproxen on kidney function, as described in literature, are not clear 
(Brater et al, 1985; Dixey et al., 1987; Eriksson et al., 1987). In the IPK we see a dose 
dependent influence of naproxen on kidney function. Low naproxen doses (0.0375 to 0.375 μg) 
did not influence kidney function. Naproxen doses ranging from 3.75 to 3750 μg caused a 
decrease in urinary flow, GFR, and fractional excretion of sodium, chloride, potassium, 
magnesium, and calcium, as compared to control experiments (table 6.4a). The decrease became 
significantly different from control experiments when naproxen doses greater then 37.5 μg were 
used. Fractional excretion of glucose was not influenced by these doses of naproxen, indicating 
no effect on the glucose carrier in the proximal tubule or possibly no effect on the proximal 
tubule at all. Beside the decrease of GFR, naproxen therefore probably exerts a direct or indirect 
distal tubular effect causing the decrease in the fractional excretion of electrolytes. This is in 
agreement with the proposed most probable site of effect of NSAIDs in vivo in humans: the 
thick ascending limb of Henle (Kaojarem et al., 1983). 
It is well known that NSAIDs can reduce GFR and renal blood flow (Give and Stoff, 
1984; Dunn et al, 1988). In the IPK we also see a reduction in GFR afta- the addition of 
naproxen, while perfusion flow was unchanged. Studies in which the effect of naproxen was 
examined using healthy volunteers, showed no reduction in GFR (Brater et al, 1985; Dixey et 
al, 1987). Addition of naproxen to patients with ccngestive heart failure however resulted in a 
reduction of the GFR although this reduction was not significant (Eriksson et al., 1987). The 
effects of NSAIDs on renal hemodynamics are probably dependent on the physical condition of 
the human beings or animals (Clive and Stoff, 1984). 
In contrast with naproxen, addition of 375 μg 1-NA did not influence kidney function. 
This difference might be caused by a different potency of both enantiomers in reducing the 
PGE, synthesis. Naproxen has been shown to be a very potent inhibitor of the PGE, synthesis, 
while 1-NA is a much less potent inhibitor (Tomlinson et al, 1972). The decrease of PGE, 
amount in the kidney might be the cause of the increased electrolyte reabsorption seen after 
addition of naproxen to the IPK (Kaojarem et ей., 1983). The presence of relatively low PGE, 
concentrations (13.3 ng/ml) in the perfusate could not undo (he effects of naproxen cm the 
kidney function. The presence of ten times higher PGE, concentrations (133 ng/ml), however, 
fully opposed the effects of naproxen. The effects of naproxen on kidney function therefore are 
the result of the inhibition of the PGE, synthesis by naproxen. After comparing the effects of 
different naproxen concentrations, a lowest concentration at which first an effect is seen, can be 
deduced. This concentration is about 0.21 μ&ΊηΙ (dose 37.5 μg). Because the influence of 
naproxen on kidney function is caused by the PGE, synthesis inhibition, this naproxen 
concentration is probably within the same range as the lowest naproxen concentration at which 
the PGE, synthesis is inhibited. Matsuda et al. (1983) found that a naproxen concentration of 
about 0.25 μ&ΊηΙ was able to inhibit 50 % of the PGE, synthesis in fibroblast cells. This value 
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is comparable to the lowest naproxen concentration at which first an effect on kidney function 
is seen and supports the idea that the inhibition of the PGE, synthesis is the cause of the effects 
of naproxen on kidney function. 
Addition of PGE, to the perfusate did not influence kidney function. It is known that 
PGE, can cause vasoconstriction in the IPK, resulting in an increase in perfusion pressure 
(Malik and McGiff, 1975; Rosenthal and Pace-Asciak, 1980). Because the increase in perfusion 
pressure only lasted a few minutes and because in our experiments the kidneys were perfused 
with PGE, from the moment of isolation, no increase in perfusion pressure is seen in our 
experiments. However, if PGE, is added to the perfusate after the stabilization period, we also 
observe a short lasting increase in the perfusion pressure (results not shown). 
Very high doses naproxen and 1-NA caused an increase in urinary flow and fractional 
excretion of sodium, chloride, potassium, glucose, and calcium. GFR and fractional excretion of 
magnesium remained uninfluenced as compared to the control period. These very high doses 
therefore exert a nonstereoselective tubular effect, which is quite different from the 
(stereoselective) influence on kidney function caused by low naproxen doses. Goto et al. (1982) 
reported Stereoinversion of 1-NA to naproxen. Inversion of the d-enantiomer to the 1-enantiomer 
was not observed. Whether Stereoinversion occurred in the kidney is not clear. Addition of 37S 
μg 1-NA did not influence kidney function. Addition of 37.S and 3.75 μg naproxen had an 
influence on kidney function, although (he influence of 3.75 μg naproxen did not reach the 5 % 
level of statistical significance. If only 1 % of the 1-NA dose was inverted to naproxen, an 
effect on kidney function would be expected after addition of 375 μg 1-NA to the IPK. 
Therefore it seems unlikely that large amounts of 1-NA are converted to the d-enantiomer, 
although this possibility cannot be ruled out completely. 
In conclusion, renal handling of naproxen and 1-NA probably involves glomerular 
fíltration, active secretion, and passive reabsorption. Both enantiomers accumulate considerably 
in the IPK. The kidney is a major site of demelhylatioa Renal handling and metabolism do not 
appear to be stereoselective. Very high naproxen and 1-NA doses (I+IO* μg) affect kidney 
function in a nonstereoselective manner. Lower doses (37.5 to 3750 μg) exert a different, 
specific and stereoselective influence on kidney function. Lower naproxen doses cause water and 
salt retention, while similar 1-NA doses have no influence. These effects of naproxen on kidney 
function are probably the result of the decrease of the PGE, amount caused by inhibition of the 
PGE, synthesis by naproxen. 
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CHAPTER 7 
RENAL HANDLING AND EFFECTS OF 
S(+)-IBUPROFEN AND R(-)-IBUPROFEN 
IN THE ISOLATED PERFUSED RAT KTONEY1 
P.O.F. Cox, W.M. Moons, F.O.M. Rüssel and CA.M van Ginneken 
1
 Br. J. Phannacol. 103, 1542 -1546 (1991) 
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7.1 SUMMARY 
We studied renal handling and effects of both ibuprofen enantiomers in the isolated 
perfused rat kidney (IPK). S(+)- and R(-)- ibuprofen were reabsorbed extensively and 
accumulated in the kidney in a concentration dependent manner. No pharmacokinetic differences 
were observed between the two enantiomers. S(+)-ibuprofen concentrations ranging from 0.2S to 
25 μg.ml'1 (1.2 to 120 μΜ) caused a decrease in urinary flow, glomerular filtration rate (GFR), 
and electrolyte excretion. Urinary pH and excretion of glucose were not influenced. R(-)-
ibuprofen concentrations ranging from 2.S to 25 μgJnΓl (12 to 120 μΜ) also decreased urinary 
flow and electrolyte excretion. This decrease, however, was less than observed with S(+)-
ibuprofen. GFR, urinary pH, and glucose excretion were not affected by R(-)-ibuprofen. 
Prostaglandin E, (PGEJ concentrations of 133 ngjnl'1 reversed the effects on renal function of 
both enantiomers. Very high S(+)- and R(-)-ibuprofen concentrations ( > 400 μgJnl"1) resulted in 
an increase in urinary flow and fractional excretion of sodium, chloride, potassium, glucose, and 
calcium. We conclude that the pharmacokinetic behavior of ibuprofen in the kidney is not 
stereoselective. Relatively high concentrations of both enantiomers increased the urinary flow 
and electrolyte excretion in a nonstereoselective manner. Lower concentrations of S(+)-ibuprofen 
decreased urinary flow and electrolyte excretion. The pharmacologically inactive R(-)-ibuprofen 
was also able to affect renal function in a similar way, however, at different concentrations. 
These effects on renal function are probably caused by inhibition of the PGE, synthesis. 
72 INTRODUCTION 
An important group of nonsteroidal anti-inflammatory drugs (NSAIDs) are the 2-
arylpropionic acids. These drugs possess an asymmetric carbon atom and can therefore occur 
either as the S(+)- or R(-)-isomer. They are marketed as racemates, except for naproxen, which 
is marketed as the pure S(+)-enantiomer. The S(+)-enantiomers have been shown to possess 
essentially all the phannacological activity (Adams et al., 1976; Hutt & Caldwell, 1983). In 
vivo, chiral inversion occurs from the pharmacologically inactive R(-)-enantiomer to the active 
S(+)-enantiomer, predominantly in the liver (Hutt & Caldwell, 1983; Jamali, 1988; Knadler & 
Hall, 1990; Knihinicki et al., 1989). 
NSAIDs are well known to influence renal function and are usually associated with a 
decrease in urinary flow and electrolyte excretion, which is related to the inhibition of the 
prostaglandin synthesis (Clive & Stoff, 1984; Dunn & Zambraski, 1980). (S,R)-Ibuprofen is 
widely used as an analgesic, but its effects on renal function are not clearly documented. Allon 
et al. (1990) reported a decrease in urinary flow and sodium excretion caused by (SR)-
ibuprofen. Brater et al. (1985) observed that (5Д)-іЬиргоГеп affected only the chloride excretion, 
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while Passmore et al. (1989, 1990) found no influence on kidney function. The varying results 
might be caused by the use of different (S,R)-ibuprofen doses and by different study protocols. 
The physical condition of the human beings or animals under investigation is also important 
(Clive & Stoff, 1984). The influence of the separate stereoisomers S(+)- and R(-)-ibuprofen on 
renal function is unknown. 
Renal handling might also play a role in the nephrotoxic action of NSAIDs. It 
probably involves glomerular filtration, active secretion, and passive reabsorption. As a result of 
active secretion, drugs can accumulate in the proximal tubular cells and exert a damaging effect. 
Previously we have shown that the IPK is a good model for investigating renal 
handling and influence of NSAIDs on renal function (Cox et al., 1990a). Using this model, we 
have studied both enantiomers of naproxen (Cox et al., 1990b). The aim of the present 
investigation was to provide detailed data on the renal handling of the active S(+)- and the 
inactive R(-)-enantiomer of ibuprofen. We also looked at the influence of both enantiomers on 
renal function with and without concomitant administration of PGE,. 
7.3 METHODS 
Materials 
Sodium pentobarbital was obtained from Aphanno (Arnhem, The Netherlands). Heparin, 
insulin and aldosterone were from Organon (Oss, The Netherlands). Pluronic F-108 was 
purchased from BASF (Arnhem, The Netherlands), lysine-vasopressin from Sandoz (Basel, 
Switzerland) and angiotensin Π from Beckmann (Palo Alto, Ca., USA). Synthamin 14 was from 
Travenol (Thetford, Norfolk, England). LiChrosorb RP-18 was from Merck (Dannstadt, FRG). 
All other chemicals were of analytical grade and were purchased either from Sigma (St.Louis, 
Mo., USA) or Merck (Darmstadt, FRG). 
EPK experiment 
The IPK experiments were performed as described in detail elsewhere (Cox et al., 
1990a). In short, male Wistar rats (225-275 g) were used in all experiments. The right kidney 
was isolated without interruption of the blood flow and placed in a fluid bath with a constant 
temperature of 37.5° С The perfusion fluid was recirculated and continuously oxygenated. It 
was based on a Ringer's solution supplemented with amino acids and did not contain any 
protein. Instead of albumin, the perfusate contained pluronic F108 (25 g.l') as colloid osmotic 
agent GFR was determined instantaneously and continuously, using cyanocobalamin as a 
marker, as described in detail elsewhere (Brink and Siegers, 1979). 
After isolation, the kidney was allowed to stabilize for 30 min. During this period no 
urine or perfusate samples were taken. Kidneys with a fractional water reabsorption of less than 
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93 % were excluded. The subsequent experimental time was 150 min, during which urine was 
collected over 10 min periods. The first 30 min were used as control values for renal function. 
In this control period total perfusate volume was 300 ml. After this period a new reservoir was 
connected with a total perfusate volume of ISO ml, in which S(+)- or R(-)-ibuprofen woe 
already dissolved. Both enantiomers were added as sodium salt. Perfusate samples (SO - ISO μΐ) 
were taken from the reservoir at the midpoint of the urine collection periods. Two additional 
samples were taken. One, before perfusion with drug and one at the end of the experiment 
At the end of the experiment the kidney was removed from the system, blotted, 
weighed and frozen. S(+)- or R(-)-ibuprofen concentrations in the kidney, in the perfusate 
samples, and in the urine samples were determined. 
Average values are expressed as mean ± SD. Statistical differences between means 
were established using Student's t-test. A difference was considered significant if Ρ < 0.0S. 
Analytical methods 
Urine samples and perfusate were analyzed for sodium, potassium, chloride, glucose, 
magnesium, calcium, and (S,R)-ibuprofen. Sodium and potassium were determined by flame 
photometry. Chloride was determined by electrochemical titration, magnesium by atomic 
absorption flame photometry. Calcium was determined by a colorimetrical method, based on the 
formation of a deep blue calcium complex of methylthymol blue (RAPID STAT diagnostic kit 
of Lancer, Athy, Ireland). The GLUCO-QUANT glucose kit from Boehringer (Mannheim, FRG) 
was used for glucose analysis. This analysis is based on the enzymatic transformation of glucose 
and the simultaneous formation of NADPH which is measured by UV spectroscopy. 
Perfusate and urine (S,R)-ibuprofen concentrations were determined by a high-
performance liquid chromatographic method which is a modification of the method described by 
Askholt & Nielsen-Kudsk (1986). Chromatography was performed on a stainless steel column 
(10 cm χ 4.6 mm ID) packed with LiChrosorb RP-18 (particle size S μιη) using as eluent a 
mixture of 60 % methanol and 40 % Η,ΡΟ« (SO mM, pH 4.6). The elution rate was 1 ml.min' 
and tbufenac was used as the internal standard. The compounds were detected by UV absorption 
at 220 nm. Under these conditions the retention times of ibufenac and (S,R)-ibuprofen were 8 
and 12 min, respectively. 
Depending on the drug concentration, 0.4 to 4 μg ibufenac was used in each sample, 
and 20 to 100 μΐ urine or perfusate was added. After addition of SO μΐ l.S M HCl, total 
volume was adjusted to ISO μΐ using distilled water. Di-ethyl ether (1.3S ml) was added, the 
mixture was vortexed for 10 sec and centrifuged for 10 min at 6000 χ g. The di-ethyl ether 
layer was removed, evaporated under a stream of dry filtered air on ice, 0.2 to 1 ml of the 
elution fluid was added and the mixture was vortexed. An aliquot (20 μ!) of the solution 
obtained was injected onto the column. Calibration was performed using peak area ratios of 
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(S,R)-ibuprofen and ibufenac after spiking samples of blank perfusate with various amounts of 
(S,R)-ibuprofen. Linear calibration curves were obtained in all cases (R1 > 0.980). 
(S>R)-Ibuprofen concentrations in the kidneys were determined in a similar way. The 
kidney was homogenized in 5 to 10 ml distilled water with a Polytron homogenizer on setting 
10 for 2 times 60 sec. To 250 μΐ of the homogenate, 1 to 5 μg ibufenac and 50 μΐ 0.004 M 
HCl were added. The mixture was vortexed, 1.2 ml di-ethyl ether was added and it was 
vortexed again for 15 sec. After centrifugation for 30 min at 6000 χ g, the di-ethyl ether layer 
was removed and the extraction was repeated. The di-ethyl ether fractions were collected and 
evaporated under a stream of dry filtered air on ice, 0.5 to 1 ml elution fluid was added and 
the solution was vortexed. An aliquot (20 μΐ) of the clear solution obtained was injected onto 
the column. Calibration was performed using peak area ratios of (ЗД)-іЬирк^еп and ibufenac 
after spiking samples of blank kidney homogenates with various amounts of (S3)-ibuprofen 
(recovery > 90 %). Linear calibration curves were obtained in all cases (R2 > 0.987). 
The limit of detection for the determinations of (S,R)-ibuprofen was 0.5 μg per ml 
fluid injected onto the column. 
7.4 RESULTS 
Renal handling 
The kinetic data of several S(+)- and R(-)-ibuprofen doses are shown in table 7.1. The 
excretion of both enantíomers into the urine was low. As a result, the perfusate concentration 
showed practically no decrease during the experiments. The excretion rate was nearly constant 
after its maximal value was reached (usually within the first 30 min after addition). 
The amount of S(+)- and R(-)-ibuprofen in die kidney was determined at the end of 
the experiment. In order to determine whether the drugs accumulated, the kidney to perfusate 
(K/P) ratio was calculated. This ratio is the drug amount Qig) per g kidney divided by the 
perfusate concentration. A rabo higher than one indicates accumulation of drug. As shown in 
table 7.1, S(+)- and R(-)-ibuprofen accumulated in the kidney in a concentration dependent 
manner. Increasing the perfusate concentration decreased the K/P ratio. The presence of 133 
ngjnl"' PGEj in the perfusate resulted in a significantly higher excretion rate of S(+)-ibuprofen. 
The excretion rate of R(-)-ibuprofen was also increased, although not significantly. 
No significant differences between the kinetic data of both enantiomers were observed. 
Effects on kidney function 
Renal function was monitored by determination of the GFR, urinary flow, urinary pH, 
and fractional excretion of sodium, chloride, potassium, glucose, magnesium and calcium. S(+)-
ibuprofen decreased GFR, urinary flow and fractional excretion of all electrolytes (table 72). 
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Table 7.1. Renal handling of S(+)- and R(-)-ibuprofen' 
Dose S(+)/R(-) Perfusate Filtration Excretion FE" Amount in K/P 
concentration1" rate"1 rate' kidney ratio' 
^g) ^g-ml·') ^g-min') (Hg-min') (%) ^g.g"1) 
37500 
3750 
375 
375' 
37500 
3750 
375 
375« 
S(+) 
S(+) 
S(+) 
S(+) 
R(-) 
R(-) 
R(-) 
R(-) 
199 ± 16 
20.5 ± 1.2 
1.9 ± 0 . 2 
1.8 ± 0 . 2 
183 ± 12 
18 ± 2 
1.7 ±0.3 
2.0 ± 0.4 
57 ± 9 
5.4 ± 1.2 
0.50 ±0.14 
0.62 ±0.13 
55 ± 11 
4.9 ± 1.0 
0.44 ±0.12 
0.58 ±0.17 
2.11 ±0.19 
0.22 ±0.03 
0.019 ± 0.003 
0.031 ± 0.003" 
1.8 ± 0.3 
0.19 ±0.02 
0.023 ± 0.005 
0.026 ± 0.004 
3.7 
4.0 
3.8 
5.0 
3.3 
3.8 
5.1 
4.5 
276 ± 19 
31 ± 3 
4.0 ± 0.5 
3.7 ± 0.2 
303 ± 13 
31 ± 4 
3.1 ± 0.4 
4.0 ± 0.9 
1.44 ± 0.18 
1.6 ± 0 . 2 
2.4 ± 0 . 3 
2.46 ± 0.18 
1.17 ± 0.13 
1.86 ± 0.16 
2.3 ±0.5 
2.7 ± 0 . 2 
" N = 4 for all doses. " Ρ < 0.01 vs. experiments in which no PGE¡ was added. 
* Mean values of the period 0 -120 min are presented. 
' Mean values of the period 30 - 120 min are presented. 
4
 Filtration rate = GFR * perfusate concentration. 
' FE = fractional excretion = 100 * excretion rate I filtration rate. 
1
 KIP ratio = amount drug (pg) in kidney per g kidney divided by the perfusate concentration. 
' Perfusate contained 133 ng.ml' PGE2. 
Urinary pH and fractional excretion of glucose were not influenced. The change occurred mainly 
in the first 30 min after drug addition, thereafter it was practically stable. 
The effects of a broad concentration range of S(+)- and R(-)-ibuprofen on renal 
function are shown in figure 7.1. The functional parameters are expressed as normalized values. 
S(+)-ibuprofen concentrations ranging from 0.0025 to 0.025 μκ-ΐηΓ1 did not affect renal function. 
At concentrations between 0.25 and 25 μgJnΓ1 GFR, urinary flow, and fractional excretion of 
electrolytes decreased as compared to control experiments. The presence of 133 ng.ml"1 PGE, in 
the perfusate completely abolished the effects of S(+)-ibuprofen on kidney function. 
A R(-)-ibuprofen concentration of 0.25 μg.ml"1 did not affect renal function. 
Concentrations ranging from 2.5 to 25 μg.ml~1 caused a decrease in urinary flow and fractional 
excretion of electrolytes, which was less than observed with S(+)-ibuprofen. GFR, urinary pH, 
and fractional excretion of glucose were not affected. The effects of R(-)-ibuprofen on urinary 
flow and fractional excretion of sodium, chloride, magnesium, and calcium were reversed by 
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Table 7.2. Renal function of control experiments and experiments with S(+)-ibuprofen' 
Parameter 
Urinary flow (цілпіп1) 
GFR (ці.тіп"') 
Urinary pH 
FE of glucose (%) 
FE of sodium (%) 
FE of chloride (%) 
FE of potassium (%) 
FE of calcium (%) 
FE of magnesium (%) 
Exp 
. 
S(+) 
-
S(+) 
-
S(+) 
-
S(+) 
-
S(+) 
-
S(+) 
-
S(+) 
-
S(+) 
-
S(+) 
cO - c30 
25 ± 5 
26 ± 5 
430± 80 
480±60 
5.8 ± 0.2 
5.9 ± 0.2 
2.5 ± 0.4 
3.1 ± 0.9 
2.6 ± 0.6 
2.8 ± 0.8 
3.2 ± 0.8 
2.8 ± 1.1 
38 ± 13 
29 ± 8 
4.5 ± 1.4 
4.0 ± 1.2 
47 ± 9 
39 ± 10 
O'- 30 
24 ± 5 
22 ± 4 
400±70 
400±50 
5.7 ± 0.2 
5.9 ± 0 ^ 
2.9 ± 0.8 
3.8 ± 1.4 
2.5 ± 0.6 
2.4 ± 0.7 
3.4 ± 0.8 
3.2 ± 1.0 
45 ± 17 
37 ± 6 
4.6 ± 1.4 
4.4 ± 0.8 
48 ± 10 
39 ± 11 
Time (min) 
3 0 - 6 0 
22 ± 5 
15 ± 3 " 
340±50 
300±40 
5.8 ± 0.2 
5.9 ± 0.2 
3.7 ± 1.5 
5.0 ± 1.7 
2.6 ± 0.7 
1.7 ± 0.4* 
3.6 ± 0.9 
2.3 ± 0.8* 
46 ± 18 
23 ± 7" 
4.5 ± 1.5 
3.3 ± 0.5* 
41 ± 9 
27 ± 9 ' 
1 
6 0 - 90 
21 ± 5 
13 ± 2 " 
290±50 
240±20· 
5.8 ± 0.3 
5.9 ± 0.2 
6 ± 3 
7.2 ± 2.6 
2.8 ± 0.8 
1.6 ± o . r 
3.8 ± 1.0 
1.7 ± 0.6'" 
39 ± 1 5 
15 ± 5 -
4.4 ± 1.8 
2.9 ± 0.5" 
34 ± 8 
19 ± r 
9 0 - 120 
21 ± 7 
13 ± 2" 
240І50 
210± 40 
5.9 ± 0.3 
5.9 ± 0 ^ 
10 ± 6 
12 ± 3 
3.9 ± 1.4 
1.8 ± 0.4-
5.0 ± 1.6 
1.8 ± 0.6~ 
41 ± 15 
16 ± 5'" 
6 ± 3 
3.0 ± 0.9* 
30 ± 7 
16 ± 5 " 
" Mean values of three wine 10 - min periods are given. - = control experiments (N = 12) and 
S(+) = experiments with 1.9 ± 0.2 [ig.mt' S(+)-ibuprofen (N = 4). FE = fractional excretion, с = 
control period. ' Ρ < 0.05, " Ρ < 0.01 and '" Ρ < 0.001 vs. control experiments. 
* Time at which the reservoir is switched to perfusate with or without S(+)-ibuprofen. 
PGE, (133 ng.ml·1). Fractional excretion of potassium, however, was decreased in the presence 
of PGE,, although not statistically significant as compared to R(-)-ibuprofen experiments without 
PGE,. In the absence of (S,R)-ibuprofen, PGE, did not influence kidney function. 
High concentrations of S(+)- and R(-)-ibuprofen (250 μgJnΓ )^ resulted in the same 
parameter values as in control experiments (figure 7.1). S(+)- and R(-)-ibuprofen concentrations 
above 400 Mg.mT1 increased signifîcantly the urinary flow and fractional excretion of sodium, 
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potassium, chloride, glucose, and calcium. GFR and fractional excretion of magnesium were not 
affected. The experiments with these very high concentrations were performed only once, 
because of the limited amounts of the enantiomers available. 
Neither the perfusion flow, nor pressure were affected by S(+)- or R(-)-ibuprofen. The 
mean perfusion flow of all Ibuprofen experiments (N = 48) was 14.3 ± 1 . 5 mljnin"1 and the 
mean perfusion pressure was 86 ± 5 mm Hg. 
7.5 DISCUSSION 
A very broad concentration range (0.0025 to 500 μg.mΓ1) of both Ibuprofen 
enantiomers was studied in the IPK. The normal therapeutic range is 1 - 50 μg.mΓ^  (Aarons et 
al., 1983). In vivo, Ibuprofen is highly bound to plasma proteins (99 %). The concentration 
range we examined included the therapeutically used total as well as unbound concentrations. 
Like other 2-arylpropionic acids, R(-)-ibuprofen can be inverted to its active S(+> 
enantiomer, whereas Stereoinversion from S(+)- to R(-)-ibuprofen does not occur (Hurt & 
Caldwell, 1983; Jamali, 1988; Knihinkki et al., 1989). The inversion predominantly takes place 
in the liver and there are no indications for the occurrence of inversion in the kidney (Knadler 
& Hall, 1990; Knihinkki et al., 1989). In the present study, we added S(+)- and R(-)-ibuprofen 
separately to the IPK and analysed urine samples, perfusate samples and kidneys for (5Д)-
ibuprofen using a nonstereoselective high-performance liquid chromatographic assay. 
S(+)- and R(-)-ibuprofen must be reabsorbed extensively in the IPK, since only a small 
fraction of the filtered amount was excreted into the urine (table 7.1). Reabsorption is probably 
a passive process, dependent on the urinary pH and flow. Active reabsorption, however, cannot 
be excluded although this seems unlikely because no saturation of the reabsorption could be 
detected over the broad concentration range studied. 
PGE, (133 ng.ml'1) reversed the decrease in urinary flow caused by both Ibuprofen 
enantiomers. The higher urinary flow resulted in a decreased passive reabsorption and an 
increased excretion rate. 
Both stereoisomers accumulated to the same extent in die IPK as can be deduced from 
the K/P ratios. Accumulation is probably the result of active secretion. Saturation of the active 
secretion at higher perfusate concentrations would lead to a decrease in K/P ratio, as observed 
in our experiments. 
S(+)- and R(-)-ibuprofen did not possess different kinetic parameters (table 7.1). This 
indicates nonstereoselective renal pharmacokinetics. In vivo, stereoselective pharmacokinetics are 
observed, which at least partly is caused by inversion of R(-)- to S(+)-ibuprofen (Geisslinger et 
al., 1989; Geisslinger et al., 1990; Knadler & Hall, 1990; Knihinkki et al., 1989, Lee et al, 
1985). Stereoselective metabolism, predominantly occurring in the liver, and other nonrenal 
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factors probably also play a role in the in vivo observed stereoselective pharmacokinetics. 
NSAIDs are usually associated with a decrease in urinary flow and electrolyte excretion 
(Clive & Stoff, 1984). In the IPK, S(+)-ibuprofen concentrations ranging from 0.2S to 25 
μg.πlΓ1 decreased the urinary flow, GFR, and fractional excretion of electrolytes. Urinary pH and 
fractional excretion of glucose were not influenced. Besides the decrease of GFR, S(+)-ibuprofen 
probably exerts a distal tubular effect causing the decrease in electrolyte excretion and urinary 
flow. This is in agreement with the proposed most probable site of effect of NSAIDs: the thick 
ascending limb of Henle (Kaojarem et al., 1983). R(-)-ibuprofen concentrations ranging from 2.5 
to 25 Ц8.т1'' affected renal function in a similar way. As compared to S(+)-ibuprofen, the 
lowest concentration which was able to affect kidney function was at least ten limes higher. 
Because the effects of NSAIDs on renal function might be related to the inhibition of 
prostaglandin synthesis, we investigated the influence of PGE,. The presence of 133 ngjnl"1 
PGE, in the perfusate was able to reverse the renal effects of both Ibuprofen enantiomer .^ The 
effects, therefore, are probably caused by the reduction of the PGE, synthesis. 
Flower (1974) reported that 0.3 μg.ml"> (S,R)-ibuprofen was able to inhibit 50 % of the 
prostaglandin synthesis. Humes et al. (1983) observed a similar value of 0.2 μg.ml~l. Although 
racemic mixtures were used in these studies, these values are comparable to the lowest S(+)-
ibuprofen concentration at which an effect on renal function was observed (0.25 μg.mΓ,). 
Previously, we investigated the effects of naproxen and its enantiomer on renal 
function (Cox et al., 1990b). Naproxen caused similar effects on kidney function as S(+>-
ibuprofen. Also the concentrations needed to bring about the effects were similar (0.25 to 25 
μg.ml",). The inactive enantiomer of naproxen did not affect renal function. In contrast, at the 
same concentration (2.5 μg.ml"l) R(-)-ibuprofen did affect renal function in a similar way as its 
S(+)-enantiomer and naproxen. R(-)-ibuprofen is 160 times less potent in inhibiting the PGE, 
synthesis than S(+)-ibuprofen (Adams et al., 1976). The inactive enantiomer of naproxen, 
however, is only 75 times less potent as compared to naproxen (Tomlinson et al., 1972). The 
difference in potency of inhibiting the prostaglandin synthesis, therefore, cannot explain the 
different effects of R(-)-ibuprofen and the enantiomer of naproxen. Stereoinversion of R(-)- to 
S(+)-ibuprofen could explain the difference. However, there are several arguments against such 
an inversion. Firstly, it has been shown that inversion does not or only to a very small extent 
occur in the kidney (Knadler & Hall, 1990; Knihinicki et al., 1989). Secondly, the lowest R(-)-
ibuprofen concentration needed to affect kidney function is at least 10 times higher than the 
lowest S(+)-ibuprofen concentration. If inversion would be the cause of the R(-)-ibuprofen 
effects on renal function, then at least 10 % of the R(-)-ibuprofen amounts must have been 
inverted. Such a large scale inversion seems unlikely in the IPK, especially considering the 
relatively short experimental time. Thus, although unlikely, inversion of R(-)- to S(+)-ibuprofen 
cannot be excluded and further studies in this direction are needed. 
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Besides the decrease in urinary flow and electrolyte excretion, high concentrations of 
S(+)- and R(-)-ibuprofen increased urinary flow and electrolyte excretion in a nonstereoselective 
manner. At concentrations of 250 μg.ml'l these opposite influences are practically balanced, 
leading to an unchanged renal function as compared to control experiments (figure 7.1). At very 
high concentrations (> 400 μg.mΓ') the nonstereoselective influence is prevailing, resulting in an 
increase in urinary flow and fractional excretion of sodium, chloride, potassium, glucose, and 
calcium. GFR and fractional excretion of magnesium were not affected. Previously, we have 
shown that very high concentrations of naproxen and its enantiomer ( > 500 μgJnl"^) caused a 
similar nonstereoselective influence on renal function (Cox et al., 1990b). 
In summary, renal handling of S(+)- and R(-)-ibuprofen does not appear to be 
stereospecific. Very high concentrations of S(+)- and R(-)-ibuprofen ( > 400 μg.ml'l) increased 
the urinary flow and fractional excretion of electrolytes (except magnesium) in a 
nonstereoselective manner. Lower S(+)-ibuprofen concentrations decreased GFR, urinary flow 
and fractional excretion of electrolytes. R(-)-ibuprofen affected kidney function in a similar way, 
however, at higher concentrations. These effects on renal function are probably caused by the 
inhibition of the PGE, synthesis. Because R(-)-ibuprofen is pharmacologically inactive and 
because it affects renal function, it might be beneficial to use the pure S(+)-enantiomer 
clinically, instead of the racemate. 
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CHAPTER 8 
TRANSPORT OF SALICYLIC ACID AND INDOMETHACIN IN 
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8.1 ABSTRACT 
The basic transport properties of salicylic acid (SA) and indomethacin in freshly 
isolated proximal tubular (PT) cells from the rat kidney were investigated. A PT cell suspension 
was prepared by collagenase digestion, followed by filtration and isopycnic centrifugatíon. 
Glucose transport, studied by a-methylglucose uptake, was dependent on sodium and had an 
apparent K,, of 6.2 ± 1.1 mM and a V^, of 5.2 ± 0.4 nmol/mgjnin. SA uptake was 
concentration-dependent and could be inhibited by probenecid. The kinetic parameters of the 
probenecid-dependent uptake were: apparent K„ 115 ± 55 μΜ and V^, 0.54 ± 0.11 
nmol/mg.min. SA accumulated in the PT cells, and therefore, transport is probably an active 
process. In the presence of probenecid, no SA accumulation was observed. Indomethacin uptake 
increased with time up to 2 min. Thereafter, a sharp decrease occurred, probably caused by 
inhibition of the oxidative phosphorylation. In the presence of probenecid, uptake was 
significantly reduced and no longer time-dependent. Indomethacin accumulated in the PT cells 
by a factor more than 20. Accumulation was decreased with increasing concentrations. In the 
presence of probenecid, indomethacin also accumulated in the PT cells. This is probably the 
result of the high protein binding of indomethacin. Cooling to 4° С did not lead to a decrease 
in SA and indomethacin uptake. The anion-exchange inhibitor DIDS decreased uptake of both 
drugs at 37° С and 4° С Preloading the PT cells with a-ketoglutarate caused a significant 
increase in uptake of both drugs. We conclude that SA and indomethacin accumulate in the PT 
cells as a result of active transport by a probenecid-sensitìve anion-exchanger. 
8.2 INTRODUCTION 
Although salicylic acid (SA) and indomethacin are generally regarded as safe, a 
number of side-effects have been associated with the administration of these drugs. In particular, 
the potential of renal toxicity which can lead to renal failure is a matter of concern (Boynton et 
al., 1988). The mechanism behind this nephrotoxicity is not fully understood, but renal 
disposition probably plays an important role (Brune et al., 1976; Brune, 1977). 
Renal excretion of SA involves glomerular filtration, active secretion, and passive 
reabsoiption by non-ionic and facilitated back-diffusion (Roch-Ramel et al., 1978; Schild and 
Roch-Ramel, 1988; Chatton et ai, 1990). Renal handling of indomethacin is probably similar. 
Because indomethacin is highly bound to protein (97 - 99 %), only a small unction is filtered 
by the kidney. Secretion of indomethacin involves secretion of unchanged drug, as glucuronide 
conjugate от as inactive metabolites and their glucuronides (Brune and Lanz, 1985). 
Reabsorption of SA and indomethacin is passive and, therefore, dependent on urinary pH and 
flow (Bekersky et al., 1980; Cox et al., 1991а). 
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Active secretion takes place in the proximal tubule. Proximal tubular (FT) cells possess 
two functionally different membranes: the basolateral membrane (BLM) facing the peritubular 
capillary and the brush border membrane (BBM) facing the lumen. The transport of para-
aminohippurate (PAH) in the proximal tubule has been studied in great detail (Ross and 
Holohan, 1983; Shimada et al, 1987; Burckhardt and Ullrich, 1988; Prìtchard, 1988; Rüssel et 
al, 1988; Ullrich and Rumrich, 1988a; Aronson, 1989). Two steps are probably involved: active 
uptake across the BLM and facilitated diffusion across the BBM. Uptake at the BLM is likely 
to be tertiary active (Shimada et al., 1987; Prìtchard, 1988). The required energy is delivered by 
the Na'-IC-ATPase which builds up a sodium gradient across the cell membrane. Krebs cycle 
intermediates, such as dicarboxylates, are accumulated by sodium cotransport in the cells. 
Subsequently, these intermediates can exchange with extracellular PAH at the BLM, resulting in 
a concentration of PAH intracelhilarly. At the BBM, PAH can leave the cell down its 
electrochemical gradient via an anion-exchange mechanism. As a result of active uptake of PAH 
across the BLM and facilitated diffusion across the BBM, PAH can accumulate in the PT cells. 
Since SA and indomethacin are weak organic acids, it is assumed that they are 
transported by the PT cells by the PAH transport system. This assumption is supported by the 
findings that SA influences the transport of PAH and that PAH influences indomethacin 
transport (Ferrier et al, 1983; Ullrich et al., 1988b; De Zeeuw et al., 1988). As a result of 
active transport, both drugs can accumulate in the cells. It has been shown that SA and 
indomethacin accumulate in the whole kidney (Forster and Copenhaver, 1956; Putney and 
Borzelleca, 1973; Graf et al, 197S; Rainsford et al, 1981; Cox et al., 1991a, 1991b). 
In the present study, we examined the transport of SA and indomethacin in isolated PT 
cells from rat kidney. Kinetic parameters of active transport, cellular accumulation values, and 
interaction with other drags were investigated. 
8J MATERIALS AND METHODS 
Chemicals 
Collagenase and bovine serum albumin (BSA) were obtained from Boehringer-
Mannheim (Mannheim, FRG). Sodium pentobarbital was from Aphaimo (Amhem, The 
Netherlands) and heparin from Organon (Oss, The Netherlands). The radiolabelled compounds 
pHJ-HjO (sp.act. 1 mCi/gr), ["C]-indomethacin (sp.act. 39.9 mCi/mmol), [7-"C]-salicylic acid 
(sp.act. 56.1 mCi/mmol) and [U-,4C]-a-methylgIucose (sp.act. 275 mCi/mmol) were purchased 
from New England Nuclear (Boston, Mass., USA). Hy<lroxy-[MC]-methyIinulin (sp.act. 9.45 
mCi/mmol) was from Amersham (Buckinghamshire, UK). Nycodenz (iodohexol) was obtained 
from Nycomed AS (Oslo, Norway). All other chemicals were of analytical grade and were 
purchased from Merck (Darmstadt, FRG) and Sigma Chemical Co. (St.Louis, MO, USA). 
144 
Isolation of proximal tubular cells 
Male Wistar rats, weighing 180 to 220 g, were used and cells were isolated by renal 
perfusion with collagenase, essentially as described by Boogaard et al. (1989). In short, after 
anesthesia with i.p. pentobarbital (45 mg/100 g), the femoral vein was carmulated and heparin 
(125 IU/ 100 g) was injected. The aorta was cannulated and kidneys were perfused with 150 ml 
of a modified Hanks-Hepes (HH) buffer (NaCl 137 mM, K O 5 mM, MgSO, 0.8 mM, Να,ΗΡΟ« 
0.33 mM, КіуОд 0.44 mM, NaHCO, 26 mM, and Hepes 25 mM), pH 7.4 containing 0.5 mM 
EGTA. All perfusion fluids were carbogen saturated at 37° С and perfusion flow was 7.5 
ml/miii. After perfusion with 15 ml HH buffer to remove the EGTA, kidneys were perfused for 
20 min in a recirculating system with 30 ml HH buffer containing 4 mM CaClj and 0.12 % 
(w/v) collagenase. After perfusion, the capsule was removed and the tissue was suspended in 
HH buffer (4° C) supplemented with 1.8 mM CaClj and 2.5 % (w/v) BSA (HH-BSA). The 
resulting suspension was filtered through two layers of nylon gauze (80 цш), centrifuged (3 
min, 4° С, 80 g), and the resulting cell pellet was washed with HH-BSA buffer. The pellet was 
resuspended in 4 ml HH-BSA buffer and mixed with 2 ml of a solution containing 34 % (w/v) 
Nycodenz, dissolved in 6.7 mM KCl, 1.22 mM CaCI? and 10 mM Hepes adjusted to pH 7.40 
by NaOH. The suspension was divided over two tubes. Above this suspension, 1 ml of a 
solution containing 200 μΐ of the 34 % (w/v) Nycodenz solution and 800 μΐ of the HH-BSA 
buffer was layered. On top of these two layers 500 μΐ HH-BSA buffer was added. The tubes 
were centrifuged for 3 min at 2300 g (4° Q. The band at the interface of the two Nycodenz 
layers was removed and washed with cold HH-BSA buffer. Cells were washed twice with 
incubation buffer (ТВ), a modified Krebs-Henseleit buffer containing 117.5 mM NaCl, 4 mM 
KCl, 0.95 mM ΚΗ,ΡΟ,, 1.2 mM MgSO« 22.5 mM NaHCO,, 11.1 mM glucose, and 23 mM 
CaCl,. 
The isolation procedure yielded 15 - 25 . 10* cells per kidney. Viability was higher 
than 85 % as judged by trypan blue exclusion and lactate dehydrogenase release. Cell yield and 
viability were comparable to those found by others (Boogaard et al., 1989; Lash and Tokarz, 
1989). Protein was determined by the Bio-Rad commercial assay using BSA as protein standard. 
Incubation 
In the uptake experiments, cells were incubated in carbogen saturated Ш at 37° С in a 
rotary shaker (200 rotations/min). Per sample approximately 2 . 10' cells were used. Total 
volume was 500 μΐ and carbogen was led over during incubation. Cells were preincubated 
during 15 min. Incubations were stopped by adding 5 ml ice-cold stop buffer (SB), which was a 
modified Krebs-Henseleit buffer pH 7.40 (140 mM NaQ, 4 mM KCl, 0.95 mM ΚΗ,ΡΟ«, 1.2 
mM MgSO*, 2.5 mM CaClj, and 11.1 mM glucose). After rapid centrifugation, cells were 
washed twice with 5 ml SB. 
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Intracellular volume 
For determination of the intracellular volume varying cell amounts (0.5 to 6 . 10* cells) 
were used. Cells were preincubated during 15 min in the presence of pHJ-HjO (100 nCi). After 
preincubation, hydroxy-[14C]-methylinulm (50 nCi) was added and cells were incubated for 2 
min. After rapid centrifugation, the pellet was suspended in 1 ml distilled water and 
radioactivity was determined by liquid scintillation counting. Total pellet volume (extracellular 
volume and intracellular volume) could be determined by the [3Н]-Н20 amount, and extracellular 
volume by the hydroxy-[uC]-methylinuline amount. The calculated difference is the intracellular 
volume. 
For each sample, two blanks without radioactivity added, were handled in the same 
way to determine the protein content of the sample. 
a-Methylglucose (aMG) uptake 
aMG concentration-dependent uptake was determined by incubating the cells during 2 
min with 25 nCi "C-aMG and different concentrations non-radiolabelled aMG. After incubation 
and washing, cells were lysed in 500 μΐ distilled water. Samples were deproteinated by 
centrifugation after addition of 500 μΐ aqueous trichloroacetic acid (20 %, w/v). Radioactivity of 
the supernatant was determined by liquid scintillation counting. The pellet was resuspended in 
80 μΐ NaOH (10 %, w/v) and 920 μΐ distilled water to determine the protem content. 
Concentration dependent aMG uptake was also determined in the absence of sodium. 
In the incubation and stop buffer, sodium chloride was replaced by choline chloride and sodium 
bicarbonate by choline bicarbonate. 
SA and indomethacin transport 
After 15 min preincubation of the cells, SA (50 nCi per sample) and indomethacin (25 
nCi per sample) uptake experiments were performed. After washing, the cells were lysed in 1 
ml distilled water and radioactivity was determined. Protein content was determined in blank 
samples instead of the trichloroacetic acid protein pellet, because the pellet was slightly 
radioactive and we wanted to avoid radioactive contamination of the UV spectrophotometer. 
Sodium-dependent uptake was examined by replacing sodium in the buffers by choline. 
Data handling 
Average values are expressed as mean ± S.D.. Statistical differences between means 
were established using Student's t test. 
aMG sodium-sensitive and SA probenecid-sensitive uptake as a function of 
concentration were fitted to the Michaelis-Menten equation. The goodness of fit was evaluated 
through the deviations between the observed and model-predicted values as R2 = 1 -
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Z(dev)V£(obs)2, where £(obs)2 is the corrected sum of squared observations and Z(dev)2 the sum 
of squared deviations. 
8.4 RESULTS 
Intracellular volume 
Intracellular volume of isolated PT cells was determined using cells from at least 4 
different preparations. The intracellular volume was linearly related to the amount of protein and 
was 8 ± 2 μΐ per mg protein (y = 0.00882 . χ - 0.397, R1 = 0.973). Ibis value is similar to a 
value of 5.7 μΐ/mg protein which is described for LLC-PK, cells (Chung et al, 1982) 
oMG uptake 
oMG is often used as a substrate to investigate glucose uptake in PT cells. We 
investigated aMG uptake in order to compare our preparation with literature values. In the 
absence of sodium, uptake was linearly related to the oMG concentration indicating only 
diffusion. In the presence of sodium, nonlinear uptake was observed (figure 8.1). The difference 
m aMG uptake with and without sodium was fitted to the Michaelis-Menten equation resulting 
aMG uptake (nmol/mg.min) 
15 20 25 
aMG c o n c e n t r a t i o n (mM) 
Figure 8.1. Concentration-dependent aMG uptake in the presence (A) and absence (o ) of 
sodium Cells were incubated for 2 mm with aMG and cells from five different preparations were 
used represents the sodium dependent aMG uptake analyzed according to the Michaehs-
Menten equation. 
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Figure 8.2. Time-dependent SA (5 μΜ) uptake (fig. 82A and 82B), determined at 37° С (A) as 
well as 4° С (о) (fig- 82B). Cells from four different preparations were used. 
in an apparent K„ of 6.2 ± 1.1 mM and V,,^  of 5.2 ± 0.4 nmol/mg-min (R2 = 0.991). The 
apparent K. was somewhat higher than that found by Boogaard et al. (1989) in PT cells but it 
was similar to that found in cortical slices (Segal et al. (1973), apparent K„ of 6 mM). V„„ was 
comparable to a value of 4.1 ± 0.9 nmol/mgjnin found by Boogaard et ai. (1989). 
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Kinetics of SA transport 
Figures 8.2A and 8.2B show Ae uptake of SA (S μΜ) as a function of time. Uptake 
increased during the first 10 min, thereafter a maximal uptake value was reached. Incubating 
cells for periods longer than 10 min, led to a decrease in SA uptake. This decrease was not the 
result of a decrease in viability (table 8.1). 
Table 8.1. Cell viability in the presence of SA, indomethacin and probenecid" 
Experiment 
control 
probenecid 
(S mM) 
SA 
(300 μΜ) 
indomethacin 
(300 μΜ) 
Incubation 
time 
(min) 
0 
5 
10 
60 
0 
5 
10 
60 
0 
5 
10 
60 
0 
5 
10 
60 
Viability expressed 
as percentage of control 
at time 0 min 
lOO" 
97 
95 
89 
98 
93 
91 
82 
98 
92 
92 
88 
94 
93 
94 
90 
± 
± 
± 
± 
± 
± 
± 
± 
± 
± 
± 
± 
± 
± 
± 
2 
3 
3 
4 
3 
3 
3* 
2 
4 
3 
4 
4 
3 
3 
5 
* Viability was determined by lactate dehydrogenase release. 
* The initial viability of control experiments at time 0 min was 
88 ± 2 %. Viability is expressed as a percentage of this initial value. 
' Ρ < 0.05. 
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Figure 83. Concentration-dependent SA uptake with ( о ) and without ( Δ ) concomitant 
administration of S mM probenecid. Cells were incubated for 2 min with SA and cells from four 
different isolation preparations were used. represents the probenecid-sensitive SA uptake 
analyzed according to Michaelis-Menten kinetics. 
i/E r a t i o 
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SA concentration (μΜ) 
Figure 8.4. Accumulation ratio, expressed as intracellular I extracellular concentration (HE) 
ratio, as a function of the extracellular SA concentration. Incubations were performed at 37° С 
during IO min. The ratio was determined in the presence ( о ) and absence ( Δ ) of 5 mM 
probenecid. Cells from 4 different preparations were used. 
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Time-dependent SA uptake was also perfonned at 4° С instead of 37° С At low 
temperature, SA uptake was not different from the uptake at 37° С for 10 min (fig. 8.2B). 
Thereafter, uptake at 4 е С was significantly higher as compared to 37° С 
Concentration-dependent uptake was detennined at incubation periods of 2 min in the 
presence and absence of probenecid (5 mM) (fig. 8.3). The probenecid-sensitive uptake was 
fitted to a Michaelis-Menten equation and resulted in an apparent Κ„ of 114 ± 55 μΜ and a 
V«, value of 0.54 ±0.11 nmol/mgjnin (R2 = 0.977). 
Since peak uptake was seen after 10 min of incubation, the accumulation ratio, 
expressed as intracellular / extracellular concentration (I/E), was detennined by incubating cells 
for 10 min. Accumulation ratios above one were found at low SA concentrations (fig. 8.4). In 
the presence of probenecid the accumulation ratio was reduced to 1, indicating no accumulation. 
At 4° С concentration-dependent SA uptake was slightly higher as compared to 37° С 
(fig. 8.5). Lowering the temperature had no influence on SA uptake in the presence of 
probenecid (fig. 8.5). 
SA uptake (rmol/mg.min) 
1.50 -
1.00 
0.50 
0.00 
50 100 150 200 250 30O 350 
SA concentration (μΜ) 
Figure 8.5. Concentration-dependent SA uptake in the presence of 5 mM probenecid at 37° С 
(A) and at 4" С (·), and uptake in the absence of probenecid at 37е С (A) and at 4° С (о). 
Cells were incubated for 2 nun and were from four different preparations. 
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Figure 8.6. Time-dependent indomethacin (5 μΜ) uptake with (o) and without (A) concomitant 
administration of 5 mM probenecid (fig. 8.6A). Uptake was determined at 37° С (A) and at 4" 
С (о) (fig. 8.6B). Cells from four different preparations were used. 
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Kinetics of indomethacin transport 
Indomethacin uptake was increased up to 2 min, thereafter, a sharp decrease was 
observed (fig. 8.6A). In presence of probenecid, uptake was independent of time. 
The sharp decrease in indomethacin uptake after 2 min could not be attributed to a negative 
effect on cell viability because no significant decrease in viability was observed as compared to 
control experiments (table 8.1). 
Incubating the PT cells at 4° С for a period longer than 3 mis resulted in a 
significantly higher uptake than at 37° С (fig. 8.6B). 
Concentration-dependent indomethacin uptake was measured after 2 min of incubation 
with and without probenecid and is shown in figure 8.7. Probenecid decreased uptake 
considerably. Figure 8.8 shows the accumulation, expressed as I/E ratio, as a function of the 
extracellular concentration. At low concentrations, the ratio was higher than 25, indicating that 
indomethacm was extensively accumulated. Accumulation decreased with increasing extracellular 
concentrations. In the presence of S mM probenecid, a considerable decrease in accumulation 
was observed, although I/E values were still higher then one. 
A decrease in temperature did not affect indomethacin uptake significantly (fig. 8.9). 
However, in the presence of probenecid uptake was increased at 4° С 
INDO uptake (nmol/mg.min) 
20 -
15 
10 -
SO 100 150 200 250 300 350 
INDO concentration (μΜ) 
Figure 8.7. Concentration-dependent indomethacin uptake at 3T С with (o) and without (A) 5 
mM probenecid. Cells were incubated for 2 min and were from four different preparations. 
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Figure 8.8. Accumulation ratio, expressed as intracellular I extracellular concentration (HE) 
ratio, as a function of the extracellular indomethacin concentrations. The ratio was determined in 
the presence (O) and absence (Δ) of 5 mM probenecid, and was calculated from the uptake 
values shown in figure 7 and the intracellular volume. 
INDO u p t a k e (nmol/mg.min) 
150 200 250 300 350 
INDO concentration (μΜ) 
Figure 8.9. Concentration-dependent indomethacin uptake in the presence of probenecid (5 mM) 
at 3T С (A) and at 4° С (9), and uptake in the absence of probenecid at 37° С (Δ) and at 40C 
(o). Cells from four different preparations were used. 
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Further characterization of SA and indomethacin uptake 
Interaction studies (table 8.2) revealed that SA uptake was decreased significantly in 
the absence of sodium. Indomethacin uptake, however, was not significantly affected by the 
absence of sodium. Transport of both drugs was inhibited by probenecid and DIDS (4,4'-
diisothiocyanostilbene-2,2'-disulfonic acid). Preincubating PT cells with probenecid and DIDS 
together, resulted in a higher inhibition of the uptake than with only one of these drugs. Neither 
preincubation nor simultaneous addition of PAH, affected SA and indomethacin uptake. 
Preloading the PT cells with a-ketoglutarate resulted in a significant stimulation of uptake of 
both drugs at 37° С as well as 4° С 
Table 8.2. Effects of various agents and conditions on SA (5 \xM) and 
indomethacin (5 \lM) uptake" 
Interfering agents and 
condition 
Sodium replaced by choline 
Probenecid (5 mM) 
Probenecid (5 mM), 4° С 
DIDS (0.1 mM) 
DIDS (0.1 mM), 4 е С 
DIDS (0.1 mM), probenecid (5 mM) 
PAH (10 mM) 
PAH (10 тМУ 
oKG (10 mM) 
OKG (10 mM), 4 е С 
SA uptake 
(% of control) 
49 ± 18* 
61 ± 14* 
51 ± 6* 
78 ± 9* 
69 ± 1Г 
39 ± 6" 
111± 10 
132 ± 34 
217 ± 30' 
173 ± 1Г 
Indomethacin 
uptake 
{% of control) 
83 ± 18 
62 ± 5" 
48 ± 17* 
67 ± 10* 
61 ± 16* 
30 ± 14* 
107 ± 9 
107 ± 15 
137 ± 15* 
164 ± 29* 
* Cells were preincubated with interfering agents for 15 min and incubated 
with drug for 2 min. 
' PAH was added simultaneously with SA and indomethacin to the samples. 
' Ρ < 0.05. 
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8.5 DISCUSSION 
The measured uptake of drugs in PT cells is the net result of influx and efflux. Two 
functionally different membranes with different carrier systems are involved, the BLM and the 
BBM Passive diffusion (in - and efflux) can occur at both membranes, facilitated diffusion (in -
and efflux) probably occurs at the BBM, while active transport is located at the BLM. 
In time, there was an increase in SA uptake up to 10 min. Thereafter, uptake was 
decreased gradually, not as a result of a decreased cell viability (table 8.1), but probably as a 
result of SA efflux. The time-dependent uptake of indomethacin was clearly different from SA. 
The sharp decrease in indomethacin uptake was not a result of a decrease in viability (table 
8.1). Efflux of indomethacin might be involved but this would not lead to such a sharp decrease 
in uptake. A more likely explanation is the known ability of indomethacin to disrupt oxidative 
phosphorylation at concentrations of 100 μΜ (Tokumitsu et al, 1977; Kawai et al., 198S). The 
time-dependency experiments were performed with S μΜ indomethacin. Because indomethacin 
accumulated by a factor of more than 25, the intracellular concentrations were high enough to 
disrupt energy metabolism. As a result, active transport is blocked and the observed uptake 
probably is the result of diffusion and/or binding to protein. This effect was not observed with 
SA although SA is also able to inhibit the oxidative phosphorylation (Tokumitsu et al., 1977). 
However, SA accumulation is lesser and inhibition occurs only at much higher concentrations as 
compared to indomethacin. 
For the probenecid-sensitive SA uptake an apparent K. value of 114 ± 55 μΜ was 
determined. Schild and Roch-Ramel (1988) found a similar apparent K„ of 80 μΜ for the 
secretory transport of SA in isolated perfused rabbit proximal tubule (S2 segment). Putney and 
Borzelleca (1973) reported a K„ of 1SS μΜ for the uptake of [,4C] -salicylate in cortical slices of 
rat kidneys. 
Uptake values of SA and indomethacin were concentration-dependent and sensitive to 
probenecid, indicating that carrier-mediated processes are involved. This can be either facilitated 
diffusion or active transport Since both drugs accumulated in the PT cells, it seems likely that 
an active process is involved in transport. 
SA and indomethacin accumulation decreased with increasing concentrations. This can 
be explained by active transport: increasing the extracellular concentration leads to a saturation 
of the carrier system, which results in a relatively lower accumulation ratio. 
In presence of probenecid, the SA accumulation ratio decreased to 1, indicating that 
uptake is caused by diffusion only and not by active transport. In contrast to SA, indomethacin 
accumulation is decreased in presence of probenecid but still is considerable. Accumulation in 
presence of probenecid is probably the result of extensive protein binding of indomethacin. The 
decrease in accumulation observed with probenecid, is probably caused by inhibition of active 
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uptake and the partly displacement of protein bound indomethacin. Because SA is much less 
bound to protein, this phenomenon is not observed with SA. 
Previously, we have investigated SA and indomethacin accumulation in the isolated 
perfused rat kidney (IPK). At a perfusate concentration of about 12S μΜ the accumulation ratio 
of SA was 1.5 (Cox et al., 1991a), which is comparable to the ratio in the PT cells. At 
indomethacin perfusate concentrations of about 7 μΜ, the accumulation ratio was 5.2 in the IPK 
(Cox et al., 1991b), a value considerably less than observed in the PT cells. Accumulation is 
probably caused by active transpon. Because this transport process occurs in the proximal 
tubule, the indomethacin concentration in the PT cells will be higher than in other parts of the 
kidney. Therefore a lower indomethacin accumulation ratio can be found in the whole kidney as 
compared to the PT cells. Because SA concentrations which were examined in the IPK were 
relatively high and because SA accumulation ratio was low (<« 1.5), no difference in 
accumulation ratio between the IPK and the PT cells could be detected. 
Unexpectedly, a decrease in temperature did not cause a decrease in SA and 
indomethacin uptake. In the presence of probenecid, indomethacin uptake was even higher at 4° 
С as compared to 37° C. Thus, even at 4" С both drugs accumulate in the PT cells. Because at 
low temperatures cellular energy production is absent, it is very likely that active transport has 
decreased. No decrease in the drag uptake was observed, which indicates that also the efflux of 
drugs must have been decreased with lower temperatures. This decrease in efflux is probably 
more dependent on temperature than the influx system because at longer incubation times both 
SA and indomethacin uptake were significantly higher at 4° С than at 37° C. Similar 
observations were made for the uptake of indomethacin in human polymorphonuclear leucocytes 
(Raghoebar et ai., 1989). 
Interference of PAH with SA and indomethacin transport has been reported (Femer et 
al., 1983; De Zeeuw et al., 1988; Ullrich et al, 1988a). However, in the PT cells we did not 
observe inhibition by PAH. Besides interference with uptake of drugs into the PT cells, PAH 
might also have an effect on the efflux of drugs out of the cells. 
Because transport of SA and indomethacin can be inhibited by DIDS and trans-
stimulated by a-ketoglutarate, an anion-exchange mechanism is probably involved in SA and 
indomethacin active transport. 
In conclusion, the present experiments have shown that SA and indomethacin are 
transported actively into PT cells, probably by an anion-exchange mechanism, resulting in 
intracellular accumulation of both drugs. 
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SUMMARY AND CONCLUSIONS 
Nonsteroidal anti-inflammatory drugs (NSAIDs) are widely used. They can have severe 
side-effects on the gastro-intestinal tract, liver, and kidney. Inhibition of the prostaglandin (PG) 
synthesis plays an important role in their renal effects. Concentration of NSAIDs within the 
kidney is also important. Pharmacodynamically NSAIDs do not differ much. However, 
considerable pharmacokinetic differences exist, which might lead to differences in renal effects. 
More insight in the pharmacokinetic behaviour, especially within the kidney, of different 
NSAIDs in relation to their influence on renal function might lead to conclusions important for 
a more rational use of these drugs. 
This thesis is divided into four parts: 
I introduction 
Π studies on renal handling and effects of salicyluric acid, salicylic acid, and indomethacin 
ΠΙ studies on renal handling and effects of the chiral NSAIDs naproxen and Ibuprofen 
IV mechanism of transport and accumulation of salicylic acid and indomethacin in proximal 
tubular cells 
Two models were used to study renal disposition and influence of NSAIDs: 
1. Isolated perfused rat kidney (IPK): with this model not only the pharmacokinetics, but also 
the effects of NSAIDs on renal function could be studied. An important advantage of this 
preparation is the absence of extrarenal influences. 
2. Proximal tubular (PT) cells isolated from rat kidney: because active transport is localized in 
the proximal tubule, these cells were suitable for studying the transport processes in more 
detail. 
I Introduction 
In chapter 1 a general introduction is given. The different classes of NSAIDs are 
described, their mechanisms of action, and their renal effects. Drag transport is discussed in 
relation to kidney anatcxny and renal function. The mechanisms of organic anion transport are 
described in detail as NSAIDs are probably substrates for this system and, as a result, can 
accumulate in the kidney. Attention is given to the aspect of stereoselectivity because a number 
of NSAIDs are stereoisomers. Although only the d- or S(+)-enantiomer is anti-inflammatory 
active, most chiral NSAIDs are marketed as racemates. Not much is known about a possible 
stereospecific renal handling and about a difference in influence of both enantiomers on renal 
function. 
Chapter 2 describes the IPK technique, its characteristics and the usefulness for 
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studying NSAIDs. By determination of glomerular nitration rate (GFR), perfusion pressure, 
urinary flow, urinary pH, and excretion of glucose and electrolytes kidney function is monitored. 
Π Isolated perfused rat kidney: salicyluric acid, salicylic acid and indomethacin. 
In chapter 3, studies on salicyluric acid (SU), the major metabolite (glycine conjugate) 
of salicylic acid (SA), are reported. A large SU concentration range (S - 400 μgƒml) was 
investigated and no influence on renal function was observed. SU was filtered by the IPK, 
actively secreted, and reabsorbed. Reabsorption was probably a passive process, dependent on 
the urinary pH and flow. Active secretion data could be analyzed according to the Michaelis-
Menten equation: the apparent Michaelis-Menten constant (KJ was 18.7 ± 1 . 8 μg^nl and the 
maximum transport capacity (T„) was 69.8 ± 1 . 4 μg/mш. These values were in good agreement 
with reported in vivo data in dog. Accumulation, expressed as SU amount in the kidney divided 
by the perfusate concentration (K/P ratio), was higher than 20 at low concentrations. 
Accumulation decreased with increasing perfusate concentrations, indicating that it was caused 
by active secretion. High perfusate concentrations led to saturation of the active secretion and to 
a smaller accumulation. 
In chapters 4 and 5, renal handling and effects on kidney function of salicylic acid 
(SA) and indomethacin are characterized. In contrast to SU, only a fraction of the filtered SA 
and indomethacin amounts were excreted. This was caused by an extensive reabsorption, 
dependent on urinary flow and pH. In the IPK, SA was partly metabolized to SU. The drug 
amount in the kidney at the end of an experiment was determined and K/P ratios were 
calculated. At low concentrations, SA accumulated slightly in the IPK. Increasing the perfusate 
concentration above 100 μg/ml led to K/P ratios of approximately 1. Indomethacin accumulated 
extensively in the IPK. The K/P ratio decreased from 8.8 to 5.2 with increasing perfusate 
concentrations (0.2S to 2.5 μg/πll). This can be explained by saturation of active secretion, 
leading to a decrease in accumulation. 
SA concentrations above 200 μg/ml resulted in an increase in urinary flow and 
fractional excretion of sodium, potassium, chloride, glucose, and calcium. GFR and fractional 
excretion of magnesium were not affected. These effects are probably caused by inhibition of 
the oxidative phosphorylation by SA. In contrast to the renal effects of SA, indomethacin, at 
concentrations ranging from 2.5 ng/ml to 2.5 μg/m], caused a decrease in urinary flow and 
fractional excretion of glucose and electrolytes. Prostaglandin E2 (PGEj) could reverse these 
effects, indicating that inhibition of the PG synthesis is the mechanism by which indomethacin 
exerts these actions. 
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Ш Isolated perfused rat kidney and chiral NSAIDs: naproxen and Ibuprofen. 
Because a number of NSAIDs are chiral compounds the aspect of stereoselectivity has 
been studied. Most chiral NSAIDs are marketed as racemates, while only the d- or S(+)-
enantiomer is pharmacologically active. In chapter б the renal disposition and influence on renal 
function of naproxen and its I-enantiomer are described. Naproxen (d-naproxen) is the only 
NSAID which is marketed as active enantiomer. Metabolism, accumulation, and excretion rates 
turned out to be not stereoselective. As observed with SA and indomethacin, naproxen was 
extensively reabsorbed and accumulated in a concentration-dependent manner in the IPK. 
Accumulation was smaller than observed with indomethacin (maximal K/P ratio: 3.4). Up to 10 
% of (he naproxen dose was metabolized to desmethylnaproxen. Naproxen concentrations 
ranging from 0.2 to 25 μg/ml caused a decrease in urinary flow, GFR, and electrolyte excretion. 
This decrease was reversed by PGE,. The 1-enantiomer of naproxen did not affect renal function 
at similar concentrations. Relatively high concentrations ( > 400 μg/ml) of both enantiomers 
caused an increase in urinary flow, urinary pH, and fractional excretion of sodium, potassium, 
chloride, glucose, and calcium. These effects were the same as observed with high 
concentrations of SA ( > 200 Ц^ті). 
Chapter 7 deals with studies on both enantiomers of a chiral NSAID which is 
marketed as racemate: Ibuprofen. The pharmacokinetics of Ibuprofen were not stereoselective. 
Both enantiomers were reabsorbed extensively and accumulated to a similar extent as naproxen. 
Relatively low S(+)-ibuprofen concentrations (0.2S to 25 μ^πιΐ) caused a decrease in urinary 
flow, GFR, and electrolyte excretion. In contrast to 1-naproxen, the pharmacologically inactive 
R(-)-ibuprofen exerted also an effect on kidney function. R(-)-ibuprofen concentrations ranging 
from 2.5 to 25 μ^πιΐ caused similar effects as S(+)-ibuprofen. The effects could be reversed 
completely by PGE,. High concentrations of both enantiomers (> 400 μg/ml) resulted in an 
increase in urinary flow and fractional excretion of sodium, potassium, chloride, glucose, and 
calcium. 
The conclusions of the combined results of part Π and Ш, partly shown in table S.l, 
are: 
A Renal handling of NSAIDs in the isolated perfused rat kidney involves glomerular filtration, 
passive reabsorption, and probably active secretion. 
В Metabolism takes place: SA is converted to its glycine conjugate SU and naproxen is 
metabolized to desmethylnaproxen. 
С AU NSAIDs accumulate in the IPK, however to a different extent: SA < S(+)/R(-)-ibuprofen 
« d/1-naproxen < indomethacin. 
D Renal disposition does not appear to be a stereoselective process. 
E The studied NSAIDs all affected kidney function. 
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Table S.l. Accumulation and effects ofNSAIDs in the isolated perfused rat kidney 
accumulation 
ratio" 
lowest concentrations Qxg/ml) 
causing effects related to 
prostaglandin 
synthesis 
_b 
2.5 
0.25 
0.25 
_b 
0.0025 
oxidative 
phosphorylation 
200 
200 -400 
200-400 
200 -400 
200 -400 
not determined 
SA 
R(-)-ibuprofen 
S(+)-ibuprofen 
d-naproxen 
1-naproxen 
indomethacin 
1.5 (1.5) 
2.3 
2.4 
2.7 
2.9 
5.2 (27) 
' Determined at concentrations of 25 μ^ /m/, except for SA (20 \igtml). Values between brackets 
represent accumulation ratios in PT cells at similar concentrations. 
* No significant prostaglandin synthesis related effects were observed up to concentrations of 200 
\iglmlfor SA and 25 \iglml for ¡-naproxen. 
Two different influences on renal function can be distinguished: 
At relatively low concentrations, a decrease in urinary flow and electrolyte excretion can be 
seen, probably caused by inhibition of the prostaglandin synthesis. SA, which is a weak 
inhibitor of the prostaglandin synthesis, does not influence kidney function in this manner. 
Indomethacin exerts this renal effect at very low concentrations compared to the other 
studied NSAIDs, which correlates with its strong potency for inhibiting prostaglandin 
synthesis and with its extensive accumulation. Probably because enantiomers of chiral 
NSAIDs have different potencies for inhibition of prostaglandin synthesis, this renal 
influence is stereoselective. In contrast with d-naproxen, no influence is observed with the 
pharmacologically inactive 1-naproxen. The inactive enantiomer of Ibuprofen affects kidney 
function in the same manner as the pharmacologically active S(+)-enantiomer but at higher 
concentrations. 
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2. At high SA, d/1-naproxen and S(+)/R(-)-ibuprofen concentrations an increase in urinaiy flow 
and electrolyte excretion can be seen, probably as the result of inhibition of the oxidative 
phosphorylation. This influence is not stereoselective. 
TV Proximal tubular cells from rat kidney. 
In chapter 8, some studies on SA and indomethacin transport are described in proximal 
tubular (FT) cells. SA uptake increased with incubationtime up to 10 min, whereafter, a 
maximal uptake value was reached. Incubating the cells for periods longer than 10 min led to a 
decrease in uptake, probably due to SA efflux out of the FT cells. SA uptake was 
concentration-dependent and could be inhibited by probenecid. The probenecid-sensitive uptake 
could be described by Michaelis-Menten kinetics: K„ = 115 ± 55 μΜ and V_ - 0.54 ±0.11 
nmol/mgjnin. The accumulation ratio, which is the intracellular concentration divided by the 
extracellular concentration, was higher than 3 at extracellular SA concentrations of 5 μΜ and 
decreased with increasing concentrations. This indicates that accumulation is a result of active 
transport. Probenecid inhibits active transport and no accumulation was observed in the presence 
of probenecid. 
Indomethacin uptake increased in time during 2 min, thereafter, a sharp decrease in 
uptake was observed. This decrease might be caused by inhibition of the oxidative 
phosphorylation. As a result no metabolic energy is produced and active transport stops. In the 
presence of probenecid uptake was probably the result of passive diffusion and protein binding. 
Indomethacin accumulated extensively in the PT cells: accumulation ratios were higher 
than 20 at low extracellular concentrations. Increasing the concentration resulted in a decrease in 
accumulation ratio. Accumulation ratios of indomethacin in the PT cells were higher than in (he 
IPK (table S.l). Because accumulation is probably the result of active transport, which occurs in 
the proximal tubule, it is clear that accumulation in the whole kidney will be smaller than the 
accumulation in the PT cells. In the presence of probenecid, accumulation was decreased, but 
still considerable. This was probably due to the extensive binding of indomethacin to cellular 
proteins. Because SA and indomethacin uptake could be inhibited by DIDS, an anion-exchange 
inhibitor, and stimulated by preloading the cells with a-ketoglutarate, it is likely that an anion-
exchange mechanism is involved in the active transport process. 
From these studies, it can be concluded that SA and indomethacin are actively 
transported by the PT cells, probably by an anion-exchanger and as a result accumulate in the 
cells. 
The results of the studies described in this thesis help to understand renal transport and 
effects of NSAIDs. The studies with ibuprofen indicate that it might be beneficial to use the 
anti-inflammatory active enantiomer instead of the racemic form. 
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SAMENVATTING EN CONCLUSIES 
Niet-steroïdale anti-inflammatoire drugs (NSAID's) worden veel gebruikt bij de 
behandeling van pijn, koorts, ontstekingen en rheumatische aandoeningen. Ze kunnen velerlei 
bijwerkingen veroorzaken, vooral op het maag-darmkanaal, de lever en de nier. Remming van de 
prostaglandine-synthese (PG-synthese) speelt een belangrijke rol bij de invloed op de nierfunctie. 
Locale accumulatie van NSAID's in de nier is waarschijnlijk ook belangrijk. Farmacodynamisch 
gezien zijn er weinig verschillen tussen NSAID's. Aanzienlijke verschillen bestaan er echter op 
farmacokinetisch gebied, welke kunnen leiden tot verschillen in effecten op de nierfuncüe. 
Kennis van de farmacokinetiek van verschillende NSAID's, vooral met betrekking tot de nier, in 
relatie met hun invloed op de nierfunctie zou kunnen leiden tot een meer rationeel gebruik van 
deze stoffen. 
Dit proefschrift is opgebouwd uit 4 delen: 
I inleiding 
Π studies naar transport en effecten op de nierfunctie van salicyluurzuur, salicylzuur en 
indomethacine 
Ш studies naar transport en effecten op de nierfunctie van de chirale NSAID's naproxen en 
Ibuprofen 
IV mechanismen en interacties van het transport van salicylzuur en indomethacine in proximale 
tubuluscellen 
Twee studiemodellen werden gebruikt om het renale transport en de effecten van 
NSAID's te bestuderen: 
1. De geïsoleerde geperfundeerde rattenier dit preparaat bleek uitstekend bruikbaar om zowel 
de farmacokinetische aspecten van NSAID's te onderzoeken als hun effecten op de 
nierfunctie. Een belangrijk voordeel van dit preparaat is de afwezigheid van extrarenale 
factoren. 
2. Proximale tubuluscellen geïsoleerd uit de rattenier: omdat NSAID's waarschijnlijk actief 
getransporteerd worden in de proximale tubulus, zijn deze cellen geschikt om het transport 
nader te karakterizeren. 
I Inleiding. 
Deel I begint met een algemene inleiding (hoofdstuk 1) waarin een beschrijving van de 
verschillende NSAID's, hun werkingsmechanisme en de bijwerkingen op de nier met de 
mogelijke oorzaken wordt gegeven. Het transport van stoffen door de nier wordt beschreven in 
relatie tot de bouw en de functie van de nier. Het mechanisme van het organisch-aniontransport 
wordt in detail beschreven omdat NSAID's waarschijnlijk ook een substraat voor dit systeem 
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zijn en omdat deze transportwijze accumulatie in de tubuluscel tot gevolg kan hebben. Ook 
wordt er aandacht besteed aan de stereoselectiviteit, aangezien verscheidene NSAID's 
stereoisomeren zijn. Hoewel alleen de d- of S(+)-enantiomeer ontstekingsremmend is, worden 
deze stoffen toch voornamelijk als racemaat gebruikt Weinig is bekend over de bijdrage van 
beide enantiomeren aan de effecten op de nierfunctie en over een eventuele stereospecifïeke 
uitscheiding in de nier. 
Hoofdstuk 2 geeft een gedetailleerde beschrijving van de geïsoleerde geperfundeerde 
rattenier (IPK) en het nut van het gebruik ervan voor de bestudering van NSAID's. Door 
bepaling van glomerulaire filtratiesnelheid (GFR), perfusiednik, urine-flow, urine-pH en 
uitscheiding van glucose en electrolieten kan de nierfunctie gemeten worden. 
Π Geïsoleerde geperfundeerde rattenier: salicyluurziiiir, salicylzuur en indomethacine. 
In hoofdstuk 3 wordt salicyluurzuur (SU), de belangrijkste metaboliet van salicylzuur 
behandeld. Een breed concentratiegebied (S tot 400 μ^πιΐ) werd onderzocht, waarbij er geen 
invloed op de nierfunctie werd waargenomen. SU werd gefìltreerd in de glomerulus, actief 
uitgescheiden en gereabsorbeerd. Reabsorptie was waarschijnlijk passief en afhankelijk van de 
urine-flow en -pH. De actieve uitscheiding kon geanalyseerd worden volgens de Michaelis-
Menten vergelijking: de Michaelis-Menten constante (KJ was 18.7 ±1.8 μg/ml en de maximale 
transportcapaciteit (T
n
) was 69.8 ± 1.4 μg/min. Deze waarden zijn vergelijkbaar met data 
gevonden in vivo bij de hond. De accumulatie-ratio, uitgedrukt als SU-hoeveelheid in de nier 
gedeeld door de perfusaatconcentratie, was hoger dan 20 bij lage concentraties. Bij stijgende 
concentraties nam deze factor af. Dit is een aanwijzing dat de accumulatie een gevolg is van 
actieve uitscheiding: een toename in concentratie leidt tot verzadiging van het transportsysteem 
waardoor er een relatief kleinere accumulatie ontstaat. 
In hoofdstuk 4 en S worden de uitscheiding en de invloed op de nierfunctie van 
salicylzuur (SA) en indomethacine belicht. In tegenstelling tot SU, werd slechts een klein 
gedeelte van de gefiltreerde hoeveelheid SA en indomethacine uiteindelijk uitgescheiden. Dit 
bleek veroorzaakt door een hoge, pH-afhankelijke, passieve reabsorptie. De nier was in staat SA 
om te zetten in SU, een glycineconjugaat. Accumulatie werd bepaald door analyse van de 
hoeveelheid SA en indomethacine in de nier. De accumulatie van SA was gering bij lage 
concentraties (ratio 1.5) en nam verder af (tot 1.0) bij hogere concentraties. Indomethacine werd 
in sterke mate opgehoopt in de nier. De accumulatie-ratio nam af van 8.8 tot 5.2 bij 
toenemende perfusaatconcentraties (0.25 tot 2.5 μg/ml)· Dit kan net als bij SU verklaard worden 
door verzadiging van de actieve uitscheiding. 
SA-concentraties boven 200 μg/ml veroorzaakten een stijging in de urineproductie en 
uitscheiding van natrium, kalium, chloor, glucose en calcium. De GFR en de uitscheiding van 
magnesium werden niet beïnvloed. Deze effecten werden waarschijnlijk veroorzaakt door 
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remming van de oxidalieve fosforylering. In tegenstelling tot SA, veroorzaakte indomethacine bij 
zeer lage perfusaatconcentraties (2.5 ng/ml) een verlaging van de diurèse en de fractionele 
excreties van glucose en electrolieten. Deze water- en zout-retentìe wordt waarschijnlijk 
veroorzaakt door remming van de PG-synthese, want in aanwezigheid van Prostaglandine Б, 
(PGE,) in het perfusaat traden deze effecten niet op. 
Ш Geïsoleerde geperfundeerde rattenier en chirale NSAID's: naproxen en ibuprofen. 
Omdat verscheidene NSAID's chirale verbindingen zijn, is er bijzondere aandacht 
gegeven aan het aspect van de stereoselectiviteit. De meeste chirale NSAID's worden als 
racemaat gebruikt, hoewel alleen de d- of S(+)-enantiomeer farmacologisch actief is. In 
hoofdstuk 6 worden het transport en de invloed op de nier van naproxen en zijn l-enantiomeer 
beschreven. Naproxen (d-naproxen) is de enige chirale NSAID die als enantiomeer op de markt 
is. Metabolisme, accumulatie en uitscheiding bleken niet stereoselectief te zijn. Evenals de in 
deel 2 bekeken NSAID's SA en indomethacine, bleek naproxen sterk gereabsorbeerd te worden 
en accumuleerde het op een concentratie-afhankelijke manier in de geïsoleerde geperfundeerde 
rattenier. De accumulatie was kleiner in vergelijking met indomethacine (maximale ratio was 
3.4). Bij lage naproxen doseringen werd meer dan 10 % van de dosering gemetaboliseerd tot 
desmethylnaproxen. Naproxen-concentraties variërend van 0.2S tot 25 μ^/πΛ veroorzaakten een 
verlaging van de diurèse, GFR, en fractionele excretie van electrolieten. Deze verlaging kon 
geheel teniet gedaan worden door toevoeging van PGE, aan het perfusaat. Vergelijkbare 
concentraties van de inactieve l-enantiomeer van naproxen hadden geen invloed op de 
nierfunctie. Hoge concentraties ( > 400 μ^πιΐ) van beide enantiomeren resulteerden in een 
toename van de urineproductie en de fractionele excretie van natrium, kalium, chloor, glucose en 
calcium. Deze effecten waren vergelijkbaar met die van hoge SA-concentraties ( > 200 Mg/ml). 
In hoofdstuk 7 worden beide enantiomeren van een chirale NSAID onderzocht, die als 
racemaat gebruikt wordt: ibuprofen. De fannacokinetiek van ibuprofen bleek niet stereoselectief 
te zijn en beide enantiomeren werden strak gereabsorbeerd en accumuleerden in de IPK in 
dezelfde mate als naproxen. Relatief lage concentraties S(+)-ibuprofen (0.25 tot 25 μg/ml) 
veroorzaakten een verlaging van de diurèse, GFR en electrolietuitscheiding. In tegenstelling tot 1-
naproxen, had het inactieve R(-)-ibuprofen wel een invloed op de nierfunctie. R(-)-ibuprofen-
concentraties van 2.5 μg/ml gaven een vergelijkbare verlaging van de diurèse en 
electrolietuitscheiding als S(+)-ibuprofen. Zowel de invloed van de S(+)-enantiomeer als de R(-)-
enantiomeer werd geheel teniet gedaan door PGE,. Hoge concentraties van beide stereoisomeren 
( > 400 μg/ml) veroorzaakten een afname van de diurèse en fractionele excretie van natrium, 
kalium, chloor, glucose en calcium. Evenals bij naproxen zijn dit niet-stereoselectieve invloeden, 
die waarschijnlijk het gevolg zijn van remming van de oxidatieve fosforylering. 
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Tabel S.l. Accumulatie en effecten van NSAID's in de geïsoleerde geperfimdeerde rattenier 
accumulatie laagste concentraties (jig/ml) die effecten 
ratio' veroorzaken gerelateerd aan de 
Prostaglandine 
synthese 
_b 
2.5 
0.25 
0.25 
ь 
0.0025 
oxidatieve 
fosforylering 
200 
200 -400 
200-400 
200 -400 
200 -400 
niet bepaald 
SA 
R(-)-ibuprofen 
S(+)-ibuprofen 
d-naproxen 
1-naproxen 
indomethacine 
1.5 (1.5) 
2.3 
2.4 
2.7 
2.9 
5.5 (27) 
Bepaald bij concentraties van 25 \igliTU, behalve de SA-ratio (20 \iglml). De waarden 
vermeld tussen haakjes zijn gevonden in proximale tubuluscellen. 
Er werden geen prostaglandine-synthese gerelateerde effecten geobserveerd bij concentraties 
tot 200 \i.glml voor SA en 25 \xglml voor l-naproxen. 
De conclusies van deel Π en Ш, deels vervat in tabel S.l, zijn: 
A Alle NSAID's worden gefiltreerd, passief gereabsorbeerd en waarschijnlijk actief 
getransporteerd in de geïsoleerde geperfimdeerde rattenier. 
В Er treedt metabolisme op: SA wordt omgezet in z'n glycineconjugaat SU en naproxen in 
desmethylnaproxen. 
С Alle NSAID's blijken in de nier in verschillende mate te accumuleren: 
SA < S(+VR(-)-ibuprofen - d/l-naproxen< indomethacine. 
D Metabolisme, accumulatie en uitscheiding blijken niet stereoselectief te zijn. 
E Alle onderzochte NSAID's beïnvloeden de nierfunctie. 
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Twee verschillende effecten op de nierfunctie kunnen worden onderscheiden: 
1. Bij relatief lage concentraties kan er een afname van de diurèse en electrolietexcretie 
optreden, welke waarschijnlijk veroorzaakt wordt door remming van de PG-synthese. SA is 
geen sterke remmer van de PG-synthese en veroorzaakt dit effect niet In vergelijking met 
andere NSAID's veroorzaakt indomethacine al bij zeer lage concentraties deze renale 
effecten. Dit correleert met de sterke mate van remming van de PG-synthese en met de 
hoge mate van accumulatie. Waarschijnlijk omdat de enantiomeren van chirale NSAID's de 
PG-synthese in verschillende mate remmen, zijn deze effecten stereoselectief. In tegenstelling 
tot d-naproxen, veroorzaakt de farmacologisch inactieve 1-enantiomeer geen effecten op de 
nierfunctie. De inactieve enantiomeer van Ibuprofen daarentegen, veroorzaakt wel dezelfde 
effecten op de nierfunctie als de actieve S(+)-enantiomeer, maar bij hogere concentraties. 
2. Bij hoge concentraties kunnen salicylzuur, d/l-naproxen en S(+)/R(-)-ibuprofen een niet-
stereoselectieve toename van de diurèse en electrolietuitscheiding veroorzaken. Deze effecten 
moeten waarschijnlijk worden toegeschreven aan remming van de oxidatieve fosforylering. 
Г Proximale tubuluscellen uit de rattenier. 
In hoofdstuk 8 wordt het onderzoek naar de transportmechanismen en accumulatie van 
salicylzuur en indomethacine in proximale tubuluscellen beschreven. De SA opname nam toe bij 
incubatietijden tot ongeveer 10 min, waarbij er een maximum bereikt werd. Bij incubatietijden 
langer dan 10 min daalde de opnamecurve, waarschijnlijk ten gevolge van efflux van SA uit de 
cellen. Concentratie-afhankelijke SA-opname werd geremd door 5 mM probenecide. De 
probenecide-afhankelijke opname kon beschreven worden met een Michaelis-Menten vergelijking: 
K„ = 115 ± 55 μΜ en ν . . . = 0.34 ±0.11 nmol/mg-min. SA accumuleerde in de proximale 
tubuluscellen want de accumulatie-ratio, uitgedrukt als de intracellulaire concentratie gedeeld 
door de extracellulaire concentratie, was hoger dan 3 bij concentraties van S μΜ De ratio nam 
af bij toenemende concentratie. Waarschijnlijk is de accumulatie het gevolg van actief transport 
Probenecide remt het actief transport, waardoor er geen accumulatie gevonden werd in 
aanwezigheid van deze remmer. 
Bij incubatietijden tot ongeveer 2 min, name de opname van indomethacine toe, waarna 
er een sterke daling optrad. Een mogelijke verklaring hiervoor is dat indomethacine de 
oxidatieve fosforylering remt waardoor er geen metabole energie meer geproduceerd wordt. Dit 
heeft tot gevolg dat de actieve opname stopt waarna het in de proximale tubuluscellen 
geaccumuleerde indomethacine uit de cel kan diffunderen. Dit leidt tot een sterke daling in de 
opname. In aanwezigheid van 5 mM probenecide was er geen tijdsafhankelijkheid. 
Waarschijnlijk blokkeert probenecide het actieve transport volledig. Indomethacine accumuleert in 
hoge mate in de proximale tubuluscellen. De accumulatie-ratio was groter dan 20 bij een 
extracellulaire concentratie van 5 μΜ. Bij toenemende concentraties nam de ratio af, 
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waarschijnlijk als gevolg van verzadiging van het actieve transport. In aanwezigheid van 
probenecide was de accumulatie verlaagd, maar toch nog aanzienlijk. Dit is waarschijnlijk een 
gevolg van de sterke binding van indomethacine aan de cellen. 
De anion-exchange-remmer DIDS kon de opname van SA en indomethacine remmen. 
Opladen van de cellen met ct-ketoglutaarzuur had een sterke stimulatie van de opname van beide 
stoffen tot gevolg. Deze resultaten leiden tot de conclusie dat SA en indomethacine actief 
getransporteerd worden door de proximale tubuluscellen via een anion-exchange-mechanisme. Als 
gevolg van dit proces treedt er accumulatie van beide stofen in de cellen op. 
De resultaten van de studies beschreven in dit proefschrift leveren een bijdrage aan het 
inzicht in het renale transport en in de effecten van NSAID's op de nierfunctie. De studies met 
Ibuprofen geven aan dat het wellicht beter is om de ontstekingsremmende actieve enantiomeer te 
gebruiken in plaats van het racemaat 
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STELLINGEN 
I 
De geïsoleerde geperfundeerde rattenier (IPK) is een bruikbaar onderzoeksmodel om zowel de 
kinetiek als de invloed op de nierfunctie van NSATO's te bestuderen. 
Dit proefschrift. 
Π 
De in vitro in de IPK gevonden farmacokinetische parameters van de actieve renale uitscheiding 
van salicyluurzuur zijn vergelijkbaar met data gevonden in vivo in de hond. 
F.GM. Rüssel, A.C. Wouterse en CAM. van Ginneken, Drug Metab. Dispos. 15, 695 - 701, 
1987. 
Dit proefschrift. 
m 
NSATO's kunnen in de IPK zowel een afname als ook een toename van de diurèse en de renale 
zoutuitscheiding veroorzaken. 
Dit proefschrift. 
IV 
De faimacokinetiek van chirale NSAID's blijkt in de nier niet stereoseiectief te zijn, in 
tegenstelling tot hetgeen geldt voor het gehele organisme. 
F. /amali, Eur. J. Drug Metab. Pharmacokin. 13, 1 - 9, 1988. 
Dit proefschrift. 
V 
Aangezien de renale effecten van chirale NSAID's wel stereospecifiek zijn, is het van belang de 
enantiomeren afzonderlijk te bestuderen in plaats van het racemaat. 
EJ. Ariëns: Stereochemistry, a Basis for Sophisticated Nonsense in Pharmacokinetics and 
Clinical Pharmacology. Eur. J. Clin. Pharmacol. 26: 663 - 66«, 1984. 
Dit proefschrift. 
VI 
Als aanvulling op de werkwijze van Boogaard et al. is bet in verband met de opbrengst van 
proximale tubuluscellen aan te bevelen deze cellen te isoleren na voorafgaande heparinisatie van 
de rat. 
PJ. Boogaard, GJ. Mulder en JF. Nagelkerke, Tox. Appi. Pharmacol. 101, 135 - 143, 1989. 
П 
Salkylzuur «a indomethacine accumuleren in geïsoleerde proximale tubuluscellen van de 
rattenier ten gevolge van саггіег-gemedieerd transport. 
Dit proefschrift. 
Ш 
Als gevolg van bet asbestprobleem aan de Katholieke Universiteit Nijmegen, is er tijdens bet 
onderzoek dat beschreven is in dit proefschrift ruime ervaring opgedaan met verhuizen. 
EX 
Beter één Wistar-rat in de hand dan tien riool-ratten in de kelder. 
Eigen waarneming. 
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